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Abstract 
Amyloid diseases are a group of protein misfolding disorders characterised by the 
formation of highly ordered filamentous assemblies known as amyloid fibrils. 
Soluble aggregation intermediates whose formation precedes that of mature fibrils 
are commonly considered the major source of toxicity in amyloid diseases. 
Oligomer toxicity has often led to mature amyloid fibrils being referred to as inert 
end products of aggregation. Recent evidence, however, has shown that fibrils 
themselves are capable of facilitating toxicity by a variety of mechanisms. One such 
protein, β2-microglobulin (β2m), has been shown to form amyloid fibrils that bind to 
liposome membranes causing deformations and disruption in a pH dependent 
manner.  
In this thesis, the in vitro mechanisms of β2m fibril-induced membrane disruption are 
explored to elucidate why reducing the pH from 7.4 to 6.4 leads to an enhancement 
in fibril membrane disruption. A combination of chemical kinetics, NMR and 
liposome dye-release assays show that at both pH values, membrane disruption is 
mediated through the shedding of soluble species induced upon diluting fibrils 
formed at low pH into either buffer. Fibril depolymerisation at pH 6.4 leads to the 
persistence of membrane-active non-native species, whereas depolymerisation at pH 
7.4 is driven rapidly to membrane-inactive native monomer. Further analysis reveals 
that these non-native species are structurally disordered, spherical particles that 
display significant surface-exposed hydrophobicity. 
The observed pH-dependent formation of oligomers shed during depolymerisation is 
likely to play an important role in mediating cellular effects upon incubation with 
fibrils. Consistent with this, chemical cross-linking of fibrils and co-incubating 
fibrils with Hsp70-1A prevents the depolymerisation of β2m fibrils at both pH 7.4 
and 6.4 in vitro and reduces metabolic defects associated with β2m fibril 
depolymerisation. The results suggest that kinetically stabilising fibrils to prevent 
molecular shedding could be a means of helping to remedy amyloid-associated 
toxicity. 
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INTRODUCTION 
1.1 Forethought  
Amyloid diseases are an expanding class of disorders typically characterised by the 
formation of protein aggregates defined by their gain-of-toxic-function (1–4). The 
ubiquity of amyloid diseases are increasing as the onset of many are linked to 
ageing. With an ageing population worldwide, the prevalence of amyloid diseases is 
set to increase (5). 
The relationship between amyloid and ageing is complex, although it is likely to be 
related to the down-regulation of proteostatic mechanisms commonly associated 
with ageing; as the proteostatic capacity decreases, the deposition of specific proteins 
into amyloid assemblies increases, which upon meeting a critical aggregate 
concentration threshold, leads to the manifestation of pathological features (6–8). 
Not all amyloid disorders are age-related however, familial variants associated with 
early-onset phenotypes often carry mutations within amyloidogenic polypeptide 
sequences that accelerate amyloid aggregation (9–13). Early-onset phenotypes can 
also be the result of mutations that render proteins responsible for processing and 
clearing amyloidogenic precursors significantly impaired in comparison with their 
wild-type (wt) counterparts (14–17). These features add weight to the amyloid 
aggregate toxic gain-of-function hypothesis in mediating disease, and hence has been 
the focus of intense research activity for more than two decades (18). 
The ubiquity of amyloid diseases (see Table 1.1.1 for some well-known examples), 
with around 50 known disorders currently classified by amyloid deposition (19), and 
the common biochemical and biophysical signatures of amyloid aggregation, to 
which you shall be introduced, led to initial efforts to identify a unifying cytotoxic 
entity amongst many of these diseases (20, 21). Hitherto, it has become increasingly 
clear that a single pathological event does not underlie the complex mechanisms of 
cytotoxicity associated with amyloid diseases. For example, in Alzheimer’s disease, 
perhaps the best known amyloid disease, a vast array of aggregates have been 
characterised in vitro and display varying degrees of toxicity in vivo, via highly 
diverse cellular mechanisms (22–25). The reality is that, in vivo, an ensemble of 
structures are just as likely to form than any individual species predominating, thus 
creating a complex network of pathological cascades which require intervention to 
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inhibit disease progression. Therefore, a paradigm shift in the approach to tackling 
and classifying amyloid diseases is required; instead of the development of 
therapeutic strategies focusing on pacifying a single cytotoxic entity, the array of 
amyloid structures, and other genetic abnormalities, that contribute to disease 
progression must be elucidated before effective therapies can be developed. 
With this in mind, this thesis presents work towards our attempts to understand the 
complex mechanisms that underpin amyloid fibril-mediated toxicity by using the 
model protein β2-microglobulin. Traditional theories have often cast amyloid fibrils 
as inert end-stage products of amyloid assembly, whose contribution towards 
toxicity is negligible (26–28). By using a range of biochemical, biophysical and cell 
biological assays, I hope this in-depth investigation, along with other recently 
published studies, will help to establish the role of amyloid fibrils in an array of 
processes critical to the multi-faceted nature of amyloid diseases. 
Table 1.1.1 A selection of diseases associated with amyloid formation 
Precursor protein Disease 
 Neurodegenerative diseases 
α-synuclein Parkinson’s disease 
Amyloid precursor protein (APP) Alzheimer’s disease 
PolyQ-expanded huntingtin Huntington’s disease 
Prion protein Spongiform encephalopathies 
Superoxide dismutase 1, TDP-43 Amyotrophic lateral sclerosis 
Transthyretin mutants Familial amyloid polyneuropathy 
 Systemic amyloidosis 
β2m Dialysis related amyloidosis 
Immunoglobulin light chain Amyloid light chain (AL) amyloidosis 
Lysozyme Lysozyme amyloidosis 
wt Transthyretin Senile systemic amyloidosis 
 Localised amyloidosis 
Islet Amyloid polypeptide Type II diabetes mellitus 
Insulin Injection localised amyloidosis 
  
Introduction 
 
3 
 
1.2 Protein folding in the cell 
Proteins are the chief mediators of the majority of cellular processes and are 
therefore of critical importance to understanding the fundamental principles of life. 
From an essential tool kit of 20 amino acids, a vast number of polypeptide sequences 
can be derived whose range of functions is diverse, including processes such as DNA 
replication, cargo transport, ATP synthesis, muscle contraction, light sensing, smell, 
digestion and so on. In order to carry out their encoded functions, the majority of 
proteins must obtain a native fold. It has long been known that the information 
encoded within a polypeptide sequence can be sufficient for the folding of a protein 
to its native functional state (29). However, the study of protein folding is perhaps 
the last paradigm of 20
th
 century biology that remains to be fully chartered. Even in 
the age of computer assisted experimental design and analysis, correctly predicting 
the fold of an existing polypeptide sequence, or predicting the fold of a novel 
sequence, is not a trivial exercise. This is because polypeptide sequences have 
evolved to encode a vast array of different characteristics; folds, functions, lengths 
and dynamic behaviours. These impede our ability to spot trends within sequence 
motifs that determine not just three-dimensional structure but function (30). The 
ability to design in silico polypeptide sequences and fully recapitulate the predicted 
structure and function therefore remains a significant challenge. The serendipitous 
acquisition of mutations that lead to novel or altered functions in vivo occludes the 
composition of a generalised set of rules for de novo protein design (31, 32). 
Even so, we have learnt much over the last 50 years about how proteins obtain their 
three dimensional structures. Principally, obtaining the native fold in vitro requires a 
fully synthesised polypeptide to traverse a downhill energy landscape to reach a low 
energy ‘native conformation’ (33) (Figure 1.2.1). This spontaneous folding activity 
is largely inaccessible to the majority of proteins within the cell however, and is 
exacerbated by the hugely crowded cellular environment (34). In response, the cell 
has developed a catalogue of proteins, known as molecular chaperones, whose 
predominant function is to promote the correct folding of polypeptide sequences. 
Wherever protein folding takes place, such as the endoplasmic reticulum (ER) or the 
cytosol, a wealth of cellular resources is dedicated to guiding a variety of client 
proteins to reach the functional, folded, native state.  
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Obtaining a native state is not the only means of controlling protein activity in the 
cell. Other phenomena can equally affect protein structure and function in addition to 
post-translational misfolding. These processes are often critical for tuning protein 
activity and are therefore tightly coordinated throughout a protein’s life cycle. One 
such regulatory process is time, as different proteins are required for distinct periods 
of a cell’s life cycle. Some, such as collagen, exist for the entire lifespan of the cell. 
Others, such as HIF-1, exist for minutes (35, 36). The regulated half-life of a 
protein is a necessary feature of a cell being able to tune its chemistry in response to 
the environment. Therefore, the existence of the functional native state must also be 
tightly regulated temporally. In addition, proteins undergo a library of different post-
translational modifications which affect function, structural stability and turn-over of 
proteins (37). Some proteins also require assembly into higher order macromolecular 
machines for function and folding. Most, if not all, also undergo extensive 
modifications during ageing which, left unchecked, can have damaging 
consequences for the fold and function of a protein (38). 
These limited examples begin to illustrate the inherent plasticity of proteins in vivo 
and the subsequent importance of cellular monitoring of protein folding throughout 
the lifetime of the cell. Given the unique features of individual proteins, it is perhaps 
surprising that damaging protein misfolding events do not take place more frequently 
than they do. In order to minimise the aberrant misfolding of proteins, or the 
accumulation of redundant or aged-damaged species, the cell has also developed a 
Figure 1.2.1 Free energy landscape depicting an idealised view of downhill protein 
folding.  A fully synthesised, unfolded polypeptide chain (black lines) folds 
spontaneously to a low energy well that is the native state. Adapted from (33) 
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myriad of protein quality control networks that ensure the misfolded protein burden 
is maintained at levels that are safe for the health of the entire proteome (39).  
The turnover of proteins is not restricted to those that have aged or outlived their 
function. Processes of regulated turnover begin with monitoring of protein folding 
even before the full synthesis of a polypeptide has taken place. Up to 300 proteins 
have been characterised as participants in the process of translation, with many of 
these involved in controlling translation rates and correct folding of the nascent 
polypeptide chain during synthesis (40). Both of these processes are equally 
important in facilitating a protein to reach and maintain its native fold. Translation 
rates are tempered by the sequence of the polypeptide being synthesised and the 
corresponding mRNA codons used. The rate of translation is often slowed during the 
synthesis of hydrophobic stretches of amino acids. Slowing translation affords more 
time for chaperones to bind and mask aggregation prone sequences as they emerge 
from the ribosome (41). For other proteins, the rate of translation can be increased or 
decreased to ensure a greater percentage of folding of the nascent chain towards a 
native state (42, 43). This is especially true for the synthesis of enzymes, where 
translation rates can impact upon the efficiencies of down-stream catalytic processes 
(44).  
The rate of translation of mRNA into individual polypeptides is therefore an 
important step for determining the folding outcome of a protein, but there are 
processes that affect the global translation network. Whole-scale control of protein 
translation is usually initiated through the induction of particular stress responses. 
These responses are designed to afford the cell additional time to redress proteostatic 
imbalance when a critical protein-misfolding threshold has been exceeded. Examples 
of these so called stress responses include the induction of translation inhibition 
through the unfolded protein response (UPR) or after acute heat shock (45, 46). In 
both, the general strategy of preventing the synthesis of new proteins enables the cell 
to concentrate resources towards redressing the initial seeding event of proteostatic 
imbalance. Only once the cell has overcome such stresses will translation be re-
initiated. The induction of stress responses are therefore rapid and involve concerted 
activities of a large array of different proteins. For example, the UPR is initiated 
upon sensing of terminally misfolded secretory proteins within the lumen of the ER. 
Terminal misfolding of proteins in the ER can be sensed via a variety of different 
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mechanisms. Distinct, but integrated, signalling pathways sense ER protein 
misfolding and transduce signals to the cytosol via transmembrane sensors in order 
to shut down translation through phosphorylation of translation initiation regulatory 
factor eIF2 (47, 48). Shutting down standard 5’-cap dependent translation initiation 
is coupled to increased translation of UPR mRNAs such as the transcription factor 
(TF) ATF-4 (49, 50). ATF-4 and other UPR up-regulated TFs increase the 
expression of genes designed to alleviate ER stress. Only once the ER misfolded 
protein burden has recovered is the UPR ‘switched off’ and translation re-initiated. 
Translation is similarly affected upon acute heat shock which is most commonly 
associated with protein misfolding in the cytosol. Upon induction of the heat shock 
response, Hsp40 and Hsp70 chaperones, proteins that have evolved to assist protein-
folding, are re-distributed from nascent chains emerging from ribosomes in order to 
catalyse the refolding of stress induced unfolded sequences (51). In both these cases, 
the reduction in translation prevents the production of aberrantly folded proteins 
which otherwise would lead to a catastrophic protein misfolding event. 
These are only a few of the mechanisms that have evolved to keep the cell safe from 
the consequences of protein misfolding. Others include chaperone-mediated 
autophagy, lysosome-mediated degradation, ubiquitin-dependent proteasomal 
degradation of cytosolic proteins, retro-translocation of terminally misfolded 
proteins from the ER, co-translational ubiquitin tagging of proteins for degradation, 
juxtanuclear positioning of membrane-bound misfolded protein clusters, formation 
of insoluble cytosolic inclusions, and nuclear shuttling of proteins for degradation. 
Together, these form complex communicative networks that ensure the general 
health of the proteome is maintained (52–59) (Figure 1.2.2). These 
compartmentalized defence mechanisms can also involve signalling between 
different cells (60).  
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The array of resources dedicated to maintaining specialised protein function in the 
cell is not only an indicator of the importance of obtaining (and maintaining) the 
native fold, but also of preventing misfolding events from accumulating. Genetic 
abnormalities that perturb the folding landscape of a single protein can manifest in 
significant metabolic defects, leading to disorders such as lysosomal storage diseases 
(61). Perhaps the most well-known loss-of-function protein misfolding disease is 
cystic fibrosis, where mutations within the CFTR chloride ion channel prevent 
Figure 1.2.2 Integrated protein quality control mechanisms within the cell.  The cell has 
developed a myriad of compartments and processes to alleviate protein misfolding. 
Terminally misfolded proteins can be degraded through the ubiquitin proteasome system, by 
forming cytosolic p body inclusions that sequester into IPOD for phagosomal degradation or 
chaperone –mediated autophagy in the lysosome (CMA). Proteins can also be ubiquitin-
tagged for degradation during translation, or retro-translocated from the ER (ERAD) for 
proteasomal degradation. P bodies can also position themselves into juxtanuclear inclusions 
(JUNQ), where they can undergo chaperone-assisted refolding or be degraded. 
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correct protein folding. Many of the clinical features of cystic fibrosis are the result 
of this single protein misfolding event (62). These diseases help illustrate the 
biological impact of incorrect protein folding. 
 In addition to loss-of-function protein misfolding disorders, there are also an 
expanding class of protein misfolding diseases that are more typically characterised 
by a gain-of-toxic function of misfolded protein aggregates. These diseases, known 
as amyloid, are unique in that disease progression is thought to be due to the aberrant 
activity of proteins that can adopt toxic conformations (1, 2, 4). Amyloid disorders 
are commonly associated with ageing due to the decline in protein homeostasis that 
allows the accumulation of disease-associated proteins and their subsequent 
‘misfolding’ into tightly packed, and highly ordered macromolecular assemblies. 
The formation of these species can be thought of as taking place within a partitioned 
energy landscape not normally accessible within a healthy cellular environment (63) 
(Figure 1.2.3). The assembly of amyloid is driven by the formation of inter- as 
opposed to intra-molecular contacts that usually define protein folding. It is the 
formation of these species that is often associated with within the onset of amyloid 
disease, and not the loss of the native function of the misfolded protein, as is the case 
for the protein misfolding diseases discussed above. 
Figure 1.2.3 The alternative folding landscape of amyloidogenic aggregates.  
Amyloidogenic precursors can be partitioned within a separate energy landscape that is 
dominated by intermolecular contacts that drive amyloid formation. Proteins can 
transition to the amyloid landscape via a partially folded conformation that leads to the 
exposure of aggregation prone sequences. Molecular chaperones have evolved to prevent 
to the prolonged exposure of aggregation-prone sequences during protein folding to 
prevent amyloid formation taking place Adapted from (63). 
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1.3 Amyloid – A beginners guide 
The term amyloid is actually a misnomer, originally coined due to the unusual 
capacity of tissue deposits to develop a blue colour upon binding to an iodine stain in 
the presence of sulphuric acid (64). This property was described over 150 years ago 
in the first documented cases of amyloid diseases, with the name giving reference to 
the starch-like behaviour of the deposits characteristic of the disease. It has 
henceforth been established that this starch-like behaviour of amyloid in vivo is due 
to the associated carbohydrates (glycosaminoglycans (GAGs)) that bind tightly to 
amyloid assemblies (3). Although it is now a well-known fact that deposits are 
overwhelmingly composed of protein, the term amyloid has remained very much in 
use (65). 
1.3.1 Generic features of amyloid fibrils 
All amyloid assemblies share a common set of characteristics. This is despite the 
large-scale sequence heterogeneity of amyloid precursors. The ability of a wide 
range of sequences to form amyloid has also raised intriguing questions as to 
whether the amyloid fold is theoretically accessible from almost any polypeptide 
sequence (4, 66, 67). These generic features are also used to ascertain whether a 
newly described aggregate is an amyloid or not. Chief among these properties are the 
long, unbranched filamentous structures seen upon observing amyloid fibrils using 
techniques such as transmission electron microscopy (EM) or atomic force 
microscopy (AFM) (Figure 1.3.1a). The core of the amyloid fibril is typically rich in 
β-sheet, whereby β-strands are arranged perpendicularly to the length of the fibril 
axis in a highly ordered fashion (Figure 1.3.1b). This arrangement, known as cross-β, 
is often diagnosed by the conserved X-ray fibre diffraction pattern observed for a 
large subset of fibril types (68). Two scattering arcs are usually seen, ~4.8Å 
meridonal reflections and ~10 Å equatorial reflections, which arise from the highly 
regular molecular spacings of intra-sheet β-strand packing and the inter-sheet 
distance of two individual units that typically associate to generate the final fibril 
architecture (68, 69) (Figure 1.3.1c). The core is frequently arranged in a parallel in-
register array, whereby β-strands are bound tightly by neighbouring segments 
through side chain and backbone hydrogen bonds. Protruding side chains tend to 
inter-digitate between two sheets to form a self-complementing, dry interface (70, 
71). This vast hydrogen bonding network is thought to be responsible for the 
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remarkable thermodynamic stability of amyloid fibrils, which make them looked 
upon favourably as materials within the nanotechnology industry (72–76). 
Amyloid fibrils also tend to display conserved tinctorial properties, including 
exhibiting red/green birefringence under polarised light upon binding the dye Congo 
Red (77, 78), binding and increasing the fluorescent properties of aromatic 
compounds such as Thioflavin T (79) and they usually contain a conformational 
epitope recognised by the monoclonal W01 antibody (80, 81) (Figure 1.3.1d-f). 
Figure 1.3.1 The generic morphological features of amyloid fibrils.  Amyloid fibrils exhibit 
a classic, unbranched filamentous morphology as viewed by EM (a) and AFM (b, scale bar 
1µm). (b) X-ray crystal structure of the steric zipper motif of an amyloid fibril core (70). (c) 
The X-ray fibril diffraction pattern of TTR(105-115) amyloid fibrils. Red and white arrows 
indicate the meridonal and equatorial scattering arcs respectively (69). (d) Amyloid fibrils 
formed after an initial lag phase bind and enhance the fluorescence of ThT. (e) Congo Red 
red/green birefringence exhibited under polarised light upon binding amyloid (82). (f) 
Amyloid fibrils composed of a range of precursor sequences bind the monoclonal W01 
antibody. Monomer controls are in grey (80). 
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Many of these properties as conserved between amyloid fibrils isolated ex vivo and 
those which are formed from the same precursor sequence in vitro (82). These 
similarities make amyloid fibrils formed in vitro an invaluable tool for elucidating 
fundamental processes that underlie amyloid formation and mechanisms of amyloid-
associated toxicity. 
1.3.2 Structural heterogeneity of amyloid fibrils at the macroscopic level 
Although the above features are required for an aggregate to be defined as amyloid, 
as the number of known diseases in which insoluble assemblies form increases, so 
does the polymorphism within the resulting fibril architecture. The definition of 
amyloid has become looser in order to encompass fibril polymorphs that exhibit 
large degrees of heterogeneity from these classical amyloid properties (19, 83). 
These fibril types are often called ‘amyloid-like’ and display many of the 
pathological and biophysical features that one expects from a true amyloid, such as 
the presence of the cross-β spine (84–86). Amyloid-like fibrils include those formed 
as intracellular inclusions, or in vitro, as traditionally amyloid is a term associated 
with the extracellular deposition of insoluble, highly ordered aggregates (1, 71, 85).  
Amyloid polymorphisms can be observed at the level of secondary structure and are 
not restricted to structural heterogeneity observed between assemblies composed of 
different precursors. Fibrils composed from the same precursor have been shown to 
exhibit entirely different packing arrangements within the fibril core. For example, in 
addition to the parallel in-register cross-β array described above, A40 fibrils have 
been shown to form out-of-register, parallel cross- cores, or entirely antiparallel 
cross-β architecture (87–89). These large-scale polymorphisms have been most 
frequently described within amyloid fibrils composed of smaller peptides (70, 88, 
90–92), but polymorphisms are still observed in fibrils formed from longer 
amyloidogenic precursor sequences (87, 93–97). Numerous factors, including ionic 
strength and pH influence the final fibril architecture. Therefore, assembly 
conditions can promote the formation of entirely distinct fibril morphologies which 
often, but not always, retain the classical hallmarks of amyloid (98–104). 
Polymorphisms have also been observed within fibril populations grown in identical 
solution conditions (87, 91). 
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Structural polymorphisms of amyloid fibrils formed from the same precursor can 
significantly influence the biophysical properties of amyloid assemblies (93, 94, 98, 
105–112). The consequences of propagating a distinct polymorph can also manifest 
in unique biological activities. For one such example, two fibrillar polymorphs of α-
synuclein, the causative agent of Parkinson’s disease, possess entirely distinct 
seeding capacities in vivo (108). Seeding is the process by which amyloid fibrils 
catalyse the aggregation of soluble pools of the amyloidogenic precursor. Similarly, 
distinct α-synuclein ‘strains’ were shown to induce differing degrees of aggregation 
of not just endogenous α-synuclein, but also of pathological tau inclusions (108). 
Different fibrillar polymorphs found to predominate within the brains of Alzheimer’s 
patients have also been suggested as a possible explanation for the difference in 
disease progression between sufferers (113). The difference in seeding capacity can 
have dramatic consequences for the propagation of ‘infectious’ amyloids, thus 
enhancing or repressing the progression of the disease. Whether the predominant 
fibril morphology propagating within patients of Alzheimer’s disease can be used to 
serotype the severity of disease is now being investigated (113). Amyloid 
polymorphism may therefore be an important determinant of the aggressiveness of 
disease, which adds an additional layer of complexity towards treating amyloid 
disorders. The variety of pathological mechanisms associated with amyloid 
polymorphisms is further compounded by the newly emerging phenomenon of co-
polymerisation, or cross-seeding, of distinct precursors and by the ability of familial 
variants of precursors to favour certain polymorphs over another (87, 90, 114–119). 
Nevertheless, most amyloid and amyloid-like structures exhibit a parallel, in-register, 
cross-β core. The greatest degree of heterogeneity is present at the quaternary level, 
where proto-filaments can arrange into an array of higher-order assemblies. The 
ability to build atomic models of amyloid fibrils has only become a reality within the 
last decade. This is primarily due to advances in structural techniques like cryo-
electron microscopy and solid-state NMR (120). These techniques have helped to 
reveal differences in parallel, antiparallel, and β-helical cross-β arrays that can 
arrange to generate structures that differ significantly, but still retain the majority of 
the classical amyloid characteristics as described above (87, 91, 92, 95, 97, 113, 
120–125). A selection of amyloid fibril atomic models are shown in Figure 1.3.2.  
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Figure 1.3.2 The structural polymorphisms within amyloid fibrils.  (a) The β-solenoid 
arrangement of the Het-S amyloid-like fibril core solved by solid-state NMR (121). (b) 
Cryo-EM-derived electron density map of wt-β2m fibrils formed at pH 2.0 (92). The 
fibril is composed of 6 protofilaments arranged in two banana-like arrays as seen from 
the top-down view. (c) Structural polymorphisms of Aβ1-40 fibrils shown with fibres 
containing two-fold or three-fold symmetry (95, 97). Models were derived using ss-
NMR. (d) Model of the α-synuclein amyloid fibril derived from ss-NMR and HDX-
NMR (125). Each tricoloured filament is composed of stacked α-synuclein monomers 
arranged in a parallel in-register array. (e) Polymorphism of TTR (105-115) peptide-
derived amyloid fibrils seen to propagate in identical solution conditions. Below shows 
cross-sectional view of the fibril cores (91) 
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1.3.3 Exploiting the cross-β fold in nature – functional amyloid 
While the formation of amyloid is most often associated with disease, there has been 
a significant increase in the discovery of ‘functional’ amyloids. Functional amyloids 
are normally soluble proteins that adopt an alternative conformation in order to 
exhibit altered function. Functional amyloids were first described in yeast, and are 
perhaps more commonly known as prions. The conversion of soluble proteins into 
insoluble and inheritable amyloid-like fibres is an established epigenetic mechanism 
of phenotypic inheritance though the adoption of an altered protein conformation 
(126). The cytoplasmic inheritance of amyloid-like aggregated prions in yeast 
normally provides a selective advantage for the cells in which they are propagated 
(127).  
Yeast prions contain a prion-determining domain that is dispensable for the function 
of the ‘soluble’ domain. The typical physiological function of the non-prion-like 
domains vary and include regulatory control of transcription or translation of 
particular subsets of genes. For example, the yeast prion Ure2p expressed in 
Saccharomyces cerevisiae, is a transcriptional repressor of Gln3, a protein involved 
in nitrogen catabolism. When nitrogen sources are rich soluble Ure2p suppresses 
Gln3 transcription (128). Under conditions where nitrogen sources becoming 
limiting, however, Ure2p forms amyloid-like fibrils, thus preventing the 
transcriptional repression of Gln3 to allow the host to exploit alternative nitrogen 
sources. In a second well-known example in yeast, the formation of amyloid-like 
fibrils from Sup35 takes place in particular strains of S.cerevisiae. Sup35 sequestered 
into insoluble amyloid-like assemblies reduces the efficiency of global translation 
termination. Reducing the efficiency of translation termination promotes phenotypic 
diversity by allowing the expression of previously untapped biological code (129, 
130). Although the suggestion these mechanisms of epigenetic inheritance were once 
a laboratory artefact, more recent examples have determined the existence of 
epigenetic prions in a variety of wild yeast strains. The formation of prions confer 
selective advantages within a wide range of environmental conditions (131–133). 
The rapid conversion of soluble proteins into prion-like aggregates and back can be a 
fluid process, allowing the yeast to optimise its proteome in response to 
environmental triggers. In many ways inheritance and persistence of a prionogenic 
trait is a mechanism of adaptive memory (134) (Figure 1.3.3). 
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In addition to yeast prions, several high profile examples of functional amyloid in 
more complex eukaryotes are beginning to emerge. In mammals, peptidic hormones 
have been found to be stored in high concentrations as amyloid fibrils within 
secretory granules of the endocrine system (135). Mammalian amyloid-like fibrils 
composed of RNA and RNA-binding proteins were recently discovered in vivo 
localised within cell nuclei (135–138). The sequestration of such biological 
molecules into highly dynamic heterogeneous assemblies is thought to provide a 
mechanism for the control of gene expression in response to environmental changes. 
Sequestering these protein:RNA complexes into amyloid assemblies provides a 
means of compartmentalisation without the presence of a lipid membrane, thus 
allowing for complex dissolution to take place rapidly in order to effect an 
immediate biological response. Amyloid fibrils are not the only type of aggregate 
deemed to be a functional amyloid. In Drosophila melanogaster amyloid-like 
oligomers composed from the cytoplasmic polyadenylation-element binding protein 
Orb2 have been implicated in the persistence and maintenance of long term memory 
(139, 140). These are just a selection of functional amyloids that continue to be 
discovered and classified. Additional examples from an array of organisms can be 
found in the following references (141–145).   
Figure 1.3.3 Prion-based epigenetic inheritance of phenotypic traits.  Starting from the top 
left, yeast cells lacking the inherited prion state are favoured under condition B. 
Spontaneous processes confer a selective advantage upon prion formation. The prion strain 
is especially favoured under condition A, thus prion inherited cells dominate. The 
metastability of the prion state means a small pool will convert back to the prion negative, 
which upon changing back to condition B is re-favoured, thus ensuring the yeast thrives 
under both conditions. Inspired from (134). 
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1.3.4 Formation of disease-associated amyloidogenic species 
The previous sections have described the generic and heterogeneous features of 
pathogenic amyloid fibrils and also the emerging concept of functional amyloid, but 
how does amyloid form? The majority of amyloidogenic proteins display nucleation-
dependent growth kinetics in vitro (146–149), whereby a lag phase - a dynamic 
equilibrium of soluble oligomeric species formed from a partially or fully 
unstructured monomeric conformation - precedes an exponential growth phase, 
where monomers and oligomers are rapidly consumed via a mechanism of templated 
elongation at the nucleating particle ends (Figure 1.3.4a). This primary nucleation 
process can be readily monitored through ThT fluorescence. The lag phase of 
amyloid fibril assembly can be bypassed by the addition of preformed seeds, or 
fibrils (Figure 1.3.4a – black dashed line). Exhibiting a capacity to seed is another 
defining characteristic of an amyloid. The nucleating particles, such as fibrils, can 
multiply through secondary nucleation processes to further increase the rate of 
elongation (99, 150, 151). The most common secondary nucleation pathway is 
through fibril fragmentation, where additional fibril ends are generated to increase 
the elongation rate via the more rapid consumption of fibril subunits (Figure 1.3.4b). 
In a conventional ThT fluorescence experiment, the increased contribution of 
secondary nucleation pathways towards amyloid formation manifests itself by a 
steeper transition from the lag to the stationary phase (Figure 1.3.4b). Additional 
mechanisms of secondary nucleation will be discussed in greater detail later (152).  
This overview of how amyloid formation proceeds is the most simplistic and generic 
mechanism for describing the aggregation of many amyloidogenic precursors. There 
are, however, considerable differences within aggregation landscapes, such as what 
may be the rate-limiting step of amyloid formation (146, 153, 154). This can either 
be the formation of an energetically unfavourable nucleating particle, the 
conformational conversion of an existing oligomer, or even the dissociation of stable 
native complexes to release the aggregation-prone precursor in a process known as 
downhill polymerisation (146, 153, 154).  Each parameter of the aggregation kinetic 
profile, such as the length of the lag phase, the rate of elongation and the final fibril 
yield, are highly dependent on the precursor sequence as well as the solution 
conditions used to promote aggregation in vitro (99, 155, 156).  
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Much effort has been afforded to decipher the mechanisms of amyloid formation and 
to elucidate the structural properties of soluble species that form within the lag phase 
(Figure 1.3.4a). Reasons for this are two-fold; firstly, understanding the initial events 
that promote amyloid formation would mean that the fundamental processes 
underlying aggregation can be targeted for therapeutic intervention, and secondly, 
soluble species that form during the lag phase of amyloid fibril formation, not the 
aggregation end-stage products, are purported to be the primary source of 
cytotoxicity in a wide range of amyloid disorders (see next Section). In addition, 
especially for proteins with defined native structures, the fundamental processes that 
drive the conformational conversion of a metastable, soluble, natively folded protein 
into a partially folded, amyloid-competent state is a question of fundamental intrigue 
within the amyloid field that remains to be fully understood (156–162). 
Figure 1.3.4 The amyloid aggregation cascade.  (a) Typical ThT 
fluorescence kinetics observed during de novo (red line) and 
seeded (black dashed line) fibril formation. (b) Secondary 
nucleation mechanisms increase the rate of elongation. 
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1.3.5 Amyloid- oligomer toxicity: a case study 
As just mentioned the species purported to be the most cytotoxic are those that form 
during the lag phase of amyloid assembly. Initially, the general consensus was that 
oligomers derived from amyloidogenic precursors display conserved structural 
characteristics, indicating a potential generic toxicity mechanism. This was, in part, 
due to two pioneering studies performed between 2002-2003 which showed that 
sequences derived from proteins known to be involved in amyloid disease, along 
with several that were not, were able to form species that caused toxicity in cultured 
cells (20, 21). Between them, these studies indicated that soluble species are 
typically spherical in origin, ranging from 10 – 70 nm in size, and display a 
conserved A11 antibody binding epitope. Importantly, these species were 
significantly more cytotoxic than their fibrillar counterparts, and toxicity could be 
prevented by pre-incubating oligomers with the A11 antibody prior to addition to 
cells (21). These studies paved the way for the hypotheses of amyloid toxicity that 
largely persists today; oligomers are toxic, while fibrils are essentially inert. 
Subsequently, it has become obvious that whole arrays of soluble species are capable 
of forming within the lag phase, most of which display varying degrees of toxicity 
(Figure 1.3.5). These species can be broadly characterized as pre-fibrillar or fibrillar, 
which is a reflection on their gross morphology. In short, pre-fibrillar oligomers 
(PFO) tend to display the A11-binding epitope, while fibrillar oligomers (FO) bind 
an OC antibody (163).  The OC antibody also recognizes the mature amyloid fibril, 
thus suggesting FOs may be structurally reminiscent of the mature amyloid fibril. 
Within each class of oligomer, however, there exists a high degree of structural 
heterogeneity, even for oligomers composed from the same precursor sequence. 
The best examples of oligomer heterogeneity arising from a single precursor come 
from investigations performed on A peptides. This is largely due to the volume of 
research performed on these sequences due to their association with Alzheimer’s 
disease. Within the lag phase of A amyloid assembly, species ranging from dimers 
to Alzheimer’s Derived Diffusible Ligands (ADDLs – 24mers) have been reported to 
form and cause toxicity when applied ectopically to cellular models of disease (23, 
164, 165). In between, the array of different species that have been classified include 
trimers, 5-6mers, low number oligomers (LNOs), globulomers (12mers), 
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amylospheroids (APSDs), A*56 oligomers, annular protofibrils, A40:42 mixed 
oligos and transglutaminase 2-induced oligomers (21, 23, 166–174). Interestingly, all 
of these oligomer preparations have been shown to inhibit long-term potentiation 
(LTP) in hippocampal brain slices, a process thought to mediate the decline in 
cognitive function in Alzheimer’s patients. In addition, all of the species (apart from 
APSDs) have been shown to bind with varying degrees of affinity the A11 antibody 
and are predominantly spherical in character. This is where the similarities between 
distinct species end, as the different species contain varying degrees of unstructured 
and/or parallel or anti-parallel -sheet content, as well as being either on or off-
pathway towards mature amyloid fibril formation (25, 175). The formation of each 
species in vitro also generates a range of 1) stoichiometries, especially for larger 
aggregates (e.g. granular protofibrils), and 2) conformations for smaller ones (for 
example, dimers). The dynamism, range of stoichiometries and transient nature of 
oligomers has (for the most part) precluded their atomic-level characterization. 
Although the toxic effects of oligomers are undeniable, with several having been 
isolated from the brain tissue of Alzheimer’s patients (173, 176, 177), the sheer 
variety of species that form within the aggregation landscape make targeting 
oligomeric species as a therapeutic strategy in any amyloid disorder highly 
challenging. This is further complicated by the ability of species to readily 
interconvert between different structures and the potential co-existence of different 
species in vivo (Figure 1.3.5) (25). The multiple A-derived peptide fragments that 
are known to co-aggregate with full length A40-42 also significantly increases 
oligomer heterogeneity (153, 167, 178). In addition, as mentioned previously, there 
is another class of oligomers that have also been shown to induce cellular defects. 
These oligomers, known as FOs, share a greater degree of structural homology to 
mature amyloid fibrils. The structural similarities of FOs and fibrils, such as the 
appearance of cross- architecture, suggests FOs may form at later stages of the 
aggregation landscape (24, 179). 
Despite this section detailing A-derived oligomers, heterogeneity is observed 
within all amyloidogenic cascades, including -synuclein, the causative agent in 
Parkinson’s Disease (180–187). Oligomers composed of -synuclein are also 
dynamic. A recent study showed that oligomers formed of -synuclein were able to 
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interconvert between two structurally distinct types (188). The formation of a more 
tightly-packed, protease resistant oligomer led to an increase in the generation of 
reactive oxygen species in neurons – a key feature of Parkinson’s pathology – while 
less compact oligomers were relatively innocuous (189). Similar differences are seen 
for oligomers composed of Hyp-FN, a yeast protein, which can form two structurally 
similar, but distinct, aggregate pools. Conversely to what was found for -synuclein, 
Hyp-FN oligomers that have a higher degree of structural flexibility and enhanced 
surface hydrophobicity were more cytotoxic than their rigid counterparts (190). 
1.3.6 Mechanisms of toxicity of soluble amyloidogenic species 
In general there are two main mechanisms of amyloid-mediated toxicity. The first, 
which has been primarily linked to amyloid deposited extracellularly, is through 
membrane disruption (191–193). The ability of amyloid to disrupt membranes has 
been a consistent theme irrespective of precursor identity. Moreover, amyloid-
membrane interactions have been well documented both in vitro and in cellular and 
animal models of amyloid diseases (170, 184, 194–197). Despite the conserved 
affinity of amyloid for membranes, the mechanisms that lead to membrane 
disruption are quite diverse (Figure 1.3.7). Pore-forming oligomers have been 
Figure 1.3.5 Conformational and stoichiometric plasticity of soluble intermediates of 
amyloid fibril assembly.. An array of species have been isolated in vitro, which may be on- 
or off-pathway to amyloid fibril formation. Different coloured oligomers represent altered 
sub-unit conformations as well as heterogeneous stoichiometries. Each species can induce 
toxicity via independent mechanisms, while several may co-exist at any one time. Fibrils 
may also act as reservoirs of soluble intermediates in vivo (dashed lines). 
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identified for a range of different amyloids (198). Oligomeric pores that pre-form in 
solution and embed within the lipid bilayer cause in vitro membrane disruption 
and/or calcium influx at the plasma membrane (Figure 1.3.71) (190, 199, 200). For 
other amyloidogenic proteins, such as hIAPP and α-synuclein, unstructured, 
hydrophobic monomers embed within the lipid bilayer where amyloid formation 
proceeds (Figure 1.3.72-3) (201–203). Embedding within the lipid bilayer can lead to 
a conformational conversion of the precursor protein into an amyloid-competent 
state. The growth of amyloid aggregates at the membrane surface damages 
membrane integrity, leading to disruption (201, 204). Similar nucleation events at 
the membrane surface have been shown to generate membrane-active pores, as 
opposed to fibrils, of hIAPP (196, 205). The formation of pores within the 
membrane, as opposed to pre-formation in solution, has been proposed to induce a 
greater degree of membrane disruption (173). Recent X-ray crystallographic studies 
have elucidated the structure of a potentially pore-forming oligomer composed of a 
fragment of the amyloidogenic -crystallin (Figure 1.3.6). The oligomer exhibited 
many of the properties of other oligomeric species, including binding to the A11 
antibody and causing toxicity in cell models. The crystallographic structure revealed 
the oligomer to be formed from 6 antiparallel -strands (known as cylindrin), 
offering intriguing insights into how pore-forming oligomers may induce membrane 
disruption (206). 
Figure 1.3.6 Atomic resolution structure of a toxic amyloidogenic oligomer.  (a) Rolled 
out schematic representation of ‘cylindrin’ structure, showing β-strand orientation and 
main chain and salt-bridge mediated hydrogen bonds between strands (yellow and blue 
dashed lines). (b) Paired strands form anti-parallel dimers that orientate about a three-fold 
axis of symmetry within the cylindrin structure. (c) Side chain positioning within the 
cylindrin structure with H bonds shown in yellow. Taken from (206). 
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The cylindrin structure is only applicable to oligomers of sufficiently low order (for 
example, hexamers vs. 20-30mers) that are rich in -sheet secondary structure. 
However, as many oligomeric species are composed of highly unstructured material 
(190). Nevertheless, unstructured oligomers still induce membrane disruption. 
Several mechanisms have been proposed as to how this may be facilitated. As 
unstructured oligomers can exhibit high degrees of surface exposed hydrophobicity, 
it is more entropically favourable for these types of species to embed within the 
hydrophobic bilayer (Figure 1.3.74). Embedding of a large, bulky protein oligomer is 
proposed to cause membrane thinning, which can cause membranes to become leaky 
(207–210). Membrane leakage has also been proposed to be mediated in vivo via 
receptor-mediated mechanisms. Oligomers have been shown to bind to cell surface 
receptors as opposed to directly embedding within the bilayer. Recent experiments 
have proposed that PrP acts as a cell-surface receptor for aggregates of A, 
potentially mediated through copper binding (211–213). Similar receptor-mediated 
mammalian cell surface interactions have also been proposed for non-pathological, 
but toxic, amyloid assemblies composed from the yeast prion Sup35 (214). 
Although membrane interactions have been extensively documented in vitro and in 
cells, in vitro membrane disruption does not always correlate with cytotoxicity (197). 
This is not surprising when considering the long incubation times over which 
amyloid diseases emerge. Sometimes symptoms of disease can take decades to 
manifest, which would not be the case if cellular membrane integrity were so easily 
Figure 1.3.7 Mechanisms of amyloid-mediated membrane disruption.  (1) Oligomeric pores 
can form due to partial denaturation of the native state of an amyloidogenic precursor (blue 
to red). (2) Partially structured or intrinsically disordered proteins can undergo 
conformational conversion upon embedding within the bilayer to form pores. (3) IDPs and 
unstructured monomers that interact with the bilayer can also seed the formation of non-pore 
like aggregates, leading to membrane thinning and leakage. (4) Non-pore aggregates can 
also form in solution prior to embedding within the bilayer. (5) Finally, aggregates can also 
traverse the membrane, enabling seeding and propagation of the amyloid. 
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compromised. This is not meant to downlay the importance of amyloid-lipid 
interactions in disease, but just to suggest that the cellular effects may be more subtle 
than those observed in vitro using liposomes (197). The majority of in vitro studies 
are performed at protein concentrations that would typically exceed those found in 
vivo, and as aggregation of amyloid is normally a concentration dependent process 
(146, 148, 215), the concentration of toxic oligomers are likely to be much higher in 
vitro. Nevertheless, the formation of ionic pores and oligomer-membrane 
interactions has been documented at physiologically relevant concentrations (25, 
213). Indeed, apart from the consequences outlined above, amyloid-lipid interactions 
must take place in vivo in order for the prion-like propagation of infectious amyloid 
particles (Figure 1.3.75). For a series of different amyloid-like aggregates, including 
tau, -synuclein and SOD1, infectious particles are able to transmit from the 
endocytic pathway to the cytosol, where they can seed new amyloid formation (98, 
216–218). This must take place through the disruption of cellular membranes 
without any immediate consequences for the viability of cells (108, 188, 216, 218, 
219). Evidence to support endosomal membrane disruption is supported by the 
release of cathepsins into the cytosol upon incubation with A aggregates (220). 
The second mechanism of amyloid toxicity is generally mediated via cytosolic 
inclusions through the disruption of cellular proteostasis (Figure 1.3.8). Large 
intracellular aggregates have been shown to co-aggregate with various cellular 
factors that lead to a loss-of-function of the co-aggregated protein. Which cellular 
proteins interact within inclusions appears to be functionally indiscriminate, with 
various cellular pathways affected as a result (221). An enrichment of proteins 
involved in mechanisms of proteostasis are commonly found enriched with 
inclusions, however. These can include molecular chaperones and factors critical for 
ubiquitin-mediated proteasomal degradation. This makes sense, as cytosolic 
inclusions are often enriched in ubiquitin, but their increased stability upon 
aggregation means they are not effectively cleared (222–224). What’s more, 
sequestration of cellular factors by cytosolic inclusions does not always manifest in 
obvious metabolic defects until secondary stresses appear (225). In a study 
performed in yeast, cytosolic huntingtin exon 1 (HTT) inclusions were found 
enriched with the molecular chaperone Sis1p. Toxicity was not observed until a 
secondary, non-amyloidogenic inclusion of carboxypeptidase Y (CPY) was formed. 
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In the absence of HTT inclusions, CPY aggregates were degraded quickly, but 
competition for cellular resources upon HTT inclusion formation prevented 
clearance of CPY and led to cellular toxicity. Toxicity could be reversed upon over-
expression of Sis1p, which led to the clearance of CPY aggregates, but not HTT 
aggregates. This chaperone competition has also been shown to impede clathrin-
mediated endocytosis through the sequestration of intracellular Hsc70. Endocytic 
trafficking defects were observed in the presence of a variety of different cytosolic 
inclusions, including those of ataxin-3, SOD1 and HTT (226). Chaperone 
competition as a mechanism of amyloid toxicity could well be applicable to all 
amyloid diseases. It can also explain why so many amyloid diseases are age-related; 
as mechanisms of proteostasis decline, depleted chaperone pools are overwhelmed 
by increased aggregate deposition, reducing the clearance of misfolded, aged and 
non-functional proteins (6, 7). The reduced clearance of proteins may then induce a 
range of cellular defects. 
The disruption of endocytic trafficking (as outlined above (226)) is especially 
pertinent for neurodegenerative amyloid disorders. The correct trafficking of 
signalling molecules is fundamental to the maintenance of communicative neuronal 
networks. The disruption of these processes is likely to be a key contributor to the 
onset of symptoms. Similar trafficking defects have been observed in models of 
Alzheimer’s and Parkinson’s diseases. Aggregates of A were shown to perturb the 
function of PICALM, a scaffold protein required for the correct assembly of clathrin-
coated vesicles (16, 227). In yeast and C.elegans models of Parkinson’s disease, -
synuclein cytosolic inclusion formation induced a range of lipid-associated defects 
(228, 229). In both instances, correcting trafficking defects using small molecules 
was able to ablate amyloid toxicity in yeast and in Parkinson’s disease patient-
Figure 1.3.8 Proteostatic imbalance as a mechanism of amyloid-induced cytotoxicity. 
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derived induced pluripotent stem cells (230–232).  
Disruption of cellular homeostasis is not only restricted to the sequestration of 
cytosolic chaperones. Over-expression of aggregation-pone PrP
SC
 in the ER 
attenuates translation through activation of UPR in mice. Restoring translation by 
inhibiting phosphorylation of eIF2α delays the onset of PrPSC-induced cell death, 
without reducing PrP
SC
 aggregation (233). PrP
SC
 aggregates are proposed to mediate 
toxicity by preventing the synthesis of critical cellular proteins to replace those that 
have been turned over (233). Translation attenuation as a mechanism of amyloid 
toxicity has also been observed for other aggregates (234, 235). Irrespective of 
whether mediated by translation attenuation or chaperone competition, amyloid 
toxicity in both of these instances is mediated through the disruption of critical 
cellular pathways leading to a loss in concentration of functional proteins. 
1.3.7 Amyloid fibrils – inert end products of aggregation? 
The cytosolic inclusions mentioned in Section 1.3.6 are often insoluble in nature and 
can display morphological features similar to those observed in amyloid fibrils. This 
observation raises questions regarding whether amyloid fibrils are truly inert (28), or 
whether they contribute towards toxicity via mechanisms such as chaperone 
competition. Several amyloid fibrils have been shown to interact with a range of 
molecular chaperones in vitro (221, 236–239). For example, the interaction of A 
amyloid fibrils with ATP-independent chaperones has been shown to reduce the rate 
at which fibril subunits exchange with soluble species (237, 238). The reduced rate 
of subunit exchange upon chaperone binding illustrates the functional relevance of 
amyloid fibril:chaperone interactions. Therefore, amyloid fibrils deposited 
extracellularly, as well as intracellular inclusions such as those described above, may 
mediate elements of chaperone competition-based toxicity through the sequestration 
and inhibition of chaperone function. 
Can amyloid fibrils illicit toxicity via other mechanisms? As mentioned above, 
amyloid fibrils exhibit dynamic behaviour post-formation by subunit exchange with 
material that remains soluble under fibril growth conditions. Can the extent to which 
soluble species exchange with fibrils be modulated in order to increase the 
concentration of potentially membrane-active soluble species in solution (Figure 
1.3.9c)? For functional amyloid, the formation of (some) amyloid provides a means 
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of membrane-free compartmentalization to suppress protein function under certain 
conditions. The dissolution of these amyloid assemblies upon encountering specific 
environmental triggers allows resolubilised protein to mediate a rapid biological 
response. (136–138). Similarly, amyloid fibrils composed of peptidic hormones 
dissolute into functional, soluble units upon encountering different physiological 
conditions once trafficked and released into the extracellular environment (135, 
240). There are several more recent examples describing the role of dynamic 
amyloid formation, including controlling the ability of yeast to acquire facultative 
multi-cellularity, and higher order assembly of metabolic enzymes into filamentous 
assemblies in response to pH induced starvation (133, 241). In the latter, assembly 
into insoluble filaments inactivates the enzymes to avoid excessive consumption of 
cellular resources when nutrient supplies are deficient. 
As mentioned, the dynamic nature of pathological amyloid fibrils is an established 
fact. A study in 2005 was the first to document such activity in fibrils assembled 
from an SH3 domain. Using NMR and hydrogen exchange mass spectrometry, 
Carulla et al revealed that exchange within the fibril was dominated by a mechanism 
of dissociation and re-association of soluble species in solution at an exchange rate 
of 1x10
-4
.s
-1
 (242). Similar observations were subsequently made for fibrils 
composed of A and -synuclein, where dissociating species for the latter were 
cytotoxic oligomers (188, 243). Although the reported exchange rates are relatively 
slow (complete exchange of subunits over a time scale of weeks), exchange of 
soluble species was only investigated under the conditions employed for fibril 
growth. The exchange of species may be accelerated by subtle changes in solution 
conditions, a situation that is likely to be reflective in vivo, as extracellular amyloid 
fibrils can be routinely trafficked to environments that are distinct from those in 
which they form (188, 216–218, 220, 244–246).  
In addition to amyloid fibrils acting as reservoirs for cytotoxic oligomers (Figure 
1.3.9), the fibril surface has been shown to be an important driving force in the 
propagation of cytotoxic species (Figure 1.3.9d). A amyloid fibrils were recently 
shown to increase the pool of soluble intermediates when incubated in the lag phase 
of amyloid fibril formation, through a mechanism of surface-induced conformational 
conversion of monomeric precursors to an amyloid-competent state (151, 152). 
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Secondary nucleation processes such as these illustrate the pathological potential of 
amyloid fibrils in driving the formation of toxic species in amyloid disorders. 
As for soluble intermediates of amyloid assembly, mature amyloid fibrils have also 
been reported to mediate membrane disruption in vitro (Figure 1.3.9). This has been 
shown for fibrils composed of α-synuclein or HTT, where fibrils were shown to bind 
to unilamellar vesicles of a variety of different compositions (247). The binding of α-
synuclein to synthetic vesicles is coincident with calcein dye-release from the 
vesicular interior. Plasma membrane (PM) disruption was also observed upon the 
addition of α-synuclein fibrils to cells, as evidenced by an increase in intracellular 
calcium levels (248). Calcium influx into the cytosol is associated with, among other 
things, the onset of apoptosis. PM disruption was also shown for fibrils composed of 
the yeast prion Sup35. In this instance, PM disruption is modulated by the presence 
of GM-1 expression at the cell surface (214). This shows that fibril-induced PM 
disruption can also be receptor-mediated. PM interactions have also been reported 
for fibrillar assemblies of Aβ, which induce LTP in models of Alzheimer’s disease 
(194). As previously mentioned, disruption of LTP is thought to be the driving force 
behind cognitive decline in patients with Alzheimer’s disease. Aβ fibril-induced LTP 
Figure 1.3.9 Mechanisms of amyloid fibril-mediated toxicity.  (a) Amyloid fibrils have 
been shown to interact directly with, and perturb, the architecture of membrane bilayers.  
(b) Amyloid fibrils composed of Aβ have been shown to release cytotoxic protofibrils 
upon interacting with membranes. (c) Fibrils composed of a range of amyloidogenic 
precursors are also dynamic, with subunits exchanging with soluble material under stable 
conditions. (d) Fibril surfaces have also been shown to be important catalytic surfaces for 
the propagation of cytotoxic oligomers. 
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disruption is independent of PrP, the purported cellular receptor for toxic assemblies 
of Aβ, suggesting that fibril-induced LTP disruption in this instance is mediated by 
direct binding between fibrillar assemblies and the lipid bilayer (212).  
An additional study also observed the reversion of Aβ fibrillar assemblies into 
protofibrillar oligomers upon interacting with biological membranes (Figure 1.3.9b) 
(249). These oligomers were structurally homologous to those that form on-pathway 
to fibril formation in vitro and were shown to induce memory defects in Alzheimer’s 
disease mice models. The different mechanisms by which amyloid assemblies of the 
same precursor induce toxicity may be related to the structural heterogeneity 
observed within mature amyloid fibril assemblies (Section 1.3.2). This supports the 
hypothesis of ‘strain’ dependent phenotypes for amyloid disorder, where the range of 
symptoms observed and the aggressiveness of disease may be related to the 
predominating fibril morphology found in vivo (113).  
1.3.8 How to treat a problem like amyloid? 
Targeting the precursor 
As a result of the multitude of mechanisms of amyloid-derived toxicity, developing 
therapeutic strategies to intervene within this class of disorders is extremely 
challenging. Major research efforts have been focused in understanding the 
mechanisms that underlie aggregate formation in an attempt to find points within the 
amyloid cascade that are most amenable to intervention. The premise of this strategy 
is that preventing the formation of aggregate species will preclude the need to 
intervene downstream of amyloid-mediated toxicity. Intervening at the most initial 
stages also means that the wild-type function of the amyloidogenic precursor can be 
maintained, providing the native fold is stabilised (250). So far, this strategy has 
yielded the only commercially available treatment for any amyloid disorder: Familial 
amyloid neuropathy (FAP).  
FAP is a deadly neurodegenerative disorder caused by the aggregation of 
transthyretin (TTR) into amyloid species (251). TTR in its wild-type form assembles 
into functional tetramers whose physiological role in the blood is to transport holo-
retinol binding protein (252). Like all amyloidogenic precursors that possess a 
defined tertiary or quaternary structure, partial unfolding of the native state is 
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required for TTR assembly into amyloidogenic structures (253, 254). The misfolding 
of TTR is exacerbated by the presence of familial mutations that destabilise the 
native state and accelerate amyloid formation and the emergence of disease (255). 
There are more than 100 familial mutations known to be associated with various 
TTR amyloidoses and, in general, the more destabilising the mutation to the native 
tetramer, the earlier the onset of disease (256, 257). The rate governing step for TTR 
aggregation is related to the kinetic stability of the tetramer, although monomer 
unfolding is required for aggregation to proceed (Figure 1.3.10) (258, 259). 
For FAP, if aggregation of TTR could be prevented by kinetically stabilising the 
native tetramer to prevent monomer dissociation, disease progression could be 
slowed. Evidence for the effectiveness of this strategy is supported by the presence 
of a familial variant that reduces monomer-tetramer dissociation in families that also 
carry TTR familial variants associated with FAP (260, 261). The variant, I119M, 
increases the stability of the native tetramer by increasing the intermolecular contacts 
between the weak dimer interfaces (Figure 1.3.10). To this end, the Kelly group 
developed the small molecule ‘pharmacological’ chaperone, Tafimidis, that 
kinetically traps the native TTR tetramer to prevent monomer dissociation and 
amyloid fibril formation (Figure 1.3.10) (262, 263). They were able to do this by 
targeting the evolutionary conserved but functionally redundant (in humans) 
thyroxine binding pocket that resides within the subunit interface of native TTR, by 
using a structure-guided drug design strategy (264). Tafimidis essentially mimics the 
inhibitory I119M variant by stabilising the dimer contact interface to prevent 
complex dissociation. Phase III clinical trials reported that patients with the V30M 
Figure 1.3.10 Mechanism of action of Tafimids  Transthyretin aggregation into amyloid is 
dependent first upon monomer dissociation from the native tetramer prior to partial 
unfolding of the monomer into an amyloid competent state. The rate limiting step of TTR 
aggregation is tetramer dissociation. Tafimidis binds within the thyroxine binding pocket of 
TTR between the weak dimer interfaces, increasing dimer contacts and improving the 
kinetic stability of the native tetramer. Increasing tetramer kinetic stability prevents 
monomer dissociation and subsequent amyloid formation. Figure taken from (432). 
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FAP-associated familial mutation experienced a slowing down of neurological 
defects associated with TTR amyloidosis, showing the value of pharmacological 
chaperones in treating amyloid disorders (255). 
Despite the obvious success of this strategy, how applicable pharmacological 
chaperones are to other amyloid diseases is unclear. For disorders that require partial 
native state denaturation, such as for lysozyme or immunoglobulin heavy and light 
chain amyloidoses, stabilising the native state against unfolding is a promising 
therapeutic strategy. For other amyloid disorders, amyloigoneic precursors are 
natively unstructured. As little to no information exists regarding the monomeric 
conformations of these proteins, it is not possible to use a structure based design 
strategy to develop small molecule inhibitors of aggregation. Therefore other means 
are required. The most conservative strategies generally involve depletion of the 
monomeric precursor, due to the difficulties in targeting multiple toxic aggregates 
and the concentration dependent aggregation of most amyloidogenic proteins. For 
Aβ in particular, this can involve modulation of the activity of processing enzymes 
responsible for generating amyloidogenic Aβ fragments from the APP 
transmembrane precursor (265). Monoclonal antibodies targeted against monomeric 
or soluble oligomeric forms of Aβ have also been developed as a potential treatment 
(266). The value of monomer depletion in treating Alzheimer’s disease was recently 
shown in two papers that alleviated and even reversed Aβ-induced cognitive 
impairment by up-regulating cellular proteins that increased the removal of Aβ from 
the CNS into the circulating plasma (267, 268). In one of these studies, Cramer et al 
found that Bexarotene, an FDA-approved anti-cancer drug molecule, increased the 
production of apolipoprotein E (ApoE) and reduced the levels of soluble Aβ in the 
brain of Alzheimer’s mice (268). Mutations within ApoE are one of the greatest risk 
factors in early-onset Alzheimer’s (269). Despite the initial and continuing 
excitement surrounding this publication, several studies have attempted to 
recapitulate these findings with varying degrees of success (270–273). In addition, 
the strategy of monomer depletion is certainly not limited to Aβ, but as usual 
provides the greatest variety of examples for the types of approaches being 
developed due to its association with Alzheimer’s disease. Other monomer depletion 
strategies can be found here, such as RNA interference of precursor mRNA levels 
within the cell (274, 275). 
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Remodelling toxic species 
Another heavily investigated strategy for ameliorating amyloid toxicity is to remodel 
soluble oligomeric species into aggregate structures that are benign (26, 276–280). 
There are many different mechanisms of small molecule interference of the 
aggregation cascade, with lead compounds often identified through screening large 
libraries of molecules. Screening programmes are usually performed in vitro and 
typically rely on changes to the aggregation kinetics observed using amyloid binding 
compounds such as Thioflavin T (Figure 1.3.11a and b). Screening protocols that 
observe the kinetics of fibril formation are the most efficient way to identify 
compounds that modulate the aggregation landscape, as little structural information 
is known about intermediates of amyloid formation that cause cytotoxicity; therefore 
structural based drug design strategies cannot be performed (281).  
Most typically, compounds that inhibit or delay the formation of amyloid species are 
Figure 1.3.11 Pharmacological modulation of the amyloid aggregation cascade.   Observing 
the kinetics of fibril formation are typically used to identify compounds that modulate 
amyloid aggregation. Positive hits either result in an increased lag time (a) or a reduction in 
ThT fluorescence amplitude (b), or both. (c) Aggregation can be inhibited by stabilisation of 
the native state (blue arrow). Partially unfolded monomers can also be bound by inhibitors 
that re-direct aggregation towards non-amyloidogenic species (green arrows). Small 
molecules can be used to drive amyloid fibril formation to prevent the accumulation of 
cytotoxic species (orange arrows), or can be used to bind and remodel cytotoxic species 
(yellow and lime arrows). 
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considered hits in screens that utilise fluorescence kinetics of amyloid formation as a 
read-out (281). This manifests in an increased or infinite lag phase (Figure 1.3.11a), 
or a reduction in the amplitude of ThT fluorescence within the stationary phase, due 
to a lower fibril yield (Figure 1.3.11 b). Using a single analytical method such as 
ThT fluorescence is not wholly reliable and can provide false negative results due to 
competitive binding between small molecules and ThT to the cross-β fibril core 
(282). Competitive binding takes place as many amyloid-binding compounds share 
structural homology with ThT, in that they are rich in aromatic functional groups 
(283, 284). The mode of binding is thought to be largely hydrophobic with additional 
specificity provided by salt bridges or hydrogen bonds from small molecule 
functional groups (285). Nevertheless, monitoring the kinetics of amyloid fibril 
formation by ThT fluorescence remains at the forefront of efforts to identify agents 
that can pharmacologically intervene with amyloid aggregation and thus possibly 
prevent or ameliorate disease (281). 
One thing that should be considered when screening for amyloid aggregation 
inhibitors is the inherent heterogeneity within toxic oligomer ensembles. As the 
origins of toxicity within oligomer populations are not defined by a single species, it 
can be difficult to inhibit or divert the aggregation pathway down a route that 
favours the formation of a non-toxic aggregate. In addition, cytotoxic oligomers do 
not have to be those that form on-pathway to fibril formation, so preventing fibril 
formation by diverting aggregation down alternate routes does not necessarily mean 
that toxicity will be ablated (Figure 1.3.11c). For example, the small molecule 
rifamycin-SV was shown to divert the aggregation of β2m into non-amyloidogenic 
species. Despite inhibiting fibril formation, rifamycin-SV-generated aggregates still 
exhibit significant cytotoxic potential (286).   
Nevertheless, compounds discovered by in vitro screening have been reported to 
bind to oligomeric species and inhibit the aggregation cascade, often leading to 
reduced aggregate toxicity (26, 276, 278, 287–290). Similar anti-aggregation 
activities have been reported for a variety of other molecules, including molecular 
chaperones, antibiotics, metal chelators, anti-inflammatory agents and antibodies 
(291–298). In addition, de novo designed β breakers have recently been shown to 
end-cap oligomeric species and prevent further elongation into amyloid fibrils (299, 
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300). These β-breakers were designed based on the structure of oligomeric species 
formed from fragments of Aβ peptides resolved by X-ray crystallography (301–303).  
Small molecules that modulate amyloid toxicity are not restricted to those that 
inhibit amyloid formation (Figure 1.3.11c). Compounds have also been identified 
that accelerate fibril formation, leading to reduced overall toxicity of Aβ peptide 
preparations (26). Similarly, small molecules have been shown promote fibril 
disaggregation, in the process generating soluble species with varying degrees of 
toxicity (277, 304, 305). The competing pathways in which small molecules have 
been discovered to modulate amyloid toxicity further illustrate the heterogeneous 
mechanisms of amyloid toxicity. Therefore, the therapeutic benefit of a single small 
molecule identified through such screens remains to be established. 
Although changes in aggregation kinetics are most usually monitored using 
fluorescent amyloid dyes, other techniques, such as ion mobility spectrometry mass 
spectrometry (IMS-MS), can provide additional information as to the mode of action 
of particular small molecule modulators of amyloid aggregation (306–308). This is 
achieved through the high mass to charge resolution of MS, which can detect 
binding stoichiometries of small molecules to defined oligomeric species, and 
determine whether binding is specific to a particular oligomeric state (Figure 1.3.12). 
Because IMS-MS resolves species based on shape and well as m/z, this technique 
can also determine whether small molecules bind to particular oligomer 
conformations.  
IMS-MS has been used to reveal differences in the mode of aggregation inhibition of 
the well-established small molecule inhibitors silbinin and (-)-epigallocatechin 
(EGCG) against hIAPP aggregation (278, 308, 309) (Figure 1.3.12). Young et al. 
were able to show that although both molecules inhibit aggregation, EGCG binds 
specifically only to monomer conformations of hIAPP, preventing the formation of 
higher order species (Figure 1.3.12c and d). Silibinin, however, binds specifically to 
a particular expanded conformation of monomeric hIAPP. Binding to a specific 
conformer and preventing aggregation suggests this particular monomer 
conformation is an on-pathway species towards fibril formation (308). These results 
show that IMS-MS is more than a simple screening strategy and can reveal 
information regarding the role of particular oligomeric species in the aggregation 
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cascade. Techniques such as this may become the new standard bearer for high 
throughput screening for amyloid inhibitors able to target specific conformers, but 
are not, as yet, routinely used. 
 Intervention through modulation of the proteostatic network 
The strategies outlined so far rely on the premise of the gain-of-toxic function for 
amyloidogenic aggregates. However, a new wave of research has identified the loss 
of protein homeostasis in the presence of aggregates as a defining feature of the 
onset of amyloid disease (6, 8, 250, 310). These were discussed in the latter half of 
Section 1.3.6. Several high profile papers have shown that reversing the defects 
within the proteostatic network can alleviate symptoms associated with amyloid 
deposition. In some examples, this reversal can be achieved without affecting the 
concentration of aggregate deposition. In particular, small molecule inhibition of 
PERK kinase, a key mediator of the UPR, prevents translation inhibition in mice 
with prion disease and rescues cognitive defects associated with PrP
sc
 replication. 
Figure 1.3.12 IMS-MS as a tool to determining mechanisms of amyloid inhibition.  (a) Drift 
plot displaying the formation of oligomeric species within the lag phase of hIAPP amyloid 
aggregation. The large number gives oligomer stoichiometries, with the superscript 
indicating charge state. The 1-D m/z spectrum is shown on the left hand y-axis. (b) ThT 
kinetics if hIAPP alone (black) and in the presence of increasing amounts of EGCG. (c) m/z 
spectra of hIAPP with EGCG shows binding to both hIAPP monomer 2+ and 3+ charges 
with a range of binding stoichiometries (inset shows structure). (d) Drift plots of hIAPP in 
the presence of increasing amounts of EGCG indicates binding to monomer prevents the 
formation of higher order oligomers. Compound to protein ratios are defined on the drift 
plots. Figure adapted from (308). 
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Importantly, pharmacological intervention was beneficial even after the emergence 
of disease symptoms (311). 
More recently, similar pharmacological rescue of translation inhibition was shown to 
be beneficial for amyloid disorders associated with the deposition of cytoplasmic 
inclusions in amyolotrophic lateral sclerosis (ALS). Toxicity associated with TDP-
43 and ataxin-2 cytoplasmic stress granule formation were modulated by inhibiting 
PERK kinase in Drosophilia models of the disease. This further confirms the role of 
the dys-proteostasis in the progression of at least some amyloid diseases (234).  
1.4 β2-microglobulin, a model system for studying amyloid diseases 
1.4.1 β2m and dialysis-related amyloidosis 
Despite the progress made towards understanding the biophysical and pathological 
features of amyloidogenic proteins, there is still significant mileage ahead until 
curative, or indeed palliative, treatments for amyloid diseases become readily 
available. So, what is the rate-limiting step inhibiting the development of 
therapeutics? One thing in particular is that modulators of amyloid aggregation 
discovered in vitro are not similarly effective at ameliorating toxicity in vivo (312). 
This is likely to be due to the multifaceted nature of amyloid toxicity not normally 
accounted for during in vitro screening protocols. Therefore, in order to combat 
toxicity effectively, all species that facilitate pathological processes, and indeed the 
associated mechanisms of toxicity, need to be characterised within an amyloidogenic 
ensemble. This is especially pertinent today due to the limited number of routine 
screening protocols designed to detect early events associated with the onset of most 
amyloid disorders. Therefore, there is a significant need for treatments that intervene 
once amyloid formation has already commenced. 
In order to investigate the mechanisms of amyloid-associated toxicity we here utilise 
β2-microglobulin (β2m) as a model system. Under normal physiological conditions, 
β2m plays a central role in cellular immunology by associating non-covalently with 
the major-histocompatibility complex type 1(MHC-1) (Figure 1.4.1a). MHC-1 is 
involved in antigenic peptide presentation of short peptide fragments derived from 
proteolytically cleaved cytoplasmic proteins in all nucleated cells. β2m is a small, 99 
residue protein with a immunoglobulin-like fold that contains a stabilising disulphide 
bridge between cysteine residues at positions 25 – 80 on opposing β-sheets (313–
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315) (Figure 1.4.1b). Although non-covalently associated with MHC-1, β2m is 
essential for the correct folding of MHC-1 and thus antigen presentation. Because of 
the requirement of β2m for correct folding of the antigen presentation complex it is 
often referred to as the MHC-1 chaperone (316, 317). 
As part of its catabolic cycle, 2m dissociates from the heavy chain into the blood 
where it is trafficked to the kidneys for renal clearance (318). For patients 
undergoing long-term haemodialysis treatment due to kidney failure, β2m undergoes 
an increase in plasma concentrations (up to 60-fold) as it cannot be cleared 
effectively through dialysis membranes (319, 320). This increase in concentration is 
ultimately responsible for the tissue-specific deposition of β2m into amyloid plaques 
associated with pathological joint and bone destruction in a condition known as 
dialysis-related amyloidosis (DRA) (321–323) (Figure 1.4.2). The tissue specific 
deposition of β2m into synovial joints is thought to result from an affinity of β2m and 
collagen (324, 325). More recently, a familial variant of β2m (D76N) was discovered 
to be associated with localised systemic amyloidosis, increasing the spectrum of 
β2m-associated amyloidoses (10). 
Figure 1.4.1 Structure of human β2-microglobulin. (a) β2m in complex with the MHC-1 
heavy chain. The antigenic peptide is displayed in red. The β2m light chain component 
is shown in blue (PDB code 1QEW). (b) Structure of β2m in isolation. The ABE β-
sheet is shown orientated towards the front of the page. Cysteine residues 25and 80 are 
shown in yellow (PBD code 1J1N) (433). 
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 1.4.2 Mechanisms of β2m amyloid formation 
Like other amyloid diseases, the pathological origins of β2m amyloid formation are 
unclear. Similarly, the mechanisms that promote the aggregation of the natively 
folded protein into the amyloid cross-β fold also remain unresolved in atomic detail. 
The increase in 2m concentration, however, is fundamental to the aggregation of 
β2m (326, 327).  The increased persistence of β2m in the blood also means that 
proteolytic products of β2m are often found in patients with DRA. In particular, the 
N-terminally truncated variant, ΔN6, in which the N-terminal 6 residues are 
proteolytically cleaved, can compose up to 30% of the total β2m concentration 
associated with amyloid plaques (328, 329). The enrichment of ΔN6 within amyloid 
plaques of β2m suggests that proteolysis may play a role in initiating amyloid 
formation – wt β2m cannot form amyloid fibrils, at least in vitro, at neutral pH (330). 
In vitro studies showed that the removal of the 6 N-terminal residues provides a 
Figure 1.4.2 Dialysis-related amyloidosis. This cascade of events leads to tissue-specific 
β2m deposition, conversion to a fibrillar state and ultimately pathological joint and bone 
destruction. Factors known to associate with deposits of β2m in vivo, such as collagen, 
are indicated. Taken from (434). 
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greater degree of conformational flexibility within the β2m molecule, which upon a 
slight reduction in pH from 7.2 – 6.2 leads to a cis-trans peptidyl-prolyl 
isomerisation at residue proline 32 (157). The trans orientation of Pro32 in ΔN6 
enables the protein to adopt a conformation reminiscent of the folding intermediate 
IT (157, 159). Although highly homologous in main chain structure to wt β2m, ΔN6 
exhibits a significant rearrangement of side-chains involved in the formation of the 
hydrophobic core (157) (Figure 1.4.3). The concentration of IT can also be increased  
by mutating residue 32 to glycine, indicating the role of cis-Pro32 is restricting the 
conformational freedom of β2m to prevent amyloid formation (159, 331). The IT 
state is thought to be a structural intermediate critical for amyloid formation. The 
Figure 1.4.3 The β2m amyloidogenic variant ΔN6.  (a) The lowest energy structures of wt 
β2m(blue), ΔN6 (raspberry) and the overlaid structures (far right) (PBD codes 2XKS and 
2XKU respectively). (b) Side chain reorientation within the hydrophobic core of ΔN6 
(red). Shown in comparison with hβ2m(black) (157). (c) Model of proposed activity of 
ΔN6 (red) in promoting the aggregation of hβ2m (green) (332). 
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presence of large concentration of ΔN6, a structural mimic of the IT state, may 
therefore accelerate/initiate the formation and deposition of β2m into amyloid fibrils. 
More recent studies have shed light on the possible role of ΔN6 in promoting the 
formation of wt β2m into amyloid fibrils at near-neutral pH. Using detailed NMR 
studies, Karamanos et al. showed recently that ΔN6 can act as a catalytic converter 
to promote conformational changes within wt β2m at pH 6.2 into an amyloid-
competent state (332) (Figure 1.4.3). The interaction between ΔN6 and wt β2m 
involved the formation of weakly associated, transient head-to-head interactions, 
which was enough to destabilise the native state to allow fibril formation of wt β2m 
to proceed (Figure 1.4.3c). The partial unfolding/denaturation of β2m as an initiating 
event of fibril formation is further supported by additional in vitro analyses that have 
highlighted particular conditions under which β2m aggregation is promoted. At 
neutral pH, β2m amyloid formation can proceed in the presence of Cu
2+
 ions and 
urea; by mutagenic removal of the 6 N-terminal residues of β2m; by adding 
tetrafluoroethylene; or by destabilising the N- and C- terminal stands of β2m (329, 
333–335). Furthermore, β2m fibril formation has been shown to proceed rapidly at 
low pH under a variety of conditions. Acid denaturation of wt β2m in solutions with 
low ionic strength promotes the formation of β2m amyloid fibrils with all the 
characteristic hallmarks of amyloid fibrils (155, 336, 337). In addition, β2m amyloid 
fibrils obtained under these conditions are morphologically similar to those isolated 
ex vivo from patients with DRA (82). The similarities of fibrils formed at low pH 
with those isolated ex vivo highlight the value of in vitro experiments in determining 
the mechanisms of β2m amyloid fibril formation. They also make in vitro β2m 
amyloid fibrils a valuable resource for deciphering the mechanisms of amyloid 
formation and amyloid-associated toxicity. 
1.4.3 Morphological features of β2m amyloid fibrils 
Recent advances in structural biology have helped to elucidate the structural 
properties of β2m amyloid fibrils. Chief among the techniques used to investigate 
β2m fibril architecture are cryo electron microscopy (cryoEM) and solid-state NMR 
(SS-NMR). In 2009, White et al used cryoEM to elucidate the quaternary packing of 
protofilaments within the mature fibril core, and also determined the subunit packing 
arrangement within the protofilaments themselves (92). The study revealed that β2m 
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amyloid fibrils have a diameter of approximately 20 nm and contain a characteristic 
cross over repeat of variable length parallel to the fibril axis (Figure 1.4.4a). The 
fibril core is composed six protofilaments which arrange into two crescent-shaped 
half-fibrils (protofibrils Figure 1.4.4b and c). Each protofilament has an approximate 
dimension of 3 x 4 nm when viewed top-down and has a regular subunit repeat 
length of 5.25 nm parallel to the long fibril axis (Figure 1.4.4b). Scanning 
transmission electron microscopy (STEM) analysis of fibrils revealed a packing 
density of 52 kDa/nm, indicating that each repeat length must be composed of 24 
β2m monomers ((52 kDa/nm x 5.25 nm)/11.86 kDa). Taking into account the six 
protofilaments within the fibril, subunit repeats are most likely to be a set of stacked 
dimers of dimers, consistent with two distinct regions of density within the fibril 
subunit repeat length (Figure 1.4.4c). 
Subsequent to this analysis, SS-NMR and electron paramagnetic resonance (EPR) 
have revealed that monomers within the fibril core are arranged in a parallel in-
register array (106, 338). This architecture, as previously mentioned, is found in 
many amyloid fibrils. Similar SS-NMR analysis of fibrils composed of the N-
terminally truncated variant ΔN6 also showed a parallel in-register subunit 
orientation; albeit with a slightly different subunit packing arrangement (94, 117). 
Comparative limited proteolysis of the two fibrils revealed ΔN6 fibrils possess an 
additionally accessible cleavage site within the C-terminal region of the subunit in 
comparison with wt 2m fibrils (339) (Figure 1.4.4d). In addition, SS-NMR revealed 
an increase in the number of identifiable backbone Nα-Cα cross-peaks in ΔN6 fibril 
spectra (94). Thus, although a similar number of residues in ΔN6 participate in the 
formation of the fibril core, the region may possess elevated rigidity compared with 
fibrils formed of wt 2m at low pH. 
ΔN6 and wt β2m have also been shown to co-polymerise to form heteropolymers 
with distinct biophysical properties compared with the two homopolymers (117). 
The co-polymerisation of two distinct amyloidogenic sequences to expand the 
number of accessible fibril polymorphs has become an increasingly frequent 
phenomenon among pathogenic amyloidogenic precursors (118). More structural 
information regarding the fibril core of β2m:ΔN6 heteropolymorphs have yet to be 
determined. 
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 1.4.4 Studying mechanisms of β2m amyloid fibril-mediated toxicity 
The disease-association of β2m amyloid formation coupled with the well-
characterised and reproducible nature of β2m aggregation makes this protein an 
attractive model system for elucidating mechanisms not only DRA and familial 
amyloidosis, but also perhaps generic features of amyloid diseases. Because β2m 
amyloid formation is very well described, it provides a powerful resource for 
identifying species that form during amyloid assembly and disassembly that mediate 
cellular dysfunction. Samples can be made and characterised in vitro prior to being 
Figure 1.4.4 Structure of β2m amyloid fibrils.  (a) Negative stain TEM of β2m amyloid 
fibrils illustrating cross-over repeat motif (92). (b) His resolution cryoEM map showing 
regions of density with β2m fibril (92). The cross sectional view is shown below. (c) 
Subunit organisation within β2m amyloid fibrils. The parallel in-register array of 
monomers with the subunit repeat is shown below. Accessible cleavage sites within 
fibrils composed of β2m or ΔN6. Potential cleavage sites are shown in grey, with actual 
cleavages illustrated by blue of red vertical lines (117). 
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incubated with cells to ensure that the identity of the entire aggregate population is 
known at the starting point of the investigation (245). Even if aggregates undergo 
structural evolution during incubation with cells, whatever structure is causing 
cellular dysfunction must be accessible from the known starting conformation. In 
this thesis work is focused on investigating whether amyloid fibrils, as opposed to 
soluble aggregation intermediates, can induce cellular defects and which features of 
amyloid fibrils are responsible for potentially mediating metabolic defects. This is 
performed first by extensive characterisation of samples prepared in vitro from 
recombinant protein using the wealth of tools developed developed in the Radford 
group. Discoveries made will be discussed in more detail in a brief introduction to 
the following chapters before describing work performed as part of this thesis.  
1.5 Aims of this Project 
The principal aim of the work described in this thesis was to expand our knowledge 
of the mechanisms associated with 2m amyloid fibril-mediated cellular metabolic 
dysfunction and membrane disruption in vitro. As mentioned, studying these 
mechanisms using 2m provides an exciting opportunity to perform an in-depth 
analysis of how amyloid fibrils in general can contribute towards amyloid 
pathologies. Opinions concerning the role of amyloid fibrils in disease are varied, 
such an analysis, therefore, could reveal the importance of fibrils in facilitating 
toxicity, and whether the long accepted view that fibrils are simply inert end 
products of aggregation can be re-assessed. In order to investigate this question, a 
range of analytical techniques were performed to investigate the behaviour of 2m 
amyloid fibrils in vitro under competing sets of conditions. The presentation of 
results within this thesis is listed below. Relevant methods used are detailed in each 
chapter. 
Chapter 1 hopefully provides a general overview as to the current state of the 
amyloid research field. 
Chapter 2 provides an introduction to the construction and characterisation of 2m 
amyloid fibrils used throughout this thesis. These fibrils are then used to investigate 
the response of amyloid fibrils under two sets of conditions in which the capacity of 
fibrils to disrupt membranes is significantly different. More specifically, changes in 
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dynamic behaviours of fibrils are probed using ThT fluorescence kinetics, ESI-IMS-
MS and NMR, as well as documenting attempts to elucidate whether the dynamic 
behaviour of 2m amyloid fibrils is responsible for metabolic defects upon 
incubation with cultured mammalian cells. The work builds on several collaborations 
in which the mechanisms of pH-dependent membrane disruption were established 
and the mechanisms of 2m fibril-mediated cellular dysfunction were investigated 
(340–342).  
Chapter 3 details the use of fluorescence correlation spectroscopy (FCS) to 
investigate how the subtly different solution conditions used in Chapter 2 have 
dramatic consequences upon the equilibrium of species that populate upon dilution 
into solutions that differ by only a single pH unit. Attempts to structurally 
characterise the novel species are also described and the implications for amyloid-
associated cellular dysfunction are discussed. 
Chapter 4 describes a comparative analysis between the mechanisms of 2m 
amyloid fibril polymerisation and depolymerisation through ThT kinetic analysis and 
FCS. The results show that, at least kinetically, the two processes are not mutually 
exclusive, with fundamental differences in relation to the end-dependent nature of 
fibril polymerisation and depolymerisation existing. Moreover, FCS suggests that 
the intermediate species formed during the lag phase of 2m amyloid assembly are 
distinct from those that form during depolymerisation. This finding may expand the 
structural repertoire of oligomeric species known to cause toxicity in amyloid 
diseases. 
Finally, Chapter 5 summarises all the key findings established from the studies 
above and places them in the context of β2m amyloidosis as well as that of the 
generic principles of amyloid toxicity. Future work will also be discussed that aims 
to investigate in more detail whether the molecular shedding phenomenon is 
applicable to other fibril types and how such a process may be therapeutically 
intervened.
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The molecular mechanism of amyloid fibril-mediated membrane 
disruption 
 
2.1 Introduction 
Characterising the array of amyloid species that mediate mechanisms of toxicity is a 
key prerequisite for the development of therapeutic strategies to combat these 
disorders. Although the inherent toxicity of amyloid fibrils is lower than that of their 
oligomeric counterparts, the prevalence of fibrils at the site of toxicity (1, 343), and 
their persistence due to increased thermodynamic stability in comparison with 
soluble species (75, 93, 107, 117, 156, 344–346), means that the role of amyloid 
fibrils in contributing to disease processes needs to be investigated more thoroughly. 
The role of β2m amyloid fibrils in mediating toxicity was established in 2009, when 
Xue et al. showed a fibril length dependent relationship of amyloid-mediated 
metabolic dysfunction (245, 347). In essence, fibrils fragmented to reduce the 
average particle length displayed enhanced cytotoxicity compared with their longer, 
unfragmented counterparts at monomer equivalent concentrations (Figure 2.1.1a). 
This length dependent phenomenon was observed for α-synuclein and lysozyme 
amyloid fibrils and was also replicated in an in vitro liposome dye release assay 
(Figure 2.1.1b and c, respectively). Subsequent to this, it was found that upon 
incubation with cells, fibrils are internalised into lysosomes. Inhibition of clathrin-
mediated endocytosis using the dynamin inhibitor, Dynasore (348), reversed β2m 
fibril-mediated metabolic defects (Figure 2.1.2a), indicating that fibrils illicit toxicity 
from inside the cell (Figure 2.1.2b) (340).  In addition, 2m amyloid fibrils were also 
shown to inhibit the development of bone resorbing osteoclasts and impair the 
viability of osteoblasts, the cell type that produces bone, indicating the potential role 
of fibrils in mediating the pathological joint and bone destruction observed in DRA 
(349).  
Considering the alleged importance of amyloid – lipid interactions in mediating 
cellular toxicity (190, 191, 200–202, 213, 214, 220, 244, 247, 350–357), these 
observations inspired a systematic investigation into the molecular mechanisms of 
β2m fibril-mediated membrane disruption and cellular dysfunction. Several 
hypotheses were put forward as potential explanations for the length dependent 
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phenomenon, including the potential importance of fibril ends; shorter fibrils at 
monomer equivalent concentrations will possess a significantly greater number of 
fibril ends. Thus, if fibril ends mediate in vitro membrane disruption, then shorter 
fibrils will possess greater activity in this regard. In 2012, using cryo-electron 
microscopy, Milanesi et al. observed a direct interaction predominantly between β2m 
amyloid fibril ends and synthetic lipid bilayers which, if responsible for mediating in 
vitro liposome disruption, could explain the greater activity of short fibril samples 
(Figure 2.1.1d) (358). 
Subsequent to this, our understanding not only of fibril-mediated membrane 
disruption, but of the biological consequences of incubating cells with β2m amyloid 
fibrils, has expanded greatly. This chapter describes a body of work that has 
attempted to elucidate these processes, with special focus on in vitro studies of the 
causative agents of membrane disruption. The range of techniques encompassed 
within this work, including biochemical, biophysical and ultimately cell biological 
assays, is the result of fruitful collaborations with members of the Radford and 
Figure 2.1.1 Biological activity of β2m amyloid fibrils. (a) β2m amyloid fibrils cause 
length dependent metabolic dysfunction as judged by the MTT assay. (b) Similar 
phenomenon were observed for fibrils composed of lysozyme (b) and α-synuclein (αSyn). 
(c) β2m fibrils also cause length dependent carboxyfluorescein dye release from synthetic 
liposomes (245). (d) Direct observation of β2m fibril – lipid interactions highlights the role 
of fibrils ends in perturbing membrane architecture (358). The lipid bilayer is shown in 
blue, fibril in yellow and released lipids in orange. 
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Hewitt groups past and present, who are acknowledged for their contribution in the 
appropriate figure legends. The systematic investigation of lipid composition and pH 
upon β2m fibril-mediated membrane disruption presented in Section 2.3.3 (341) was 
primarily performed by Dr Sophia Goodchild, using fibrils samples of defined length 
provided by myself. The results are shown to provide a narrative as to the evolution 
of our understanding of the mechanisms behind β2m amyloid fibril-mediated 
membrane disruption and cellular metabolic dysfunction.  
Figure 2.1.2 Inhibiting clathrin-mediated endocytosis reverses fibril-mediated 
metabolic dysfunction. (a) MTT viability of 1.2 µM β2m fibrils in the presence (+ 
dynasore) and absence of the clathrin mediated endocytosis inhibitor dynasore 
(340). (b) Schematic representation of fibril-mediated toxicity. Fibrils are 
internalised and trafficked to lysosomes. Restricting fibril internalisation with CME 
inhibitors prevents metabolic defects associated with β2m fibril incubation. 
matrix 
cytosol 
fibrils 
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 2.2 Materials and Methods  
All chemicals (unless otherwise stated) were purchased from Sigma Aldrich and 
were of analytical grade. 
2.2.1 General analytical methods 
2.2.1.1 Quantifying protein concentration using UV absorption at 280 nm 
Proteins were diluted where necessary to obtain UV absorption values of between 
0.1 and 1 for determination of protein concentration. In general, protein solutions 
were diluted into water containing 6 M guanidinium hydrochloride (GdmHCl) to a 
final volume of 100 l. All absorption values were acquired using a reference 
standard of buffer-only solutions. Protein concentrations were determined using 
Beer-Lambert’s law. Wild-type 2m has an extinction coefficient of 20065M
-1
.cm
-1 
which was determined using Gill and Von Hippel’s method (359). 
2.2.1.2 DNA quantification 
DNA quantification was performed by diluting DNA samples into sterile water 
(typically 1 to 200) before measuring the absorbance at 260 nm given that Abs260 of 
1 is the equivalent of 50 g.ml-1 of DNA. The correct concentration was calculated 
using the appropriate programme on an Ultraspec 2100 proUV-vis 
spectrophotometer (Amersham Biosciences). 
2.2.1.3 Preparation of agar plates 
2.5 g of Luria Bertani medium (containing per L, 10 g bacto-tryptone, 5 g yeast 
extract and 10 g NaCl, Melford) and 1.5 g of bacto-agar (Melford) were added to 
100 ml of deionised water. The solution was autoclaved for 20 min at 121C min 
prior to cooling to approximately 45C before the addition of the appropriate 
antibiotic. About 25 ml of autoclaved, cooled solution was poured into each 100 mm 
diameter petri dish before allowing setting at room temperature. Agar plates were 
kept chilled at 4C and stored for up to one week. 
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2.2.1.4 SDS-polyacrylamide gel electrophoresis 
A two layered gel system consisting of a stacking gel for protein loading and a 15% 
Tris-Tricine resolving gel was used throughout. Components of the stacking and 
resolving gels are detailed in Table 2.2.1. 
 
Table 2.2.1 Composition of stacking and resolving gels for SDS-PAGE 
Solution Component Resolving gel (ml) Stacking gel (ml) 
30% (w/v) Acrylamide 0.8% (w/v) bis-
acrylamide 
7.5 0.83 
3 M Tris-HCl, 0.3% (w/v) SDS pH 8.45 5.0 1.55 
H2O 0.44 3.72 
Glycerol 2 - 
10% (w/v) ammonium persulphate 0.1 0.2 
Tetramethylethylenediamine (TEMED)  0.01 0.01 
 
Gels were electrophoresed using anode buffer (200 mM Tris-HCl pH 8.8) and 
Tris/Tricine cathode buffer (100 mM Tris, 100 mM Tricine, 0.1 % (w/v) Sodium 
dodecyl sulphate (SDS) pH 8.3,Bio-Rad) at a constant current of between 35 – 50 
mA. 
Samples were prepared for SDS-PAGE by adding 2.5 µl each of 1 M dithiotheritol 
(DTT) and 6 x loading buffer (150 mM Tris-HCl pH 6.8, 600 mM DTT, 6% (w/v) 
SDS, 0.3% (w/v) bromophenol blue and 30% glycerol) to approximately 10 l of 
sample. After electrophoresis gels were stained for 1 h with Instant Blue (Expedeon) 
and de-stained by washing in water for 3 x 5 min. 
2.2.1.5 Transmission electron microscopy imaging 
Samples were applied to a freshly glow discharged copper EM grid coated with a 
thin layer of carbon, blotted with Whatman filter paper, washed with 18 M water, 
and stained with 1% (w/v) uranyl acetate for approximately 30 sec.  Images were 
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recorded using a BM Ultrascan 2k x 2k CCD (Gatan) on a Technai T12 TEM (FEI) 
operating at 120 keV. 
2.2.1.6 Electrospray ionisation mass spectrometry 
All spectra acquired to confirm protein identity were performed using samples 
ranging from 50 – 100 µM in protein concentration in 50 – 100 mM ammonium 
bicarbonate buffer, pH 7.4. Mass spectra were acquired using a Synapt HDMS 
instrument (Micromass UK Ltd., Waters Corp, Manchester, UK) interfaced to a 
NanoMate automated sample infusion device operating in positive ion mode 
(Advion Biosciences Inc., Ithaca, NY). All spectra were calibrated using cluster ions 
generated from a separate introduction of cesium iodide solution (2 mg/ml, 1:1 
water:methanol). The spectra were smoothed using the Savitzsky-Golay method and 
analysed using MassLynx software. 
2.2.2 General cloning methods 
2.2.2.1 Transformation of plasmid DNA 
The gene encoding wt human β2m was cloned into a pET23a vector using Hind III 
and Nde I restriction sites under the control of the T7 promoter (NEB, USA). The 
vector, known as the pINK plasmid, was originally constructed and designed by Dr 
Neil Kad (336). Gene-harbouring vectors were then transformed into competent 
E.coli BL21 DE3 pLysS cells (E.coli B F-dcm ompT hsdS(rB-  mB-) gal 
(DE3)pLysS (Camr), Agilent) using the ‘heat shock’ method. In brief, 5 µl of the 
wt β2m vector was added to 50 µl of chilled (on ice) BL21 DE3 pLysS cells and 
gently agitated prior to returning to ice for 30 min. Cells were then ‘heat shocked’ by 
submerging in a water bath set to 42
o
C for 45 sec before returning to ice for 2 – 3 
min. 500 µl of pre-warmed LB media (Section 2.2.1.3) was then added to cells 
before incubating at 37
o
C 200 rpm for 1 h. Two pre-warmed agar plates were 
streaked with either 50 µl or 200 µl of transformed cells and left to incubate at 37
o
C 
overnight in agar plates containing 50 g.ml-1 carbenicillin.  
2.2.3 Expression and purification of wild-type 2m 
For expression and purification of wt 2m, colonies of BL21 DE3 pLysS cells 
transformed with the pINK plasmid were picked and used to inoculate 100 ml LB 
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medium supplemented with 50 g.ml-1 carbenicillin and 50 g.ml-1 chlormaphenicol. 
Starter cultures were grown overnight at 37C shaking at 200 rpm. Once overnight 
cultures had reached an OD600nm > 1, 10 ml of overnight starter culture was used to 
inoculate 11 x 2 litre flasks each containing 1 L of LB medium pre-warned to 37C 
and supplemented with 100 µg.ml
-1
 carbenicillin. Cells were grown at 37°C, 200 
rpm and protein expression induced once an OD600nm 0.6 was reached by adding 
isopropylthiogalactopyranoside (IPTG, Generon) to a final concentration of 0.8 mM. 
Protein expression was subsequently allowed to continue for 16 h. 
Cells were harvested using a continual action centrifuge at 15000 rpm (Heraus) and 
the pellet re-suspended in approximately 50 ml per 20 g of cell pellet of lysis buffer 
(25 mM Tris.HCl pH 8.0, 100 µg.ml
-1
 lysozyme, 100 nM phenylmethanesulfonyl 
fluoride (PMSF), 20 µg.ml
-1
 deoxyribonuclease and 1 mM 
ethylenediaminetetraacetic acid (EDTA)) by vigorous agitation. The homogenised 
cell pellet was incubated at room temperature with vigorous agitation (using a 
magnetic stirring bar) for 30 min before being further disrupted using a cell disrupter 
operating at 20 kPSi (Constantsytem). The resulting cell debris and β2m inclusion 
bodies were pelleted by centrifugation at 15,000 rpm using a Beckmann JLA 16.250 
rotor for 30 min at 4
o
C. The supernatant was discarded and a lipid film on top of the 
protein inclusion body removed by gently scraping with a spatula before re-
suspending the inclusion body in 100 ml 25 mM Tris.HCl pH 8.0. Inclusion bodies 
were then re-pelleted and cleaned (typically 5 cycles) as described above until a 
clean pellet devoid of cellular debris was obtained. 
The inclusion body pellet was re-suspended in 25 mM Tris.HCl pH 8.0 containing 8 
M urea (MP Biomedicals) and incubated at room temperature while gently stirring 
overnight to re-solubilise β2m. Soluble β2m was then dialysed (3,000 kDa cut-off, 
Fisher Scientific) against 5 L of 25 mM Tris.HCl pH 8.0 at 4
o
C for 24 h to refold 
with at least 4 buffer changes. Insoluble material was removed by centrifugation at 
15,000 rpm 4
oC for 30 min using a Beckmann JLA 16.250 rotor. Refolded β2m was 
further purified by anion exchange chromatography by loading the protein sample 
onto a fast flow Q-Sepharose (GE healthcare) column self-packed (200-300 ml) and 
previously equilibrated with 600 ml of 25 mM Tris.HCl pH 8.0 at a flow rate of 
approximately 5 ml.min
-1
. Once loaded the column was washed with 600 ml 25 mM 
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Tris.HCl pH 8.0. β2m was eluted using a linear gradient of 0 – 400 mM NaCl in 25 
mM Tris-HCl over 800 ml at a flow rate of 5 ml.min
-1
, collecting fractions 10 ml in 
size. Fractions containing β2m as judged by SDS-PAGE were pooled and dialysed 
(3000 kDa cut-off) for 48 h against 5 L 18 M water with at least five buffer 
changes at 4C prior to freeze drying the sample and storing at -20oC. β2m was then 
purified to >95% purity by gel filtration using a Superdex 75 Prep column (GE 
Healthcare) equilibrated with 25 mM sodium phosphate buffer, pH 7.4 and 
calibrated with a standard gel filtration calibration kit (GE healthcare). Freeze-dried 
protein was re-suspended in the same buffer at an approximate concentration of 10 
mg.ml
-1
 and filtered using a 0.2 m syringe filter (Millipore) before 5 ml was loaded 
onto the column using an injection loop. Protein was eluted at a flow rate of 3 
ml.min
-1
 while collecting fractions of 3 ml after 100 ml of buffer had passed through 
into waste. Fractions containing purified 2m as judged by SDS-PAGE were 
concentrated to approximately 2.5 mM using  cenitrifugal3 kDa cut-off filtration 
units (Centricon) according to manufacturer’s instructions, prior to snap freezing in 
liquid nitrogen and storage at -80
o
C. The identity of 2m was confirmed by mass 
spectrometry (see section 2.2.1.6). 
2.2.4 Fibril sample preparation 
Fibril seeds were prepared by diluting concentrated β2m solutions stored at -80°C in 
25 mM sodium phosphate buffer pH 7.4 to 120 µM in 10 mM sodium phosphate 
buffer, containing 50 mM NaCl, pH 2.0 (fibril growth buffer). 500 µl aliquots were 
then placed and sealed in screw top 1.5 ml glass vials (Chromacol) containing a 3 x 8 
mm magnetic stirring beads and placed on a custom-made precision stirrer 
(University of Leeds Physics Workshop) rotating at 1,000 rpm for 3 days at 25C. 
These seeds were then stored under quiescent conditions at room temperature and 
used in all subsequent fibrils growth experiments in the fibril growth buffer at a 
seeding concentration of 0.1% (w/w) unless otherwise stated. Typical fibril growth 
experiments were performed by diluting stored 2m to 120 M into fibril growth 
buffer before adding 0.1 % (w/w) seed and incubating at room temperature for a 
minimum of 48 h unless stated otherwise. 
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2.2.5 Tapping mode atomic force microscopy 
Samples were prepared for tapping-mode AFM by diluting samples to 0.4 µM 
monomer equivalent concentrations in 18 M water to ensure good sample 
dispersion and uniform coverage upon the imaging surface. After dilution, 20 µl of 
sample was immediately placed on to a freshly cleaved surface of mica and 
incubated at room temperature for 5 min. Surfaces were then washed with 1 ml of 18 
M water before gently aspirating the surface with a stream of N2 gas to complete 
dryness. Samples were imaged using a Dimension 3100 scanning probe microscope 
(Veeco Instruments) and PPP-NCLR silicon cantilever probes (Nanosensors, 
Neuchatel, Switzerland) with a nominal force constant of 48 N/m. Typically, 10 µm
2
 
images at a pixel ratio of 1024 x 1024 were collected for analysis. 
 
Images were analysed using scripts generated in Matlab (Mathworks) by Dr Wei-
Feng Xue (360). The script automatically picks fibrils from image surfaces to avoid 
subjective analysis of sample distributions. In order to correct for the inherent bias in 
favour of analysing short fibrils, an empirical power function was applied to the 
distributions to correct for the under-representation of long fibrils (360). Long fibrils 
are more often excluded from the analysis due to reduced surface-deposition 
efficiencies and greater frequency in which long fibrils are cut-off by image 
boundaries or overlap with other fibrils. The bias correction factor is calculated by 
assuming that since the identical original monomer concentrations of samples under 
analysis, the average weight of material observed should be equal within each image. 
2.2.6 Liposome dye release assay 
Lipid films (all lipids were obtained from Avanti Lipids) containing 12 mol% 
bis(monooacylglycero)phosphate (BMP), 7 mol% sphingomyelin (porcine brain), 36 
mol% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 20 mol% 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 25 mol% 
cholesterol (ovine wool) and 0.1 mol% rhodamine-PE (for lipid quantification) were 
re-suspended in 50 mM sodium phosphate buffer, pH 7.4 containing 50 mM 
carboxyfluorescein, 10 mM NaCl and 1 mM EDTA and left overnight at 4C. Up to 
four freeze-thaw cycles were performed the following morning using dry ice, prior to 
sonicating for 30 sec in a water bath. Free lipids at a concentration of 3.6 mM were 
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then extruded by passing through a 0.4 µm polycarbonate pore (Whatmann) up to 35 
times to generate 400 nm large unilamellar vesicles (LUVs). LUVs were 
subsequently washed by successive rounds (up to 5) of centrifugation at 13,000 x 
rpm for 30 min at 4C using a bench-top centrifuge and re-suspension of the lipid 
pellet in 50 mM citric acid/sodium phosphate buffer, pH 7.4 containing 107 mM 
NaCl and 1 mM EDTA (dye release buffer). After 5 rounds, the concentration of 
lipid was determined by comparing the rhodamine Abs595nm from before and after the 
extrusion process using a UV-vis spectrophotometer. The concentration was adjusted 
to 0.5 mM in dye release buffer and LUVs were stored on ice prior to use withing 48 
h.  
For the dye release assay, 120 M 2m fibrils formed as described (section 2.2.4) 
were diluted 4-fold to 30 µM (monomer equivalent concentration) in duplicate 
samples to a final volume of between 50 – 100 l in either pH 7.4 buffer (50 mM 
sodium phosphate buffer, containing 30 mM NaCl and 3 mM KCl) or pH 6.4 buffer 
(50 mM sodium phosphate buffer, containing 85 mM NaCl and 3 mM KCl) and 
incubated at 25C for 30 or 60 min, respectively. The concentration of NaCl was 
altered to maintain an equivalent ionic strength between buffers of 164 mM, 
equivalent to that of commercial 1 x PBS. After the initial incubation period, one 
sample was syringe filtered using a 0.2 M small-volume syringe filter (Millipore) to 
remove fibrillar material while the second identical sample remained untreated. 40 µl 
of either syringe-filtered or untreated sample was then added to 2 µl of 0.5 mM 400 
nm LUVs diluted in 158 µl dye release buffer at pH 7.4 (for pH 7.4-diuted fibril 
samples) or the same buffer at pH 6.4 (for pH 6.4-diluted fibril samples) and 
incubated at 37C for 10 min. Carboxyfluorescein dye release was then assayed by 
adding 1 ml of pH 7.4 dye release buffer before recording the emission at 513 nm 
after excitation at 492 nm using a PTI QuantaMaster spectrometer with excitation 
and emission slit widths set to 4 nm. 100% dye release values were then recorded for 
each sample by the addition of Triton X-100 to a final concentration of 0.25% (v/v). 
Normalised dye release values for each sample were then calculated using the 
following equation, where Is is the fluorescence intensity of the sample, I0 is the 
background dye release (carboxyfluorescein fluorescence from LUVs in the absence 
of fibril samples) and I100 is the fluorescence intensity after the addition of Triton X-
100. 
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% 𝐷𝑦𝑒 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 =  
𝐼𝑠 − 𝐼0
𝐼100 − 𝐼0
 
Detailed experimental protocols for dye release experiments investigating the effect 
of pH and lipid composition on the amplitude of dye release, and those performed in 
the presence of small molecules can be found in the following references (341, 342). 
2.2.7 Kinetic stability assay 
β2m fibril stability was determined by diluting 120 M pre-formed 2m fibrils to 30 
µM (monomer equivalent concentration) in either pH 7.4 buffer or pH 6.4 buffer pre-
equilibrated to 25C and each supplemented with 10 µM Thioflavin T (see Section 
2.2.3 for detailed buffer composition). The assay was performed at 25C in black, 
clear bottomed 96 well plates (Costar) at a final reaction volume of 100 l. ThT 
fluorescence (excitation wavelength 440±10 nm, emission wavelength 480±10 nm) 
was monitored under quiescent conditions using a BMG Labtech Optima plate 
reader working in plate mode with a gain value of set to 75% of the total 
fluorescence signal of one of the sample replicates. ThT fluorescence was recorded 
for up to 360 min and curves were normalised to the highest ThT fluorescence 
reading of each sample, with a baseline value used from monitoring the ThT 
fluorescence of monomer controls recorded at equivalent concentrations under each 
condition. Curves were best fit to the double exponential function shown below 
using OriginPro v8.6, where A and k1, and B and k2 are the amplitude and rate 
constant associated with the first and second exponential phases, respectively. Rate 
constants for samples from both pH values were calculated from at least six 
independent measurements.  
𝑦 = −𝐴. 𝑒−𝑘1𝑡 + 𝐵𝑒−𝑘2𝑡 + 𝑐 
Variations of this experiment, such as those presented in the presence of Hsp70, 
using diazirine-labelled 2m-containing fibrils, or at increased 2m monomer 
equivalent concentrations, were performed using an identical experimental set up to 
that outlined above with a constant ThT:2m molar ratio. Where the initial 
concentration of fibrils within the assay, the buffer used, or temperature is different 
to that outlined above it is indicated in the text. All experiments were analysed using 
baseline ThT fluorescence values obtained from controls of the exact composition of 
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the sample except substituting fibrils for the monomer equivalent concentration of 
native 2m. All curves plotted are an average of at least three independent replicate 
measurements. 
2.2.8 Soluble release assay 
The release of soluble material was quantified by densitometry from SDS-PAGE 
gels made and electrophoresed as described in section 2.2.1.4. Multiple aliquots of 
120 M pre-formed fibrils were diluted to 30 µM (monomer equivalent 
concentration) in either pH 7.4 or pH 6.4 buffer (see section 2.2.6 for detailed buffer 
composition) to a final volume of 50 l and incubated at 25°C under quiescent 
conditions. Samples diluted in pH 7.4 buffer were syringe filtered using a 0.2 m 
reduced volume syringe filter (Millipore) 0, 2, 5, 10, 20, 40, 60 or 120 min after the 
initial dilution, or 0, 10, 20, 40, 60, 90, 120, 150 min for samples diluted in pH 6.4 
buffer. 10 µl of each filtrate was then prepared for gel electrophoresis as described in 
Section 2.2.1.4 along with three standards containing known amounts of β2m of 1.25 
µg, 0.625 µg and 0.3125 µg. Standards were prepared by diluting samples of native 
2m quantified using Beer-Lambert’s law (Section 2.2.1.1). Gels were stained and 
de-stained as previously described and the mass of 2m released from fibrils and 
isolated by filtration was calculated by quantifying the intensity of bands on gels 
using Gene Tools. The known sample volume loaded for each sample was then used 
to determine the concentration of released 2m from a linear calibration curve 
constructed from the band intensities of the three standards plotted versus their 
known protein masses. 
2.2.9 Diazirine labelling of β2m 
Diazirine labelling of 2m was performed by diluting purified 2m to between 5 – 10 
mg.ml
-1
 in 25 mM sodium phosphate buffer, pH 7.2. Immediately before use, 
succinimidyl 6-(4,4'-azipentanamido) hexanoate (LC-SDA Diazirine, Pierce Net) 
was dissolved in 18 M water to a concentration of 7.66 mM. LC-SDA diazirine 
was then added to β2m in a 10-fold molar excess over the 2m concentration and left 
to react at room temperature for 15 minutes with infrequent agitation. Excess LC-
SDA diazirine was quenched to arrest labelling by adding a 5-fold molar excess of 
Tris.HCl pH 8.0. Excess label was removed using a PD-10 desalting column 
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previously equilibrated with 25 mM sodium phosphate buffer, pH 7.2 (GE 
healthcare) according to manufacturer’s instructions. An aliquot was prepared for 
ESI-MS by diluting to between 50 – 100 M in 50 mM ammonium bicarbonate, pH 
7.2 and buffer exchanging using a Zeba spin desalting column (Piercenet, 7 kDa cut-
off) according to manufacturer’s instructions. Labelling stoichiometry was 
confirmed by ESI-MS operated as outlined in Section 2.2.1.6. Diazirine-labelled 2m 
was then concentrated using a Centricon 3 kDa cut-off centrifugal filter unit 
according to manufacturers, and stored at -80C in 50 l aliquots of between 800 – 
900 M by snap freezing in liquid nitrogen. 
2.2.10 Incorporation of diazirine-labelled 2m into seeded β2m fibrils 
To determine the maximum concentration at which diazirine-labelled β2m could be 
incorporated into amyloid fibrils a titration was performed from 10% to 100% of 
diazirine-labelled β2m into seeded fibril growth assays at a final total protein 
concentration of 120 M. All fibril samples were prepared as outlined in Section 
2.2.4 by substituting wt 2m for diazirine-labelled 2m for the appropriate diazirine-
labelled 2m concentrations. The amount of soluble material remaining in solution 
after 48 h of fibril growth was determined by ultra-centrifuging 20 l samples of 
each titrant for 1 h at 4C at 400000 x g (Sorvall). The concentration of protein in the 
supernatant was then determined using Beer Lambert’s law (Section 2.2.1.1). 
To ensure labelled protein was incorporated into β2m fibrils, fibril pellets were re-
suspended in 20 µl 18 M water and 50 µl of hexafluoroisopropanol (HFIP) was 
added. Samples were incubated at 37C 200 rpm for 5 min, heated to 55C for 5 min 
with no shaking before returning to 37C 200 rpm for an additional 5 min. 
Depolymerised fibrils were then lyophilised to complete dryness using a speedvac 
and re-suspended in 50 mM ammonium bicarbonate buffer pH 7.2. Samples were 
desalted using a Zeba spin desalting column (7 kDa cut-off) according to 
manufacturers instructions prior to analysis by ESI-MS as detailed in Section 2.2.1.6. 
2.2.11 Photo-activation of diazirine-labelled fibrils 
Cross-linking of diazirine-labelled 2m-containing fibrils was photo-induced by UV 
irradiation for 20 min at 345 nm using a 6 watt hand-held UV lamp (Stratalinker) 
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(Figure 2.2.1). Samples were placed 1 cm away from the UV source in upturned lids 
cut from sterile 1.5 ml Eppendorf tubes. Samples were agitated every 2 min by 
gently pipetting solutions up and down. Cross-linking efficiency was determined by 
analyzing the production of higher order species by performing SDS-PAGE as 
outlined in Section 2.2.1.4. The dependence of the extent of crosslinking on the 
concentration of protein was also determined by serially diluting samples from 120 
M to 7.5 M (monomer equivalent concentration) in fibril growth buffer (see 
section 2.2.2) prior to UV irradiation as outlined above. Aliquots of each sample 
were then prepared for SDS-PAGE by diluting each to the same concentration of 7.5 
M to facilitate comparative analysis of the degree of higher order cross-linking.  
Figure 2.2.1 Schematic of photo-induced diazirine cross-linking. LC-SDA 
diazirine labels proteins on free primary amines such as lysine side chains 
through nucleophilic substitution of the NHS-succinimidyl ester. Once 
labelled, the diazirine moiety can be activated through UV irradiation, 
releasing N2 gas to expose a reactive carbene centre. The carbene group can 
form non-specific intra- or inter-molecular cross-links with molecules within 
the radius of the carbon linker region. Circles schematically represent 2m 
molecule labelled (black) or unlabelled (white) with the diazirine moiety. 
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UV cross-linking was then ‘scaled-up’ by photo-activating multiple 120 M 100 l 
aliquots of fibrils containing diazirine-labelled 2m monomers as outlined above. 
The resulting cross-linked fibrils were purified from non-cross-linked material by 
diluting to 30 M in pH 7.4 buffer (see Section 2.2.6 for buffer composition) and 
leaving to incubate overnight at 25C. Remaining fibrillar material was pelleted by 
centrifugation at 16300 x g at room temperature for 30 min using a sorvall rotor. The 
concentration of protein within the supernatant was determined using Beer 
Lambert’s law and fibrils were re-suspended to 120 M in fibril growth buffer by 
assuming that all pelleted material was fibrillar in origin. The process was then 
repeated until no soluble material was detected in the supernatant after an overnight 
incubation. ThT fluorescence of several aliquots were monitored alongside by 
diluting cross-linked fibrils to 30 M in pH 7.4 buffer supplemented with 10 M 
ThT using a BMG Labtech Optima plate reader operating as described in Section 
2.2.4 to show that once no soluble material is detectably released following an 
overnight incubation that ThT fluorescence had plateaued.  
2.2.12 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium Bromide 
(MTT) cell viability assay 
SH-SY5Y neuroblastoma cells were cultured in Dulbeccos Modified Eagles Medium 
(DMEM, Life Techonologies) supplemented with 10% (v/v) fetal calf serum, 1% 
(w/v) L-glutamine and 1% (w/v) penicillin/streptomycin at 37C, 5% CO2. 200 µl 
aliquots of a cell suspension containing 15,000 cells.ml
-1
 were plated out in 96 well 
plates (Nunc, Thermo Fisher Scientific, UK) and incubated for 24 h at 37°C 5% 
CO2.  
After 24 h, cell medium was removed and 1.2 µM fibril samples and controls were 
added in 200 µl of fresh DMEM (controls; 1.2 µM monomeric β2m, 1% (v/v) fibril 
buffer, or 0.2% (w/v) NaN3) prior to a further 24 h incubation at 37°C, 5% CO2. 
After incubation with fibril and control samples, 20 µl of 5mg.ml
-1
 MTT was added 
and cells were incubated at 37°C, 5% CO2 for a final 60 minutes. The cell medium 
was then removed and the resulting formazan crystals were solubilised in 50 µl 
dimethyl sulfoxide (DMSO) before measuring the absorbance at 570 nm with 
background cell debris light scattering at 650 nm subtracted. 
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For MTT assays performed in the presence of Hsp70 (recombinant Hsp70 was 
kindly provided by Toral Jakhria, University of Leeds), SH-SY5Y cells were 
prepared as above. Prior to the addition of samples, 0.3 µM or 3.6 µM Hsp70-1A 
was incubated with cells for 6 h. Medium was then removed and replaced with 200 
µl fresh complete DMEM along with samples. Cells were then incubated and 
analysed as stated above. 
2.2.13 Electrospray ionisation ion mobility spectrometry mass 
spectrometry of species formed during depolymerisation (ESI-IMS-MS) 
The analysis of soluble species that form during depolymerisation of β2m amyloid 
fibrils was performed using a Synapt HDMS (Waters, UK), which uses quadrupole-
orthogonal acceleration time-of-flight (ToF) geometry and has an built-in travelling 
wave ion mobility spectrometry device for separating ions of same mass, or m/z 
ratio, but different cross-sectional areas. The samples were sprayed using the 
NanoMate Triversa (Advion Biosciences) automated injection and nanoESI 
interface. The instrument was operated in the positive-ion mode. The ESI conditions 
were optimized for the highest sensitivity detection of the multimeric complexes in 
the gas phase: transfer wave velocity = 150 m/s, transfer wave height = 5V, backing 
pressure (Synapt HDMS source pressure) = 5.5 mbar, sample cone voltage = 40-
100V, trap collision energy = 6V, transfer collision energy = 4V and Trap gas flow 
rate of 5ml.min
-1
. Chromatograms 2 min in length were combined and smoothed 
using the Savitzky-Golay method and m/z peaks were centered by mass using 
MassLynx software. For the quantification of soluble material, 1.2 M bradykinin 
(Sigma) dissolved in 18 M H2O was added to the sample prior to ionisation. Peak 
centres corresponding to the bradykinin, Na
+
-adducted and 2xNa
+
-adducted ions 
were summed to provide a means of normalising ionisation efficiencies between 
independent samples. Peaks corresponding to 2m 8
+
, 7
+
 and 6
+
 charge states along 
with the same Na
+
-adducted peaks as described above from either 12 M 2m 
controls prepared in 164 mM ammonium bicarbonate buffer, pH 7.4 or soluble 
material isolated 30 min after the dilution of 120 M 2m fibrils to 30 M in 164 
mM ammonium bicarbonate buffer pH 7.4 at 25C were summed. The relative peak 
intensities were then normalised according to the difference in summed bradykinin 
peak intensities between controls and samples. Drift plots were constructed using 
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Driftplot software (Waters, UK). 
2.2.14 Tracking native peak reappearance during fibril depolymerisation 
by NMR 
NMR experiments were performed in collaboration with Dr Theo Karamanos 
(University of Leeds). In brief, fibrils composed 600 µM of uniformly-labelled 
15
N 
wt β2m (kindly provided by Dr Theo Karamanos) were grown quiescently at 25C 
for at least 48 h using 0.1% (w/w) seeds outlined in Section 2.2.2. 
15
N wt β2m was 
prepared by protein expression in HDMI medium enriched with 
15
N-labelled  NH4Cl 
(Table 2.2.2) . Expression and purification was carried out as described in Section 
2.2.3. 
Table 2.2.2 Reagents for the medium used to express 
15
N-labelled wt β2m.. All salts are 
made to 1L with 18 M water and autoclaved in 2L flasks (when using the HDMI medium 
only 500mL of media are included in each flask to achieve better aeration of bacteria). Just 
before culturing, the HDMI medium was supplemented with the following filter sterilised 
supplements  (added to each litre): 1M MgCl2 (2mL), 1M CaCl2 (100μL), 20% (w/v) D-
glucose-
12
C6 (20mL). *Can be replaced by heavy isotopes. 
 
 
HDMI 
Bacto-tryptone  
Yeast extract  
NaCl  
Na2HPO4- 7.5g 
K2HPO4- 10g 
K2SO4- 9g 
KH2PO4- 10g 
NH4Cl* 1g 
 
To initiate the reaction, samples were diluted in situ to 150 M in either pH 7.4 
buffer or pH 6.4 buffer supplemented with 10% D2O (detailed buffer compositions 
available in Section 2.2.3). The appearance of NMR-observable species was 
monitored over time by SOFAST 
1
H-
15
N HSQC spectra (361) at 25C using a 
Varian Inova spectrometer (Agilent) performed at a 
1
H frequency of 750MHz, 
equipped with a cryogenic probe.  The dead time of the experiment was 3-10 min 
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while the acquisition time of individual spectra varied between 10 – 15 min (4 and 8 
scans per incremental delay, respectively). At least 20 sequential HSQC spectra were 
acquired under both conditions with a final acquisition performed 24 h after the 
initial dilution into pH 7.4 or pH 6.4 buffer. Spectra of 
15
N-labelled native β2m at a 
concentration of 50 µM were acquired in both pH 7.4 and pH 6.4 buffers and the 
assignments of native amide resonances were transferred from previously assigned 
spectra of native β2m acquired under similar conditions (157). The same peak 
mapping technique was used for each HSQC spectrum and relative peak intensities 
(peak height from native amide resonances) were extracted using NMRview and 
plotted versus time on a residue-by-residue basis. The build-up of signal 
corresponding to the amide resonances due to the release of soluble material was 
fitted to the single exponential equation shown below using in house software 
written in Python by Dr Karamanos, where A and k and the amplitude and rate 
constant, respectively. 
𝑦 = −𝐴. 𝑒−𝑘𝑥 
Errors associated with the average rate constant for native amide reappearance are 
the standard deviation of all assigned native amide resonances that appear during 
fibril depolymerisation 
2.2.15 Circular dichroism 
120 µM β2m amyloid fibrils formed as described in Section 2.2.4 were diluted to 30 
µM in either pH 6.4 or pH 7.4 buffer at 25°C to initiate depolymerisation. Far-UV 
CD spectra were acquired after 30 min or 60 min after the initial dilution into pH 7.4 
buffer or pH 6.4 buffer respectively using a Chirascan plus (Applied PhotoPhysics) 
over the wavelength range of 190 – 260 nm using a 1 mm path length Hellma 
cuvette. Spectra were also acquired for native β2m samples at the equivalent 
concentrations as judged by SDS-PAGE under the same solution conditions. Scans 
were recorded at a rate of 60 nm.min
-1
 with 3 acquired spectra averaged for the final 
display. Buffer-only control spectra were also acquired and subtracted from the 
protein spectra. 
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2.3 Results 
2.3.1 Purification and formation of wt β2m amyloid fibrils 
The purification of β2m uses a well-established protocol that involves the refolding 
of β2m from insoluble inclusion bodies formed during over-expression in E.coli 
(330). Refolding of β2m was performed by first solubilising inclusion bodies in 25 
mM Tris.HCl, pH 8.0, containing 8 M urea, prior to refolding by dialysis against 25 
mM Tric.HCl, pH 8.0. The resulting refolded protein was then purified by anion 
exchange chromatography (ANEX) to remove contaminants using a self-packed Q-
Sepharose column. Refolded β2m typically elutes over a linear 0 – 400 mM NaCl 
gradient (Figure 2.3.1a – green line) at an approximate salt concentration of 200 
mM. ANEX-purified β2m was subsequently dialysed against water prior to freeze 
drying before the final stage of gel filtration purification. Figure 2.3.1b shows the 
typical elution profile of native β2m when gel filtrated using a Superdex-75 column, 
with the peak eluting at an approximate volume of 200 ml corresponding to 
monomeric β2m. The identity of protein eluting within the single peak was 
confirmed using ESI-MS, where the expected mass of β2m of 11860 kDa was 
observed (Figure 2.3.1d). From 1 L of bacterial culture about 60 mg of purified 
native β2m was routinely obtained. Figure 2.3.1c shows an SDS-PAGE gel 
Figure 2.3.1 Expression and purification of wt β
2
m. (a) Anion exchange 
chromatography of β
2
m refolded from inclusion bodies. Blue trace = Abs280nm, green 
line - linear increase in [NaCl], red trace - conductivity and cyan – temperature. (b) 
Elution of β2m during gel filtration. (c) Enrichment of β2m at each stage of the 
purification. (d) ESI-MS spectrum of purified β
2
m. Expected mass of β
2
m is 11860 Da. 
A7 and A6 denote the 7
+
 and 6
+
 charge states of ionised β2m. 
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illustrating the sequential purification of β2m through different stages of the protocol 
outlined in Section 2.2.3. 
The morphology of amyloid fibrils formed from β2m is ighly dependent upon the 
solution conditions used to promote aggregation. Different polymorphs can be 
obtained depending on the ionic strength under which aggregation takes place (155). 
For the purposes of these experiments, β2m fibrils with a long-straight morphology 
were used. These were preferred over competing polymorphs due to the structural 
homology of these amyloid fibrils formed in vitro and fibrils isolated ex vivo from 
patients suffering from DRA (82). 
Fibril formation was initiated by re-suspending 120 µM purified β2m in 10 mM 
sodium phosphate buffer, pH 2.0, containing 50 mM NaCl (fibril growth buffer). 
Fibril formation was seeded under quiescent conditions at room temperature for a 
minimum of 48 h at a seed concentration of 0.1% (w/w) (seeds were made as 
described in Section 2.2.4). Seeding fibril formation means that the same fibril 
morphology can be propagated between independent samples, thus establishing a 
degree of consistency between separate experiments that may take place at different 
times and are performed with different samples. The conformation of β2m amyloid 
fibrils formed under these conditions was observed using negative-stain transmission 
electron microscopy (TEM). Figure 2.3.2 shows a selection of seeded β2m amyloid 
fibrils formed as outlined above using protein purified from Figure 2.3.1. Images 
Figure 2.3.2 Negative-stain TEM of seeded β2m amyloid fibrils. 
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display fibrils that are formed at various stages from my PhD and highlight the 
consistency of the morphology obtained from seeding fibril formation. 
2.3.2 Characterisation of β2m amyloid fibril length distributions 
One of the fundamental principles elucidated for β2m amyloid fibril-mediated 
cellular dysfunction is its length dependence, as outlined in the introduction (Section 
2.1) (245). The analysis and biophysical characterisation of the length distribution of 
β2m amyloid fibrils enables the description of the disruptive effects of amyloid 
fibrils on a more quantitative level. Therefore the characterisation of amyloid fibrils 
is an important process underlying the analysis of mechanisms of cellular disruption 
and in vitro processes, such as fibril-mediated membrane disruption. 
In order to perform experiments evaluating differences in fibril activities based on 
length, seeded amyloid fibrils were fragmented for 48 h at room temperature on a 
custom-made precision stirrer set to 1,000 rpm. The distribution of fibril lengths was 
then quantified by imaging β2m amyloid fibrils using atomic force microscopy 
((AFM) Section 2.2.5). The resulting images were analysed and fibrils traced using 
scripts written in Matlab that extract fibril length distributions (FLD) (360). AFM 
analysis begins by initially identifying fibrils ends based on boundary differences in 
fibril height from the surface background. Only fibril ends that satisfy a particular 
width are taken forward in the analysis of fibril lengths, whereby the distance 
between two fibril ends that can be unambiguously traced will satisfy the criteria of 
being a fibril. Therefore, fibrils that overlap one another on the image surface, or are 
cut-off by image boundaries, will be excluded from analysis. Because fibrils exhibit 
length dependent surface deposition properties, a bias correction factor must be 
applied to correct for the underestimation of the population of longer amyloid fibrils 
in solution. Longer fibrils tend to clump during sample preparation and are more 
frequently interrupted by image boundaries, thus restricting the number of fibrils that 
can be unambiguously traced. The bias correction factor is calculated from the 
difference in the total length of fibrils traced from fragmented and un-fragmented 
fibril samples analysed by AFM (360). Therefore, the bias correction factor accounts 
for the differences in surface deposition properties of fibril populations that manifest 
in a perceived difference in the concentration of protein detectable on the AFM 
imaging surface.  
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After the application of the bias correction, FLDs generated from un-fragmented 
fibrils and 48 h fragmented fibrils have distribution profiles shown in Figure 2.3.3a. 
Each FLD is the sum of no less than 200 individually traced particles. Representative 
AFM images of each sample are shown alongside. The reproducibility of fibril 
fragmentation from seeded fibrils is highlighted in Figure 2.3.3b, by the similarity of 
FLDs measured from independent samples used in different studies. The average 
length of fibrils within un-fragmented samples is consistently 1.3 µm, while the 
average fibril length in fragmented fibril populations is 300 nm.  
These fibril samples were subsequently used in the following investigations (340–
342). Data presented in this and the subsequent results chapters do not focus on 
length dependent phenomena, however samples were prepared and characterised in 
the same manner as outlined above. 
2.3.3 β2m fibril-mediated membrane disruption is lipid and pH dependent 
As detailed within the introduction to this chapter, β2m amyloid fibrils cause length 
dependent metabolic dysfunction that is inhibited upon preventing endocytosis 
(340). This length-dependent behaviour is also observed in vitro using a liposome 
membrane disruption assay (245). The ability to prevent β2m amyloid fibril toxicity 
upon restricting endocytosis (Figure 2.1.2) (340), the conservation of length 
dependent phenomena between in vitro and in vivo assays (245), and the generally 
Figure 2.3.3 Fibril length distributions of unfragmented and fragmented β2m fibrils. (a) 
Normalised frequency distributions of un-fragmented (grey) and 48 h fragmented (red) β2m 
amyloid fibrils analysed by AFM. Representative sample images are shown alongside (black 
scale bar = 1 µm, white scale bar = 200 nm). (b) AFM fibril length distributions of fibril 
samples prepared from β2m on a different day. 
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accepted view of the importance of amyloid-lipid interactions in mediating cellular 
dysfunction (23, 182, 196, 197, 204, 205, 207–209, 362, 363), inspired a systematic 
investigation into the effect of lipid composition on the ability of β2m fibrils to 
induce liposome disruption, as measured using the carboxyfluorescein dye release 
(assay outlined in Section 2.2.6) (245, 341). Several complex lipid mixes consisting 
of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoethanolamine (POPE), sphingomyelin and cholesterol, in 
addition to one of the following anionic lipid components, were made (Table 2.3.1). 
These included, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) and, 
bis(monoacylglycero)phosphate (BMP) (Figure 2.3.4). POPS is most highly enriched 
within the inner leaflet of the plasma membrane, POPG is a precursor of the 
mitochondrially enriched lipid cardiolipin, and BMP is a lipid that is found almost 
exclusively within the bilayer of endocytic compartments. BMP typically comprises 
~15% of the total lipid composition of late endosomes (364–366), but can be found 
to comprise  ≥ 70% of some lipid bilayers within the endocytic pathway (364–366). 
It is also a structural isomer of POPG (Figure 2.3.4). The different anionic lipids 
were incorporated into extruded 400 nm LUVS at 12 mol% or 50 mol% of the total 
lipid composition. The other components were chosen based on their ubiquity among 
biological membranes. Detailed compositions of lipid mixtures used in this section 
can be found in Table 2.3.1.  
 
Figure 2.3.4 Structures of varied anionic lipid components 
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Table 2.3.1 Lipid composition in total mol % for the complex lipid mixes used to form 
LUVs. . LUVs containing 0 (control), 12 or 50 mol % anionic lipid component with the 
remaining lipid zwitterionic components in a mol/mol ratio of 36 POPC: 20 POPE: 7 SM: 
25 cholesterol 
 
In addition to monitoring the extent of fibril-induced dye release from liposomes 
composed of these different lipid mixes, the effect of pH was also examined. Dye 
release experiments were performed at pH 4.5, 5.5, 6.4 and pH 7.4, which are the 
cellular pH values likely to be encountered by β2m amyloid fibrils upon trafficking 
from the extracellular environment towards lysosomes. 400 nm LUVs were loaded 
with carboxyfluorescein at concentrations that promote self-quenching (50 mM), and 
the release of carboxyfluorescein into the surrounding buffer (as a consequence of 
membrane disruption) upon the addition of fibrils  was then measured.  
Figure 2.3.5 summarises the results of these experiments.  They show that β2m fibril-
mediated membrane disruption is not only lipid specific, but is also pH-dependent. 
Firstly, LUVs containing 12 mol% (Figure 2.3.5a – dashed blue line) or 50 mol% 
POPS (solid blue line), display minimal membrane disruption in the presence of β2m 
amyloid fibrils. In fact, the extent of membrane disruption is comparable to that of 
control LUVs lacking an anionic lipid component (Table 2.3.1, Figure 2.3.5a – black 
line). This can be most clearly observed in the bar graph in Figure 2.3.5a, which 
shows the extent of dye release at pH 5.5 for all samples. LUVs containing POPG or 
BMP, however, both display pH-dependent membrane disruption, with a dramatic 
increase in the extent of dye release from pH 7.4 to pH 6.4 in LUVs containing either 
12 mol% or 50 mol% BMP (Figure 2.3.5a red dashed and solid lines, respectively) 
or 12 mol% or 50 mol% POPG (green dashed and solid lines respectively). The 
amplitude of dye release in LUVs containing 50 mol% POPG displays an additional 
small increase upon reducing the pH further to 5.5. The extent of membrane 
disruption within LUVs containing 50 mol% of either BMP or POPG decreases upon 
 Anionic Lipid
1
 POPC POPE sphingomyelin cholesterol 
  0 41 23 8 28 
12 36 20 7 25 
50 21 11 4 14 
1 
Anionic lipid component: POPG, POPS or BMP 
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reducing the pH further to pH 4.5. This pH-dependent trend is less pronounced for 
LUVs containing only 12 mol% BMP or POPG, where the dye release does not 
change significantly from that observed at pH 6.4 upon further mild acidifaction 
(Figure 2.3.5a dashed red and green lines respectively). The greatest extent of dye 
release is observed in LUVs containing 50 mol% BMP, which exhibit 60% 
membrane disruption at pH 5.5, approximately 1.5-fold greater than that observed 
for LUVs containing 50 mol% POPG at the equivalent pH. Controls performed using 
native β2m monomer at equivalent concentrations do not display any membrane 
disruption activity (Figure 2.3.5b), confirming that liposome disruption is mediated 
by fibrils. 
2.3.4 The role of fibril dynamics in membrane disruption 
In parallel with this analysis, a separate study performed by Dr Tania Sheynis 
(University of Leeds, (342)) investigated the role of small molecules in modulating 
Figure 2.3.5 Lipid-specific and pH dependent β2m fibril-mediated membrane 
disruption. Relative dye release induced by β2m (a) fibrils and  (b) native 
monomer for 400 nm LUVs containing 0 % (control, black), 12% (open 
symbols, dashed line) or 50% (solid symbol, solid line) POPS (blue), POPG 
(green) or BMP (red). The corresponding bar graph displays the dye release 
at pH 5.5 in the control (black), 12% (open bar) and 50% (solid bar) of 
POPG, POPS or BMP containing LUVs.  Error on all values is SE from n=3, 
each of 3 replicates (341). Experiments performed by Dr Sophie Goodchild. 
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the extent of β2m amyloid fibril liposome disruption. The same carboxyfluorescein 
dye release assay was employed. These studies showed that in the presence of 
heparin, a known stabiliser of long-straight β2m amyloid fibrils formed at low pH  
(78), the extent of dye release was significantly reduced (342). The reduction of 
membrane disruption was achieved without affecting the extent of fibril-lipid 
interactions (342). This raises the possibility that, although β2m amyloid fibril-lipid 
interactions are known to take place (358), they may not directly mediate membrane 
disruption, but instead suggest that membrane disruption could be mediated by a 
species that forms from the amyloid fibril. Observations similar to this have been 
made before, such as the formation of ‘reverse-generated’ oligomers of Aβ40 when 
fibrils interact with cellular membranes (367) (see Section 1.3.7) Therefore, to 
further probe the mechanism of fibril-mediated membrane disruption, the dynamic 
behaviour of β2m amyloid fibrils upon dilution into pH 7.4 and pH 6.4 buffers was 
analysed – the two conditions in which the greatest difference in membrane 
disruption potential is observed (Figure 2.3.5). 
To explore the role of fibril dynamics in membrane disruption, the response of 
amyloid fibrils upon dilution into pH 7.4 or pH 6.4 buffers was investigated in the 
absence of 400 nm LUVs. 120 µM β2m fibrils formed at pH 2.0, as described in 
Section 2.2.4, were diluted to 30 µM in either 50 mM sodium phosphate buffer, pH 
7.4, containing 35 mM sodium chloride (pH 7.4 buffer) or 50 mM sodium phosphate 
buffer, pH 6.4, containing 85 mM sodium chloride (pH 6.4 buffer, buffers possess 
equivalent ionic strength of 164 mM). The effect of diluting the fibrils into these 
conditions was monitored at 25°C using the fluorescent molecule Thioflavin T (ThT) 
(79). Upon dilution into either pH 7.4 or 6.4 buffers, β2m fibrils show significant 
changes in ThT fluorescence, with an initial increase followed by a slow decrease of 
fluorescence, after 10 and 25 min respectively (Figure 2.3.6a and b). This biphasic 
behaviour can be described by a double exponential function, enabling quantitative 
kinetic information regarding the change in ThT fluorescence over time to be 
extracted (Figure 2.3.6b). The rate constants relating to both the enhancement and 
loss of ThT fluorescence are surprisingly similar between both conditions (Figure 
2.3.6b), however a larger increase in the amplitude associated with the loss of ThT 
fluorescence is observed at pH 7.4, corresponding to 60% of the total kinetic 
amplitude compared with only 30% at pH 6.4, 200 min after dilution (Figure 2.3.6a). 
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The similarity between kinetic rate constants suggests that the underlying response 
of the fibrils is similar at both pH values, although the equilibrium has shifted 
significantly at pH 6.4 in favour of maintaining cross-β architecture.  
To show that that the loss of ThT fluorescence does not simply result from fibril 
dilution, samples were diluted to the same concentration in pH 2.0 fibril growth 
buffer. Fibrils were then incubated at room temperature for 1 h alongside samples 
diluted to pH 6.4 or 7.4. After 1 h, the FLDs were determined using AFM to 
examine (a) how the loss of ThT fluorescence relates to the change in the distribution 
of fibril lengths and (b) to ensure that the FLD of samples diluted into fibril growth 
buffer remained unchanged. Figure 2.3.6c and d shows that upon dilution into pH 7.4 
buffer or pH 6.4 buffer, the FLD is shifted significantly to shorter particles, 
indicating that fibril lengths have been globally reduced in comparison with the 
Figure 2.3.6 Dynamic β2m fibril behaviour upon dilution to higher pH. (a) ThT fluorescence 
kinetics of β2m amyloid fibrils upon dilution into pH 7.4 buffer (purple) or pH 6.4 buffer 
(green) fitted by a double exponential function (residuals shown below curve). Curves are 
normalised to the highest ThT fluorescence reading within each curve Rate constants 
extracted from the fitting procedure are shown in (b). Errors are the standard deviation from 
fitting at least 5 independent curves from each condition. (c) AFM FLDs of β2m 1 h after 
dilution at pH 7.4 (c), pH 6.4 (d) or pH 2 (e). The FLD of the original fibril sample used is 
shown plotted behind the FLDs in light grey. Scale bar = 2 m. 
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original FLD (grey distribution shown behind in Figure 2.3.6c-e). Conversely, upon 
dilution and incubation of fibrils with fibril growth buffer, the FLD remains 
unchanged (Figure 2.3.6e). This indicates that the reduction in ThT fluorescence is 
specific to the increase in pH and reflects a reduction of fibril length.  
Losing fibril mass would be to expected to result in the formation of soluble species. 
This was confirmed using a filter-trap assay. Fibrils were partitioned from soluble 
material at different times after the initial dilution at pH 7.4 or 6.4 by passing the 
solution through a 0.2 µm syringe filter. The amount of soluble material released was 
then quantified using SDS-PAGE as outlined in Section 2.2.8. After 0 min at pH 7.4 
or pH 6.4, no soluble material is detectable in the fibril samples as judged by SDS-
PAGE (Figure 2.3.7a and b respectively). This is consistent with previous results 
showing that ~100% of β2m is incorporated into amyloid fibrils at low pH (146). The 
reappearance of soluble material over time is shown in Figure 2.3.7a-b along with 
the corresponding ThT fluorescence measurements from Figure 2.3.6. The amount of 
released soluble material has been normalised with respect to the total β2m assay 
concentration of 30 µM. Under both conditions, a loss of ThT fluorescence 
correlates with the reappearance of soluble material (Figure 2.3.7a – pH 7.4 and b – 
pH 6.4). The greater amount of soluble material reappearing at pH 7.4 corresponds to 
the greater amplitude of the decrease in ThT fluorescence observed from the kinetic 
experiments (Figure 2.3.7). Thus, the loss of ThT fluorescence is due to fibril 
depolymerisation that yields soluble species induced by changes in pH. 
Figure 2.3.7 Soluble material reappears upon loss of ThT fluorescence. Normalised ThT 
fluorescence kinetics of β2m amyloid fibrils incubated at pH 7.4 (a) or pH 6.4 (b, solid lines) 
and the corresponding production of soluble material quantified using SDS-PAGE 
densitometry (dashed lines, representative gel image shown above). 
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At present it is unknown why ThT fluorescence increases during the initial stages of 
depolymerisation. Upon dilution into buffers at near-neutral pH, β2m amyloid fibrils 
are known to laterally associate (358). The change in environment may increase the 
fluorescence yield of ThT. Equally; β2m fibrils may undergo conformational changes 
that create architectures with greater ThT binding affinities, or fluorescence quantum 
yields. Such changes in the fluorescence yield of ThT is known to take place for 
different amyloidogenic aggregates of β2m (368). A solution-induced conformational 
change of the β2m fibril structure is supported from CD analysis of fibrillar material. 
The negative max shifts from 217 nm under fibril growth conditions (pH 2.0) to 225 
nm, 30 min or 60 min after dilution into pH 7.4 or 6.4 buffers, respectively (Figure 
2.3.8a and b). The reason for solution-induced conformational change in the fibril 
architecture is discussed in more detail in Chapter 4. 
The consequence of releasing soluble material during depolymerisation was next 
investigated by employing the carboxyfluorescein dye release assay with vesicles 
containing 12 mol% BMP and the complex lipid mix defined in Table 2.3.1. 400 nm 
LUVs containing BMP were used in these assays as they show the greatest 
amplitude of dye release (Figure 2.3.5a). In order to assay the membrane disruption 
potential of soluble species released from 2m fibrils, duplicate samples were diluted 
to pH 7.4 or pH 6.4 before allowing depolymerisation to proceed for 30 or 60 min 
respectively. At these time points a similar amount of soluble material (~30%) has 
been released under both conditions (Figure 2.3.7a-b). Prior to adding LUVs to 
Figure 2.3.8 Conformational changes within β2m amyloid fibrils upon changes in pH. 
CD spectra of β2m amyloid fibrils under fibril growth conditions (black line) and 30 
min or 60 min after dilution into pH 7.4 buffer (a – purple dash line) or pH 6.4 buffer 
(b – green dashed line) respectively. 
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samples, one replicate was filtered to remove fibrils from solution, thus allowing a 
direct comparison between the dye release potential of total protein (filtrate + fibrils) 
and filtrate (soluble material) to be made. Under both conditions, the dye-release 
potential of the filtrate accounts for 60 – 80% of the total dye release (Figure 2.3.9a – 
pH 7.4 and b – pH 6.4). Moreover, the extent of dye release increases ~ 2-fold from 
pH 7.4 to pH 6.4, consistent with previous observations (Figure 2.3.5).  
To compare the membrane disruption potential of fibrils and soluble species, the 
extent of fibril-induced dye release was calculated by subtracting the % dye release 
of the filtrate alone from that of the total protein sample. Dye release potential was 
normalised to the amount of soluble material within each fraction by quantifying the 
protein concentration in partitioned filtrates using SDS-PAGE (gel inset, Figure 
2.3.9a and b). The fibril concentration was calculated by subtracting the filtrate 
concentration from the total assay concentration. This shows that the filtrate 
generated at pH 6.4 has 5 times the membrane disruption potential of fibrils at the 
equivalent pH and is greater than 2-fold more membrane-active than the filtrate 
generated at pH 7.4 per µM of protein (Figure 2.3.9c). Native monomeric β2m 
controls exhibit minimal dye release potential (Figure 2.3.9a - b). This suggests that 
depolymerisation must produce soluble, non-native, membrane-active species, the 
stability and concentration of which are significantly enhanced at pH 6.4. 
Figure 2.3.9 Soluble material causes membrane disruption. (a) Carboxyfluorescein dye 
release caused by β2m amyloid fibrils and soluble material (total) and isolated soluble 
material (filtrate) 30 min after depolymerisation initiation at pH 7.4. (b) Dye release 
experiments of filtrate and total protein samples after 1 h of depolymerisation at pH 6.4. 
Native monomeric β2m controls were performed at an identical concentration to total protein 
samples. (c) Dye release potential of fibrils only, filtrate and native β2m monomers, 
normalised to protein concentration calculated by SDS-PAGE densitometry. 
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2.3.5 Reducing molecular shedding via chemical cross-linking alleviates 
β2m fibril-mediated toxicity 
To examine whether fibrils mediate metabolic dysfunction through the release of 
membrane-active soluble species, a cross-linking strategy was developed to prevent 
(at least in part) the depolymerisation of β2m amyloid fibrils upon dilution into near-
neutral pH buffers. The rationale behind the choice of cross-linking moiety was to 
promote intra- over inter-fibril cross-linking, thus ensuring fibrils remain diffuse, but 
depolymerisation is disfavoured. To this end, the amine reactive and pH independent 
photo-activatable cross-linking moiety LC-SDA diazirine was used, to enable cross-
linking under fibril-growth conditions (Section 2.2.11). Diazirine-labelled native β2m 
was incorporated into β2m amyloid fibrils at 40% of the total protein without 
affecting the fibril morphology, or reducing the yield of incorporation of β2m 
monomers into amyloid fibrils (Figure 2.3.10a and b). An ESI mass spectrum of 
Figure 2.3.10 Incorporation of diazirine-labelled β2m into β2m 
amyloid fibrils. (a) Quantification of remaining soluble material 
after 48 h fibril growth with increasing % of Diazirine β2m. (b) 
Negative-stain TEM of 40% diazirine-labelled β2m monomer-
containing fibrils. (c) ESI mass spectrum of HFIP depolymerised 
fibrils formed from 60% wt 2m and 40% diazirine-labelled 2m 
monomers. 
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HFIP depolymerised fibrils containing diazirine-labelled β2m monomers is shown in 
Figure 2.3.10c. As β2m contains seven lysine residues (and a reactive N-terminal 
amine), a range of stoichiometries of diazirine-labelled β2m monomers are present in 
the fibrils. While the majority of molecules within the spectrum corresponds to 
unlabelled β2m (no diazirine, mass of 11860 Da), peaks corresponding to diazirine-
labelled 2m with 4 (12756 Da), 5 (12980 Da), 6 (13204 Da) or 7 (13428 Da) 
conjugated diazirine moieties can be observed (Each diazirine label adds 224 Da of 
mass to 2m). 2m molecules with < 3 diazirine moieties are not observed. Thus, 
diazirine-β2m can be successfully incorporated into wt β2m fibrils formed at low pH. 
To ensure that the stability of fibrils containing 40% diazirine-labelled 2m 
monomers (without cross-linking by irradiation) is similar to that of wt fibrils under 
cell culture conditions, the kinetic stability assay was again employed (Section 
2.2.7). The kinetics of depolymerisation of 1.2 M wt fibrils and non-irradiated 
fibrils containing 40% diazirine-labelled 2m were monitored within DMEM 
containing 10% (v/v) foetal bovine serum (FBS), 1% (w/v) L-glutamine, and 1% 
(w/v) penicillin/streptomycin (complete DMEM) at 37C. The kinetics of 
depolymerisation were similar for both fibril samples (Figure 2.3.11a). There is also 
no significant difference in the reduction in metabolic activity in SH-SY5Y cells 
incubated with non-irradiated fibrils containing 40% diazirine-labelled 2m 
monomers or wt fibrils, as judged by the MTT assay (Figure 2.3.11b).  
Photo-activation of fibrils containing 40% diazirine-labelled 2m monomers in fibril 
growth buffer yields a high molecular weight ladder of bands as judged by SDS-
PAGE, indicating higher-order cross-linking has taken place (Figure 2.3.11c). 
Moreover, the degree of cross-linking is independent of fibril concentration, 
suggesting that cross-linking is predominantly intra-fibrillar (Figure 2.3.11c). UV-
stabilised fibrils were then purified from non-cross-linked material through 
successive rounds of depolymerisation (Section 2.2.11) until a stable ThT 
fluorescence signal was observed upon dilution into pH 7.4 buffer (Figure 2.3.11d). 
Stabilised fibrils appeared well dispersed by EM, again supporting intra-fibril cross-
linking, but were reduced in length (approximately > 0.5 m) in comparison to the 
parent the fibril population (Figure 2.3.10b). UV-stabilised fibrils and wt fibrils were 
then incubated with SH-SY5Y neuroblastoma cells for 24 h at identical monomer-
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equivalent concentrations of 1.2 M. Cellular metabolic activity was measured using 
the MTT assay (Section 2.2.9). The results revealed that cells incubated with UV-
stabilised fibrils experience a modest, but significant, reduction in the metabolic 
dysfunction caused by the presence of β2m amyloid fibrils (Figure 2.3.11f). Thus, 
shedding of soluble material from fibrils appears to contribute towards β2m fibril-
mediated mechanisms of metabolic dysfunction. 
2.3.5 Hsp70 reduces fibril depolymerisation and rescues fibril-mediated 
metabolic disruption 
Many recent advances in identifying the mechanisms of toxicity in protein 
conformational diseases have shown that the aberrant association of aggregates with 
constitutive parts of the proteostatic network can have damaging consequences (233, 
234, 311, 369, 370). As such, modulation of the proteostatic network, in particular 
Figure 2.3.11 Diazirine stabilised fibrils display reduced cellular effects. (a) Comparison of 
kinetic stability of 1.2 M non-irradiated fibrils containing 40% diazirine-labelled 2m and 
wt fibrils incubated in complete DMEM at 37
o
C monitored by ThT fluorescence. (b) MTT 
reduction in SH-SY5Y cells in the presence of 1.2 M wt or non-irradiated fibrils containing 
40% diazirine-labelled monomer. MTT reduction is shown normalised to buffer-only 
controls (c) The concentration dependence of 40% diazirine-labelled monomer fibril cross-
linking assayed by SDS-PAGE. (d) Kinetic stability of purified cross-linked fibrils in pH 7.4 
buffer. (e) negative-stain TEM of cross-linked fibrils after purification by depolymerisation 
in pH 7.4 buffer (Scale bar = 100 nm). (h) % MTT reduction of SH-SY5Y cells treated with 
either 1.2 M wt fibrils, stabilised fibrils, native β2m monomer or buffer. Error bars are the 
standard deviation from 3 x 5 replicates. 
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redressing proteostatic imbalance, has been touted as a promising therapeutic avenue 
for amyloid diseases (8, 51, 250, 310, 311, 371–375). The molecular chaperone, 
Hsp70, is expressed upon the induction of a wide range of cellular stresses (45). The 
inducible expression of Hsp70 has made this an attractive target to increase the 
protein-assisted protein folding capacity of a cell overwhelmed with amyloid 
aggregates (372). The association of Hsp70 (and its constitutively expressed 
homologue Hsc70) with aggregates has thus been intensively investigated (236, 239, 
376–381). Here, recombinant Hsp70-1A (kindly provided by Toral Jakhria, 
University of Leeds – purified as detailed in (380) and herein referred to as Hsp70) 
was incubated with β2m amyloid fibrils in a 1:0.25 and 1:3 molar ratio to investigate 
the effect of the chaperone on fibril depolymerisation kinetics monitored by ThT 
fluorescence (Section 2.2.7). Upon dilution of 120 µM β2m fibrils to 1.2 µM in either 
pH 7.4 or 6.4 buffer at 37°C, Hsp70 rescues against the loss of ThT fluorescence in a 
dose-dependent manner (Figure 2.3.12a-b). More specifically, even at a 1:0.25 
β2m:Hsp70 molar ratio, the kinetic amplitude of the loss of ThT fluorescence after 
200 min is reduced by 3-fold or 4-fold at pH 6.4 or pH 7.4 respectively, over fibril-
only controls (Figure 2.3.12a and b). Incubating fibrils with a 3-fold molar excess of 
Hsp70 reduces significantly the decay of ThT fluorescence at pH 6.4 (although the 
initial increase in amplitude is still observed) and increases the ThT fluorescence at 
equilibrium to almost 80% of the initial ThT fluorescence intensity at pH 7.4 (Figure 
2.3.12b). Therefore at both pH 6.4 and 7.4 Hsp70 is able to restrict β2m amyloid 
fibril pH-induced depolymerisation. 
To determine whether the stabilisation of β2m amyloid fibrils upon interacting with 
Hsp70 reverses the metabolic defects induced by fibrils upon incubation with cells, 
the MTT assay was again employed. SH-SY5Y neuroblastoma cells were pre-
incubated with either 0.3 µM or 3.6 µM Hsp70 for 6 h prior to adding 1.2 µM β2m 
and incubating for a further 24 h (Section 2.2.12). Pre-incubating cells with Hsp70 
allows the chaperone to localise to endocytic vesicles prior to the addition of β2m 
amyloid fibrils. This should allow fibrils to be subsequently trafficked within the cell 
and promote in situ binding of amyloid fibrils and Hsp70 within endocytic 
compartments. Quantifying metabolic dysfunction 24 h after the addition of fibrils 
reveals a dose-dependent rescue in apparent cell viability, with 3 molar equivalents 
of Hsp70 reversing the metabolic dysfunction observed upon addition of β2m fibrils 
Chapter 2 
 
79 
 
(Figure 2.3.12c). This dose-dependent rescue is similar to that observed in the kinetic 
stability assay (Figure 2.3.12a - b). In addition, recent experiments from our 
laboratory have shown that β2m amyloid fibrils disrupt lysosomal function by 
reducing lysosomal proteolysis (340). Exogenously applied fluorescent ovalbumin 
localises to the lysosome and acts as a substrate for lysosomal proteolysis (340). 
Quantifying the fluorescence of ovalbumin 24 h after feeding the substrate to SH-
SY5Y cells in the presence or absence of β2m fibrils reveals that almost twice the 
amount of fluorescent ovalbumin persists when fibrils are present (Figure 2.3.12d). 
This indicates that fibrils impede the lysosomal proteolytic machinery. Here, pre-
incubating cells for 6 h with Hsp70 before the addition of fibrils restores ovalbumin 
fluorescence levels after 24 h to those observed for buffer only controls (Figure 
2.3.12d). This indicates that preventing the in situ depolymerisation of β2m amyloid 
fibrils within endocytic vesicles may be responsible for reducing fibril-mediated 
metabolic dysfunction, further supporting the view that shedding of soluble species 
from fibrils is an important determinant of β2m fibril-mediated metabolic 
dysfunction. 
Figure 2.3.12 Hsp70 prevents disassembly and rescues against β2m fibril-mediated 
deleterious effects. Kinetic stability of 1.2 µM β2m amyloid fibrils at 37°C in the presence 
or absence (black) of 0.25 molar (triangles) or 3 molar (circles) equivalents of Hsp70 at pH 
6.4 (a) or pH 7.4 (b). (c) % MTT reduction in cells incubated with 1.2 µM β2m fibrils after 
pre-incubating with 0, 0.25 or 3 molar eq. of hsp70 for 6 h. (d) Lysosomal degradation 
assay performed with labelled Alexa647 labelled ovalbumin. After incubating cells for 6 h 
with 3 molar equivalents of hsp70, buffer, native β2m or fibril samples were added to cells 
and incubated for a further 24 h prior to the addition of fluorescent ovalbumin. Fluorescence 
was quantified after 0 h 24 h by FACS. % fluorescence is expressed as a change in the 
levels from 0 to 24 h. Performed in collaboration with Toral Jakhria.  
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2.3.6 Detection of depolymerisation intermediates using ESI-IMS-MS 
Having established that soluble species are responsible for liposome disruption and 
appear to mediate, at least in-part, the metabolic defects elicited by β2m fibrils in 
cells, the next step was to elucidate structural properties of these species. To this end 
electrospray ionisation ion mobility spectrometry mass spectrometry (ESI-IMS-MS), 
a technique able to detect assembly intermediates on pathway to amyloid formation, 
was used (306–308, 382, 383). ESI-IMS-MS provides an even greater resolution 
than ESI-MS by separating species based on their shape/size in addition to their 
mass-to-charge ratio (m/z). This is performed by accelerating species after ionisation 
through an ion mobility ‘drift’ cell filled with an inert buffer gas (Figure 2.3.13). 
Collisions between molecules and the buffer gas slow the progress of ions in a 
manner dependent on their collisional cross section as they traverse the drift cell, 
thus separating species by shape/size. Therefore, ions with identical m/z ratio but 
distinct conformations (e.g. folded and unfolded monomer) can be resolved (Figure 
2.3.13b). For higher order assemblies, ESI-IMS-MS can provide structural 
information by reporting on the size, collisional cross sections, and stoichiometry 
(384). Combining spatial information with mass measurements allows models to be 
built to approximate the morphology of oligomers detected within the gas phase 
(308, 382, 385). The relative success of employing this technique in studying 
Figure 2.3.13 Schematic of ESI-IMS-MS. (a) Simplified schematic showing the essential 
features of an ion-mobility spectrometry mass spectrometer. Proteins are ionised at the 
ionisation source prior to being guided into the ion mobility drift cell where species are 
separated based on their size and shape. Collisions with an inert buffer gas retard the speed 
at which ions traverse the cell, with expanded, unfolded conformers exhibiting increased 
drift times in comparison with their compact natively folded counterparts. From the drift 
cell ions are separated in a time of flight (ToF) mass analyser based on their m/z ratio. (b) 
Illustration of the power of ion mobility resolve species with the same m/z. In the m/z graph 
the expanded and folded conformers appear as a single peak due to having the same m/z 
ratio. The drift time graph indicates the presence of two conformers. Combining the data 
allows the separation of ion based on m/z and drift time. 
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assembly mechanisms from several distinct amyloidogenic precursors was why ESI-
IMS-MS was used to interrogate the species forming during β2m amyloid fibril 
depolymerisation.  
In order to study fibril depolymerisation using ESI-IMS-MS alternative buffers need 
to be used. Salts, such as NaCl, form adducts to proteins during the ionisation 
process, leading to a large spread in ion intensities due to the increase in 
heterogeneity of mass in the presence of the adduct ions. Therefore, buffers, such as 
ammonium bicarbonate are more desirable (volatile buffer), as buffer ions evaporate 
during the ionisation process. To test whether observations made in sodium 
phosphate buffers are equivalent in volatile buffers of identical pH and ionic 
strength, the kinetic stability of 2m fibrils was monitored in 164 mM ammonium 
bicarbonate buffer (volatile buffer), pH 7.4 at 25°C. The rate of depolymerisation 
and appearance of soluble material were unaltered by the change to volatile buffer, 
as indicated by the good correlation between the loss of ThT fluorescence and 
appearance of soluble material, and the rate constants for the loss of ThT 
fluorescence calculated under both conditions (Figure 2.3.14a-b). Moreover, 
Figure 2.3.14 Fibril depolymerisation in volatile buffer. (a) SDS-PAGE of soluble material 
and the corresponding ThT fluorescence time points recorded during depolymerisation of 
β2m in 164 mM ammonium bicarbonate buffer, pH 7.4. (b) Rate constants for the decay of 
ThT fluorescence during fibril depolymerisation in 50 mM sodium phosphate buffer, pH 
7.4 containing 35 mM NaCl (salty buffer) and in volatile buffer, pH 7.4. Error is the 
standard deviation from a minimum of three independent replicates. (c) SDS-PAGE 
quantification of multiple replicates (reps 1-3) of soluble material partitioned 30 min after 
the initiation of depolymerisation in volatile buffer at pH 7.4. Error is the standard deviation 
of the three measurements. 
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partitioning and quantifying soluble material 30 min after the initiation of 
depolymerisation in pH 7.4 volatile buffer shows that 12 µM of protein is 
reproducibly released (Figure 2.3.14c). This is consistent with previous results 
(Figure 2.3.7) and further confirms the conservation of depolymerisation kinetics 
upon dilution into volatile pH 7.4 buffer. Depolymerisation kinetics were not 
monitored at pH 6.4 due to difficulties in buffering in volatile buffers at this pH. 
To structurally probe soluble species released during depolymerisation using ESI-
IMS-MS, spectra of soluble material partitioned after 30 min of fibril 
depolymerisation in volatile buffer were acquired (Section 2.2.13). Depolymerisation 
was initiated as previously described (Section 2.2.13) using fibrils formed at pH 2.0. 
Spectra of native monomeric β2m under equivalent conditions and identical 
concentration were also acquired, to allow side-by-side comparison of species 
Figure 2.3.15 Drift plots of soluble material and native β2m controls at 
pH 7.4. (a) Drift plot acquired 30 minutes after depolymerisation 
initiation in pH 7.4 volatile buffer and of (b) native β2m controls 
performed at equivalent concentrations in the same buffer. Monomer, , 
dimer and trimer species are indicated by m, d and t respectively. The 
superscript number indicates the charge state of the ion. 
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formed during depolymerisation and those observed in native β2m controls. Figure 
2.3.15 shows that ESI-IMS-MS was not able to detect oligomeric species released 
from fibrils that are distinct from those formed in native β2m controls. The 
oligomerisation of native β2m (Figure 2.3.15b) taking place during ionisation and has 
been previously documented (383). 
Control samples also appeared to possess a significant degree of unfolded 
monomeric protein as judged by ESI-IMS-MS. This is best observed for the 
monomer 8+ charge state (Figure 2.3.15b), as two clearly separated conformers are 
observed, with approximate drift times of 5 and 7.5 ms respectively. Unfolding of 
native β2m in control samples is a consequence of the relatively high energy 
instrument parameters required to detect higher order species. Identical monomer 
control samples subjected to ESI-MS (section 2.2.1.6) show a different charge state 
distribution in comparison with the monomer charge state distribution collected 
under ESI-IMS-MS conditions (Figure 2.3.16). The base peak shifts from the 7+ to 
Figure 2.3.16 IMS parameters promote native β2m gas phase unfolding. 
(a) m/z spectra of native β2m in 50 mM ammonium acetate pH 7.4 in 
MS-mode and IMS-MS mode (b). Monomer charge states are labelled, 
with the charge state indicated by the number. 
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the 6+ charge state from IMS to MS mode (Figure 2.3.16), indicating ions are more 
compact when the drift cell is not employed. The acquisition of charge during 
sample ionisation is related to the fold of a protein, with a more expanded, or 
unfolded, conformer often displaying an increase in the number of ionisation charges 
(386). 
Although ESI-IMS-MS was unable to detect oligomeric species whose formation is 
specific to fibril depolymerisation (Figure 2.3.15), comparison of the spectra show 
that soluble material partitioned during fibril depolymerisation is significantly 
reduced in peak intensity in comparison with native β2m controls acquired at 
equivalent concentrations. (Figure 2.3.15). This suggests that oligomeric species may 
be present in the soluble material, but are not detected by ESI-IMS-MS. This may be 
because either higher order species released during depolymerisation are too 
heterogeneous to detect, or are not ionised under the conditions employed. The 
amount of detectable monomer within the soluble material was therefore measured 
quantitatively using ESI-MS so as to demonstrate whether oligomeric species may 
be present but undetected in samples analysed by ESI-IMS-MS. Quantitative ESI-
MS was performed by incorporating bradykinin as an internal standard into soluble 
material and native controls prior to ionisation (Section 2.2.13, (387)). Normalising 
the ion intensity to the bradykinin internal standard shows that of the 12 µM soluble 
material determined to be in solution after 30 min of depolymerisation at pH 7.4 
(Figure2.3.14b), only 25% was detectable in comparison with native monomeric 2m 
controls acquired at equivalent concentration (Figure 2.3.17a-c).  
To show that the loss of β2m monomer peak intensities in spectra acquired from 
soluble material is due to the sequestration of β2m into MS-unobservable species and 
not due to the incorrect calculation of the concentration of soluble material isolated 
during depolymerisation, samples and controls were lyophilised and re-suspended in 
the equivalent volume of acid denaturing buffer (H2O containing 50% (v/v) 
acetonitrile and 0.1% (v/v) formic acid) (Figure 2.3.17d-e). Re-quantification of 
peaks under these conditions resulted in the detection 100% of monomer in the 
soluble material samples, with the overall ion intensity in good agreement with 
monomer controls (Figure 2.3.17a). This confirms that the lower ion intensity of 
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monomer in samples generated during fibril depolymerisation at pH 7.4 is not due to 
the incorrect calculation of the concentration (Figure 2.3.17a).  
There are several possible reasons why higher order or, more specifically non-native 
species are not detectable by ESI-IMS-MS. Firstly, the lack of detection of higher 
order species could be due to the heterogeneous nature of amyloidogenic aggregates, 
with no one oligomeric state populated to a high enough concentration for detection 
by ESI-IMS-MS. Secondly, the presence of higher order aggregates may also affect 
Figure 2.3.17 Quantification of monomer peak intensity during 
fibril depolymerisation. (a) The relative monomer intensity of 
soluble material ionised under native (pH 7.4 volatile buffer) and in 
acid unfolded conditions expressed with respect to the ion intensity 
of native β2m controls acquired at equivalent concentrations. 
Example drift plots of soluble material and native β2m controls 
acquired in native conditions (b and c respectively) and in acid 
denaturing conditions (d and e respectively). The 6 – 8+ monomer 
charge states used for quantification are labelled with the 
corresponding m/z spectra shown on the right-hand y –axis. 
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the ionisation of native monomer in solution, therefore generating artificially low 
detectable concentrations of native β2m with respect to the total amount of protein 
present in the soluble material. Nevertheless, ESI-IMS-MS has illustrated the 
presence of non-native species accumulating during fibril depolymerisation at pH 
7.4, as demonstrated by the reduced native β2m ion intensity in comparison with 
native β2m controls (Figure 2.3.17a). 
2.3.7 Using NMR to probe differences in species formed during fibril 
disassembly 
The experiments performed so far have indicated that the pH-dependent differences 
in liposome disruption potential of 2m amyloid fibrils cannot be rationalised simply 
through the extent of the loss of cross-β structure (or ThT fluorescence). If anything, 
the loss of ThT fluorescence is inversely proportional to the membrane disruption 
potential of soluble material generated during depolymerisation, as soluble material 
at pH 6.4 has more than twice the membrane disruption potential than that generated 
at pH 7.4 per µM of protein (Figure 2.3.9c). As non-native species must populate 
during depolymerisation (since native monomeric β2m is unable to cause membrane 
disruption (Figure 2.3.9) the species generated during depolymerisation at pH 6.4 are 
either distinct to those which form at pH 7.4, or are present in higher concentrations. 
As shown in the previous section, ESI-IMS-MS was not able to detect non-native 
species that form during fibril depolymerisation at pH 7.4. Therefore, in order to 
interrogate the formation and structure of soluble species generated during 
depolymerisation further, fibril depolymerisation was monitored in all-atom-detail 
using heteronuclear NMR (Section 2.2.12). NMR was chosen due to its ability not 
only to inform as to the reappearance of native monomer during fibril 
depolymerisation, but also because it enables the interrogation of the rate of 
production of native molecules during the fibril depolymerisation process. In 
addition, NMR may be able to detect i) small, non-native species that are 
significantly populated during depolymerisation, ii) identify residues within 2m that 
may be important for the formation of non-native species and iii) allow the kinetics 
of depolymerisation to be probed in greater detail in the sodium phosphate buffers 
used thus far.  
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Under the current experimental conditions, the monomer equivalent concentration of 
2m used in depolymerisation experiments is likely to be too low in order to 
interrogate fibril depolymerisation. Fibril depolymerisation control experiments 
performed at pH 6.4 at significantly elevated concentrations show that the kinetics of 
fibril depolymerisation do not depend on the initial fibril concentration (Figure 
2.3.18). Therefore, the initial monomer equivalent fibril concentration can be 
enhanced significantly to enable detection of species that form during 
depolymerisation using NMR.  
Measurement of the depolymerisation of β2m fibrils using real-time NMR was 
performed by diluting 600 µM 
15
N-labelled β2m fibrils formed at pH 2.0 to 150 µM 
Figure 2.3.18 The rate of fibril depolymerisation at a 
different initial fibril concentration. (a) Depolymerisation 
kinetics of β2m amyloid fibrils monitored by ThT 
fluorescence. 600 µM or 120 µM β2m fibrils were diluted 4-
fold to 150 µM and 30 µM into pH 6.4 buffer at 25°C. The 
Traces show the fitted curve, with residuals shown in (b) for 
the 150 µM  sample and (c) for the 30 µM sample. (d) 
Comparison of the two kinetic rate constants for the 
different fibril concentrations.  
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in pH 7.4 or 6.4 buffer. 
15
N – 1H HSQC spectra were acquired at evenly spaced time 
intervals after depolymerisation was initiated (see Section 2.3.12). During early time 
points at pH 6.4, significant chemical shift differences are seen for a number of 
residues as compared with native-β2m controls, including H84, K75 and R45 (Figure 
2.3.19). These non-native peaks are not observed at later time points, presumably 
due to the accumulation of native β2m amide resonances (black crosspeaks in Figure 
2.3.19 – collected 3 h after depolymerisation was initiated in either condition). 
Notably, non-native chemical shifts are not observed during the initial stages of fibril 
depolymerisation at pH 7.4 (Figure 2.3.19 and Figure 2.3.20 – purple cross peaks). 
The acquisition time of individual spectra could not be significantly reduced in order 
to determine whether similar peaks populate during the initial stages of fibril 
depolymerisation at pH 7.4 (see Section 2.2.14). 
Figure 2.3.19 
15
N-
1
H chemical shifts of resonances observed during the 
initial stages of fibril depolymerisation. Select regions of 
15
N-
1
H HSQC 
spectra collected 15 min after initiating depolymerisation at pH 7.4 (a) 
and pH 6.4 (b). Plots are overlayed with chemical shifts from the same 
region collected 3 h after depolymerisation was initiated (black). The 
identity of residues are labelled in the spectra 
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During the depolymerisation time course, the extent to which native amide 
resonances reappear is much greater at pH 7.4 than pH 6.4 (Figure 2.3.20). This 
observation is consistent with the increased amplitude of soluble material released 
during depolymerisation at pH 7.4, as monitored by SDS-PAGE (Figure 2.3.7). In 
addition, the detection by NMR of large amplitude of native monomeric 2m 
Figure 2.3.20 Reappearance of native amide resonances during 
depolymerisation of β2m amyloid fibrils. Select region of 
15
N-
1
H 
HSQC spectra acquired during depolymerisation of 150 µM 
15
N-
labelled β2m fibrils at pH 6.4 (green) or pH 7.4 (purple). Equivalent 
time points from each experiment are displayed with the identity of 
native amide resonances labelled on the t = 175 min spectrum. 
Chapter 2 
 
90 
 
reappearing during depolymerisation at pH 7.4 suggests that the presence of a small 
population of non-native species must prevent the ionisation of monomer during 
ESI-IMS-MS (Figure 2.3.15). This is as opposed to a large concentration of non-
native species accounting for the reduced ion intensities of native 2m charge states 
observed in comparison with monomeric β2m controls.  
Additional information can be extracted from NMR by calculating the rate at which 
native amide resonances reappear during fibril depolymerisation, by plotting peak 
intensity vs. time (Figure 2.3.20 and Figure 2.3.21). Native amide resonances in each 
spectrum were identified by peak mapping to spectra obtained of native β2m controls 
assigned in identical solution conditions. Peak intensities for each amide resonance 
were then extracted and plotted vs. time (Figure 2.3.21) (Section 2.2.14) (157). Time 
constants for the reappearance of all assigned native amide resonances were then 
calculated by fitting the curves to a single exponential function (Figure 2.3.21) 
Plotting the resulting time constant on a per residue basis reveals that every residue 
of 2m appears in the spectrum at a similar apparent rate (Figure 2.3.22). This is 
consistent with a global cooperative process for the formation of native 2m during 
fibril depolymerisation. Native monomer reappears more rapidly during 
depolymerisation at pH 7.4 compared with pH 6.4 (average time constant of 101 min 
and 156 min respectively). Comparison of these time constants with those 
determined using ThT fluorescence shows the two rates are in excellent agreement at 
pH 7.4 (ThT – 91 ± 7.min, NMR – 101 ± 10.min; inter-experiment error calculated 
Figure 2.3.21 Extracting rates for the reappearance of native amide resonances during fibril 
depolymerisation. Peak intensities of native amide resonances identified by peak mapping 
(see section 2.2.12) were extracted from each HSQC spectrum collected during the 
depolymerisation time course at pH 6.4 (green) and pH 7.4 (purple). Coloured blocks indicate 
time points equivalent to sections of the spectra displayed in Fig. 2.3.20. 
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from two independent experiments). This suggests that the loss of fibrillar material 
after dilution at pH 7.4 results in the rapid formation of membrane-inactive, native 
β2m. Non-native membrane-active soluble species must therefore exist transiently at 
low populations to explain why membrane disruption occurs for soluble material 
generated during depolymerisation at this pH (Figure 2.3.9). The presence of non-
native species populating during depolymerisation at pH 7.4 is supported by the 
reduced ionisation during ESI-IMS-MS of native 2m in soluble material generated 
during depolymerisation at pH 7.4 (Figure 2.3.15).  
Comparison of the two rates at pH 6.4 however, reveals a significant difference 
between the loss of ThT fluorescence and the average rate of native amide resonance 
reappearance as judged by NMR (ThT – 110 ± 10 min, NMR – 158 ± 8.5 min; p < 
0.001, student’s t-test of unequal variance). This confirms that a non-native NMR-
invisible, ThT-negative species, whose formation precedes that of native β2m, must 
be significantly stabilised and persistent during fibril depolymerisation at pH 6.4. 
The enhanced stability and accumulation of non-native soluble species at pH 6.4 
may explain why this filtrate is more than 2-fold more membrane-active per µM of 
soluble material than that generated during depolymerisation at pH 7.4 (Figure 
2.3.9c). 
2.4 Discussion 
The results presented in this chapter establish the importance of β2m amyloid fibrils 
in mediating liposome disruption and metabolic dysfunction through the molecular 
Figure 2.3.22 Per residue reappearance time constant extracted from NMR. (a) Native 
amide resonance peak intensities were extracted from 
1
H-
15
N HSQC spectra collected during 
the depolymerisation of 150 µM 
15
N-labelled β2m amyloid fibrils in pH 7.4 (a) or pH 6.4 (b) 
buffer. Black dashed lines represent the average amide resonance time constant for 
reappearance calculated by NMR. Red dashed lines represent the average time constant for 
the loss of ThT fluorescence. 
a b 
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shedding of membrane-active non-native species. Amyloid fibrils have previously 
been shown to recycle soluble species (188, 238, 242, 243) (as outlined in Section 
1.3.7). However these examples show that the exchange of soluble species with 
amyloid fibrils takes place over long timescales under conditions which promote 
fibril formation (e.g. fibrils formed from the PI3 kinase SH3 domain exchange about 
half their molecules over a period of weeks (242)). In addition, not all of these were 
shown to recycle soluble species which demonstrate toxicity (238, 242, 243). There 
is evidence to support that recycling of soluble species from amyloid fibrils is a 
contributing factor to amyloid toxicity in living systems, as evidenced by the 
oligomeric halo of cytotoxic Aβ1-42 oligomers radiating from fibril plaques in mice 
models of Alzheimer’s disease (343, 388). In addition, membrane-induced amyloid 
fibril depolymerisation has also been shown to promote the release of ‘reverse-
generated’ oligomers of Aβ1-42, identical to those that form in the lag phase of 
amyloid assembly that are cytotoxic (249). The work presented here, however, is the 
first demonstration that amyloid fibril stability can be dramatically altered by subtle 
changes in pH to enhance/supress the formation of species that interact with, and 
damage, liposomes and contribute towards the onset of metabolic dysfunction. The 
surprising sensitivity of the fibril-intermediate-monomer equilibrium to subtle 
changes in pH suggests the latent cytotoxic capacity of an amyloid fibril can be fine-
tuned by the cellular environment into which amyloid may be deposited (Figure 
2.4.1). This phenomenon is likely to have important consequences for a number of 
amyloid diseases, as fibrils are trafficked to environments which are physiologically 
distinct from those in which they are initially formed (216–219, 268, 351). 
More specifically to β2m, the modest reversal in metabolic dysfunction in the 
presence of cross-linked fibrils is mirrored by a reduction in carboxyfluorescein dye 
release assay from BMP containing liposomes. In addition, the total membrane 
disruption potential is not fully accounted for by soluble species generated during the 
depolymerisation process (Figure 2.3.9). Therefore the fibril-membrane interaction 
previously characterised is likely to mediate a proportion of the membrane disruption 
from LUVs, and additionally facilitate toxicity in cells (358). This may also be why 
Hsp70-1A inhibits the metabolic dysfunction associated with β2m amyloid fibril 
incubation; as not only does it prevent the molecular shedding of cytotoxic 
oligomers, but it may also mask the fibril surface which could contribute to the onset 
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of metabolic dysfunction. This illustrates the likely multiplicative toxic mechanisms 
exhibited in the presence of an ensemble of amyloidogenic structures. 
By combining the results presented here with the known biological processes leading 
to β2m amyloid fibril-mediated metabolic dysfunction (outlined in Section 2.1), a 
model of β2m amyloid fibril-mediated cellular disruption can be constructed (Figure 
2.4.1). This shows that, within the extracellular matrix or cell growth medium at ~pH 
7.4, fibril depolymerisation/molecular shedding is rapid and results in the formation 
of native non-toxic β2m. Coupled with a potentially unfavourable lipid composition 
low in BMP (indicated by the green bilayer. BMP is preferentially enriched within 
endocytic membranes), this could explain why β2m fibrils do not disrupt the plasma 
membrane (340) or must be internalised in order to effect metabolic dysfunction 
(340). Upon internalisation, endosome maturation combines a lowering of the pH, 
which may increase the stability of membrane-active soluble species formed during 
depolymerisation, with an increase in the concentration of BMP within the bilayer 
(green to red bilayer). This would create a hotspot from which cellular dysfunction 
could manifest (red organelle). So far, however, there is no evidence to suggest that 
amyloid toxicity is mediated through the disruption of membranes in cells (245, 340, 
349). The complexity of biological membranes however, means that the 
Figure 2.4.1 Hypothetical model of β2m fibril-mediated toxicity. 
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consequences of amyloid-lipid interactions may manifest itself in entirely different 
consequences than simply the disruption observed in the carboxyfluorescein dye 
release assay. 
Overall, the results presented in this chapter establish the pH–dependent formation of 
non-native soluble species that are responsible for the majority of fibril-mediated in 
vitro membrane disruption, and contribute to fibril-mediated metabolic defects. The 
next chapter will aim to elucidate the structural properties of soluble species 
generated during fibril depolymerisation by using fluorescence correlation 
spectroscopy, electron microscopy and a range of biochemical assays. 
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Structural analysis of molecular shedded species 
3.1 Introduction 
3.1.1 Introduction to FCS and its advantages for the study of 
amyloidogenic systems 
As evidenced from results presented in the Chapter 2, despite identifying chemical 
shift perturbations in early time point spectra acquired during fibril depolymerisation 
at pH 6.4, NMR was not able to provide structural information as to the identity of 
species formed through molecular shedding from 2m amyloid fibrils. Equally, 
although ESI-IMS-MS is a powerful technique for analysing the stoichiometries and 
structural properties of oligomers that form in the lag phase of amyloid assembly 
(286, 306–308, 382), it could not detect non-native species that form during the 
depolymerisation of β2m amyloid fibrils. Therefore another strategy was required to 
identify soluble species shed from 2m fibrils that cause membrane disruption. 
Assuming a high level of heterogeneity and low abundance of species that form 
during fibril depolymerisation, single molecule fluorescence correlation 
spectroscopy (FCS) was employed. FCS is a correlation based method which 
exploits fluctuations in fluorescent signals as molecules diffuse through a confocal 
volume (typically 0.1 fL) of known size (389). Due to the increased sensitivity of 
FCS over other diffusion based techniques (when properly optimised, picomolar 
concentrations can be detected) such as dynamic light scattering, and the ability to 
simultaneously correlate species that differ in size over several orders of magnitude, 
FCS is an ideal technique for studying and comparing the lowly abundant 
populations of highly heterogeneous species that form during fibril depolymerisation 
under different sets of conditions. 
3.1.2 Single molecule fluorescence techniques for studying amyloid 
aggregation 
Many single molecule fluorescence techniques are capable of analysing the complex 
ensembles formed during amyloid assembly. Although each technique is distinct, 
most provide similar information, such as oligomer stoichiometry, concentrations, 
and/or apparent hydrodynamic radii. One of the most powerful fluorescence methods 
currently in use is Two Colour Coincidence Detection (TCCD) (390, 391). TCCD is 
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a true single molecule fluorescence technique, as rather than relying upon the 
correlation of fluorescence signals within the residence volume, it instead relies upon 
coincident counting of fluorescence emission at different wavelengths after 
excitation by two different, spatially overlapping lasers (Figure 3.1.1a) (390). 
Equimolar concentrations of an amyloidogenic precursor labelled with either of two 
distinct fluorophores are incubated and then detected within the confocal volume. As 
aggregation proceeds, differentially labelled precursors will coalesce, resulting in a 
coincident fluorescent burst event (Figure 3.1.1b) (188, 238, 392). If the quantum 
yields of the dyes are known, then the amplitude of the dual emission can provide 
insights into the molecular weight of assembly intermediates.  The frequency of 
signatory fluorescence emissions can also provide quantitative information regarding 
Figure 3.1.1 Schematic of TCCD. (a) Experimental set-up of TCCD showing 
excitation laser, confocal objectives and separation of emission wavelengths prior 
to detection by avalanche photodiode detectors. This set up has been modified for 
using smFRET in (188), hence only single wavelength excitation at 488 nm. (b) 
Typical data output from TCCD showing predominantly monomer-derived 
fluorescent bursts detected within the confocal volume. Occasionally large 
fluorescent bursts are seen coincidently within both channels, indicating 
oligomerisation (392). 
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oligomer-specific concentrations. Monitoring these populations over time therefore 
provides accurate information regarding the evolution of assembly intermediates 
over the aggregation time course (238). By using dye labels that have overlapping 
emission and excitation spectra, TCCD can also provide insights into the 
conformational rearrangement of oligomeric species. This can be achieved by 
quantifying changes in Forster resonance energy transfer (FRET) between the two 
dyes during the lag phase of assembly (188). smFRET-TCCD was used to highlight 
conformational conversion of oligomeric species formed during the lag phase of α-
synuclein amyloid formation (188). In addition, TCCD has also been used to study 
bimolecular interactions between chaperones and oligomeric species by monitoring 
which aggregates are depleted from solution upon incubation with unlabelled 
chaperones (237, 238). One significant drawback to using TCCD, however, is the 
requirement for 100% labelled protein samples. This means that experiments have to 
be conducted within the low nM range, and as the aggregation of amyloid is highly 
dependent upon concentration (148), it may not be suitable for the study of all 
amyloidogenic systems. 
Other fluorescence-based techniques, such as fluorescence cross-correlative 
spectroscopy (FCCS) have also been used to study these types of amyloidogenic 
phenomena. FCCS in principle is performed analogously to TCCD, although dual 
fluorescence fluctuations are correlated as opposed to counted (393, 394). A high 
correlation of fluorescence signals of differentially labelled species is diagnostic of 
an intermolecular interaction. The technique has proved highly successful in 
studying in vitro protein-protein interactions and also those within living cells (395, 
396). Because of the ability to cross-correlate fluorescent signals within the low pM 
range, FCCS has been proposed as a diagnostic tool for some amyloid disorders 
(397, 398). For instance, PrP fluorescent probes can be incubated in isolated 
cerebrospinal fluid of suspected Creutzfeldt Jakob disease patients and can co-
aggregate with scrapie isoforms of PrP (PrP
SC
). A second PrP
sc
-specific fluorescently 
labelled antibody probe can then be added and cross-correlation events detected at 
aggregate concentrations in the femtomolar concentration range. Therefore FCCS is 
well suited to studying lowly populated, transient bimolecular interactions, although 
the inferior resolution of correlative measurements (in terms of defining particle 
stoichiometry), coupled with the heterogeneity of amyloid systems, means that less 
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detailed information is obtained in comparison with fluorescence counting 
experiments (399). One advantage, however, is that the limited concentration range 
in which fluorescence counting methods can be performed is not a problem for 
correlative experiments, as the latter can be carried out at concentrations identical to 
those used in standard biochemical ensemble assays. This means that, unlike TCCD, 
FCS and FCCS are not subject to potentially adverse concentration dependence 
effects of amyloid aggregation (148). A high signal to noise ratio in fluorescence 
correlative spectroscopy is instead maintained by doping in low concentrations 
(typically nM) of fluorescently labelled samples with unlabelled samples within the 
reaction. 
These are only two of a plethora of fluorescence spectroscopy techniques that have 
been developed for the study of amyloid aggregation. Other methods can be found 
here (400–402). These techniques generally rely upon the continual advances made 
towards the analysis of fluorescence fluctuation traces. The application of 
mathematical functions capable of de-convoluting complex ensembles within 
standard FCS autocorrelation curves (ACs), or fluorescent fluctuation traces, such as 
photon counting histograms or number and brightness analysis (400, 401), makes 
FCS an accessible analytical tool for the study of these systems. With correct 
calibration of the confocal volume, FCS-based experiments can also provide 
information such as the apparent hydrodynamic radius (RH). For the investigations 
described here, maximum entropy method (MEM) (403), a well-used method for the 
analysis of heterogeneous samples with providence in the study of amyloidogenic 
proteins (404–406), was used to extract population ensembles from ACs collected 
during fibril depolymerisation. 
3.1.3 General principles of fluorescent spectroscopy 
Fluorescence spectroscopy techniques rely on the ability of compounds to emit 
fluorescence once excited from the ground state by the absorption of light of specific 
wavelengths. Fluorescence emission is most usually described by the Jablonski 
diagram, which shows the excitation of a fluorophore to higher energy singlet states 
by the absorption of light (Figure 3.1.2). Fluorophores can be excited to multiple 
energy orbitals, but prior to emission, vibrational relaxations and internal 
conversions (1x10
-11 
to 10
-14
 sec) means that molecules typically relax back to the 
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ground state (S0) from the lowest energy singlet state (non-radiative decay, or 
fluorescence emission - timescale typically 1x10
-9
sec). The relaxation from S1 to S0 
is accompanied by the emission of a photon which is the cause of fluorescence 
emission (Figure 3.1.2). As the energy level from which relaxation to S0 occurs is 
typically lower than the original excited state (due to vibration relaxations - Figure 
3.1.2), the wavelength of emitted fluorescence is longer than that used for excitation. 
This property, known as the Stokes shift, is taken advantage of in commercially 
available fluorophores to reduce spectral overlap between excitation and emission 
wavelengths. There are additional pathways for the relaxation to the ground state 
(Figure 3.1.2), including intersystem crossing to the lower energy triplet excitation 
state (T1). Non-radiative decay (fluorescence emission) from T1 is typically 
forbidden, so relaxation to the ground state takes place through phosphorescence 
(comparatively long time scale ~10
1
sec). Both phosphorescence and intersystem 
Figure 3.1.2 Jablonski diagram The ground state and the S1 and S2 excited 
singlet states are depicted by S0, S1 and S2. Absorption promotes the ground state 
to excited singlet states (green arrows), which undergo vibrational relaxation and 
internal conversion from the S2 to S1 singlet states. Non-radiative relaxation takes 
place from the S1 state to the ground state, involving the emission of a photon 
(fluorescence – light blue arrow). Alternative relaxation pathways, such as 
quenching (relaxation via heat loss – purple arrow), or transition to the excited 
triplet state via intersystem crossing are also shown (blue arrow). Typical 
relaxation from the excited triplet state takes place either through 
phosphorescence (red arrow), or through photon emission (light blue arrow). 
Relation through non-radiative decay however from the excited triplet state is at 
longer wavelengths than from the S1 singlet state so therefore does not interfere 
with fluorescence measurements. Figure taken from (435) 
Chapter 3 
 
101 
 
crossing takes place on timescales that are distinct from diffusion times of biological 
molecules and therefore do not often impinge upon the measurements within FCS 
experiments of the biologically relevant molecules under investigation. 
Commercial dyes can be used to label biological molecules and thus fluorophores 
can be exploited to study a range of biological phenomena in a variety of 
fluorescence spectroscopy methods, several of which have been described (188, 238, 
392, 395, 397, 401, 405). In general, fluorescence spectroscopy techniques hold 
significant advantages over other methods in that it allows the analysis of single 
molecules. Although FCS can observe fluorescent fluctuations from single 
molecules, fluctuations from many thousands of molecules are analysed and 
averaged in a process known as autocorrelation. Therefore, strictly speaking, FCS is 
not a true single molecule technique.  
In order to utilise fluorescence for correlative measurements, fluorescence 
fluctuation traces must be obtained over a time-course. This is most commonly 
performed by illuminating a sample volume using confocal optics (Figure 3.1.3a). A 
collimated laser beam is typically focused into a sample using a high numerical 
aperture objective lens to create a diffraction-limited focal spot within the sample 
chamber. A pinhole aperture of 50 µm is placed in the pathway of the collected 
emitted light. The role of the pinhole aperture is to reduce the transmission of 
emission photons excited outside of the focal plane, thus only fluorescently-labelled 
Figure 3.1.3 Confocal configuration used in FCS. (a) A collimated laser is focused into a 
sample chamber through a high numerical aperture objective lens. A schematic zoom of the 
confocal volume is shown in (b) – with the femtolitre focal volume shown in dark blue. The 
in-focus correlated fluorescent species are shown in green, where the objective lens has 
focused the emitted fluorescence through the pin-hole aperture to the detector (solid green 
line). Fluorescence from out-of-focus species (black outline) is blocked by the pin-hole 
aperture (dashed line), thus increasing the signal-to-noise of the experiment. 
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species which diffuse through the confocal volume are recorded (Figure 3.1.3b). The 
combination of the objective lens and pinhole aperture effectively create a confocal 
volume less than a femtolitre in size. The reduced volume obtained using confocal 
objectives greatly improves the signal-to-noise ratio within fluorescence 
spectroscopy measurements, allowing detection of molecules in the low nM to pM 
range. 
3.1.4 The autocorrelation function 
The fluctuations of fluorescence signals can be quantified by temporal 
autocorrelation defined as thus: 
 𝐺(𝜏) =
〈𝛿𝐹(𝑡)𝛿𝐹(𝑡 + 𝜏)〉
〈𝐹(𝑡)〉2
 (1) 
where δF(t) is the fluorescence signal at time t from the mean fluorescence <F(t)>, 
and δF(t + τ) is the fluctuation of fluorescence at time t plus the lag time τ (Figure 
3.1.4a). Essentially, molecules with a longer residence time within the confocal 
volume will have a correlation score (G) > 0 at longer lag times (t+τ). The time it 
takes for a fluorescent molecule to traverse the confocal volume (diffusion time –τD) 
is directly related to the size of the molecule, and can be calculated by expressing the 
autocorrelation function as such: 
 𝐺(𝑡) =
1
𝑁
(1 +
𝜏
𝜏𝐷
)
−1
(1 +
𝜏
𝐾2. 𝜏𝐷
)
−0.5
[𝐹𝑇𝑒𝑥𝑝 (−
𝜏
𝜏𝑇
) + (1 − 𝐹𝑇)] (2) 
where N is the number of molecules within the confocal volume at any given time, τ 
is the delay time associated with correlating the fluorescence signal, K is the shape 
parameter approximating the size of the three-dimensional Gaussian confocal 
volume, and τD is as previously defined. Fτ and τt are photophysical phenomena 
related to the excited triplet state of the fluorescent probe used as a label (the 
amplitude and decay constant respectively). Triplet state parameters are not always 
defined within the autocorrelation function due to the rapid intersystem conversion 
time as illustrated by the Jablonski diagram (S1 – T1, Figure 3.1.2). However, 
experimental ACs almost always exhibit some degree of decay from the excited 
triplet state and therefore is usually included as an exponential function. The 
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relationship of the parameters to the shape of the AC is shown in Figure 3.1.4b and a 
full derivation of the autocorrelation function is available in (389).  
As τD is inversely proportional to the diffusion coefficient (D0 – Equation 3) small 
molecules will have large D0 and small τD within the confocal volume, while the 
opposite is true for large molecules. With knowledge of the dimensions of the 
confocal volume (K), D0 can be calculated from experimentally derived τD, and the 
apparent hydrodynamic radii (RH) subsequently calculated using the following 
equations: 
 
𝜏𝐷 =  
𝜔0
2
4𝐷0
 
(3) 
where ωo describes the 1/e
2 
decay of the 3D Gaussian confocal volume in the plane 
radial to the path of travelling light, and Stokes Einstein Equation: 
 𝐷0 =  
𝐾𝐵𝑇
6𝜋𝜂𝑅𝐻
 (4) 
Figure 3.1.4 Typical output obtained from FCS. (a) Generalised 
fluorescence fluctuations parameters used to generate ACs (b) A typical AC 
derived from a single component solution displaying features related to 
triplet state phenomena (Fτ and τT), the amplitude of the signal (1/N) and τD.  
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Where KB is the Boltzmann constant, T is the absolute temperature, η is viscosity 
and RH is the apparent hydrodynamic radius. Therefore, through the correct 
calibration of the confocal volume, one can estimate the apparent size of species 
undergoing diffusion. The confocal volume is usually calculated using a calibration 
standard, such as fluorescein, which has a known Do under particular solution 
conditions. Using the experimentally derived calibrant τD with the known Do means 
that ωo can be calculated. This parameter (ωo) can then be used to calculate Do from 
measured values of τD for the sample of interest. This can subsequently be used in 
Stokes-Einstein equation to calculate apparent RH values. Excellent reviews that 
further describe the  principles and practise of FCS can be found in (389, 407, 408). 
The remainder of this chapter describes the collection of ACs during fibril 
depolymerisation and analysis of the ACs using MEM, in order to identify the nature 
of the species released during fibril depolymerisation. This chapter also outlines 
additional structural characterisations of the species generated during molecular 
shedding. 
3.2 Materials and Methods 
3.2.1 Purification and labelling of β2m R3C for FCS experiments 
In general, β2m R3C (R3C – mutation of R at residue 3 of 2m to C so the protein 
can be labelled) was expressed and purified as previously outline for wt β2m (see 
section 2.2.3). The only differences were made in the step to initially refold β2m by 
dilution after inclusion body re-solubilisation in 8 M urea. Re-solubilised R3C was 
refolded by dilution into 10 mM Tris-HCl pH 7.5 supplemented with 400 mM 
arginine, to a urea concentration < 2 M (4-fold dilution). Samples were then dialysed 
and purified by anion exchange chromatography as previously detailed (section 
2.2.3). Fractions containing R3C were confirmed using SDS-PAGE and pooled and 
placed in dialysis tubing (Thermo Scientific). R3C was then dialysed against 5 L of 
18 M H2O at 4C for 24 h with changes to the water made at least three times. 
Dialysed R3C was then frozen in a 200 ml round-bottom flask using dry ice and 
ethanol prior to being freeze-dried and stored at -20
O
C. No gel filtration was 
performed prior to R3C labelling. 
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R3C was labelled with Alexa488-maleimide (Invitrogen) via the free thiol moiety by 
re-suspending the lyophilised protein in 25 mM Tris-HCl pH 8.0 supplemented with 
5 mM DTT. Addition of 5 mM DTT reduces the newly introduced thiol without 
reducing the native disulphide bond (409). Re-suspended R3C was incubated at 
room temperature for 10 min prior to desalting using a gravity-flow Nap-10 column 
(GE Healthcare) previously equilibrated with 25 mM sodium phosphate buffer, pH 
7.2. Once desalted, the concentration of R3C was adjusted to 100 µM by checking 
the eluent concentration using Beer-Lambert’s law (R3C  = 20065.M-1.cm-1). R3C 
was then placed into a brown 1.5 ml chromacol glass vial with a 3 x 8 mm magnetic 
stirring bar. Alexa488-maleimide was re-suspended to 10 mM in 100% DMSO and 
added in drop wise fashion to R3C using a glass Pasteur pipette until a 10-fold molar 
excess of the dye over protein was reached. The solution was gently agitated at room 
temperature on a magnetic stirring plate for 2 hours. Alexa488 labelled R3C 
(R3C488) was then separated from free dye by desalting on a Nap-5 column 
equilibrated with 25 mM sodium phosphate pH 7.2 prior to gel filtering R3C on an 
analytical Sup75 column (GE healthcare) equilibrated with the same buffer, at a flow 
rate of 0.5 ml.min
-1 
and backing pressure of 1.0 mPa (Figure 3.2.1a). Fractions of 0.5 
ml were collected and those that eluted at approximately 10 ml were pooled and 
stored at 4C (Figure 3.2.1a). A 30 M samples was prepared for ESI-MS to confirm 
labelling efficiency by buffer exchanging into 50 mM ammonium biocarbonate pH 
7.4 buffer using a Zeba Spin 7kDa 2 ml desalting column (Thermo Scientific). 
Labelling (100%) was confirmed (Figure 3.2.1b, expected mass of conjugated 
R3C488 = 12506 Da) prior to concentrating using a Centricon centrifugal filter with 
3 kDa cut-off by centrifuging at 4,000 x g for 10 min intervals at 4C. Aliquots of 
Figure 3.2.1 Purification of R3C488. (a) Labelled R3C (blue) was purified from free dye 
(red) using analytical gel filtration. (b) Labelling was confirmed using mass spectrometry, 
with the expected mass of R3C488 being 12,506 Da. 
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R3C488 at a final concentration of 75 M sufficient for fibril growth experiments  
were snap-frozen in liquid N2 and stored at -80
0
C. 
3.2.2 FCS set-up 
FCS experiments were performed using a custom-built fluorescence microscope 
equipped with a collimated laser beam (max power 5 mW) working at an 
approximate power output of 40 µW. A simplified schematic outlining the general 
features of the instrument is shown in Figure 3.2.2. The beam (488 nm, Sapphire 
OPSL, Coherent Inc., UK) was spatially filtered and collimated to obtain a TEMoo 
Gaussian beam, prior to being guided via a series of mirrors through a shortpass 
dichroic beam splitter (488DSCX, Chroma Tech., USA) to a microscope objective 
(63 x magnification, 1.4 NA, Zeiss, Germany), where it was focused into the sample 
at a depth of 30 µm from the inner surface of the coverslip chamber of 200 µl 
volume (Labtech, Nagle Nunc). The focal depth was precisely maintained by a 
piezoelectric feedback loop (Piezosystmes Jena, Germany). Contact between the 
objective lens and the coverslip chamber was maintained with low autofluorescence 
immersion oil (refractive index 1.515, type DF, Cargille Laboratories, USA) and 
Figure 3.2.2 Schematic of FCS set-up. Parts are described in Section 3.2.2. 
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samples thermo-regulated by re-circulating water around the sample holder and 
objective lens, set to 25C. Emitted fluorescence collected by the objective lens was 
focused through an aperture (50 µm pinhole), prior to passing through a dichroic 
beam splitter (565DCLP, Chroma Tech., USA) and detected and analysed by an 
ALV-5000 multiple tau digital correlator used in a single channel mode (Perkin 
Elmer, Optoelectronics, USA).  
 3.2.3 Confocal volume calibration 
Calibration of the confocal volume was performed using 1 nM Alexa488 in 
deionised 1 x PBS containing 0.001% (v/v) Tween, by calculating the diffusion time 
from multiple 30 sec acquisitions before and after each experiment. Control 
experiments were analysed by non-linear least-squares fitting with a single diffusion 
component and triplet state autocorrelation function (Equation 2) using scripts 
written in Matlab and provided by Dr Roman Tuma, University of Leeds (version 
7.11, Mathworks). Apparent Rh values for free dye were calculated from the 
measured τD and the diffusion coefficient of free Alexa488 in H2O of 3x10
-10
m
2
.sec
-1
 
(410), using equations 3 and 4 described in Section 3.1.4. 
3.2.4 Monitoring molecular shedding using FCS 
To detect oligomeric species during fibril depolymerisation, fibril growth was seeded 
with 1% (w/w) wt 2m fibril formed at pH 2 (Section 2.2.4) mixed with 120 M wt 
2m and 120 nM R3C488 at pH 2 as previously described (section 2.2.4) Solutions 
were left at room temperature for no more than 12 h. Fibrils were diluted to 30 µM 
(assay concentration of R3C488 therefore 30 nM) in either pH 6.4 or pH 7.4 buffer 
(see section 2.2.6 for buffer compositions) supplemented with 0.001% (v/v) Tween at 
25°C and placed within a sealed 200 µl volume glass coverslip chambers (Nunc). 
Multiple 20 x 30 second acquisitions were collected to provide 10 minute windows 
during the depolymerisation process. Times quoted in figures displaying ACs 
represent the median time point of the spectral window, with the average of up to 
100 ACs correlated from 30 sec acquisitions providing the raw data for MEM fitting. 
The standard deviation of the combined ACs provides the associated error for each 
time-point curve. 
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3.2.5 Maximum entropy method 
In order to de-convolute heterogeneous ensembles of species represented within the 
ACs collected during depolymerisation, MEM was employed. This technique allows 
the measured AC to be best fit by a non-continuous distribution of diffusing species 
separated over several orders of magnitude in size. The algorithm is reported to 
provide a greater degree of robustness in comparison with conventional 
multicomponent fitting regimes (403). The relationship between the multicomponent 
fitting regime and the standard AC is represented below, 
 𝐺(𝜏) =
1
𝑁
 ∑
𝑎𝑖
(1 +
𝜏
𝜏𝐷𝑖
) (√1+.
𝜏
𝐾2. 𝜏𝐷𝑖
)
𝑛
𝑖=1
 (5) 
whereby ai represents the amplitude associated with each individual τDi, which are 
logarithmically spaced in the time domain. Summation of the individual ACs 
describing each τDi should provide a good approximation of the raw AC. N, τ and K 
are as described for Equation 2. Triplet state parameters (see Equation 2) calculated 
from ACs of dye-only controls by SCA were used as initial estimates for triplet state 
parameters during MEM fitting (see Section 3.2.3). A full description of the MEM 
algorithm can be found here (403).  
The sum of individual diffusing species have to satisfy the raw experimental data, 
therefore the goodness of fit must be assessed. Qualitatively, a random distribution 
of residuals (ri) about a mean value of zero is a good estimation of the quality of the 
fit, when ri is defined as: 
 𝑟𝑖 =  
𝐺𝑐(𝑡𝑖) − 𝐺
𝑒(𝑡𝑖)
𝜎𝑖
 (6) 
In this equation G
C
 is the calculated correlation value at time t and G
e
 is the raw 
experimental value and σi is the inverse of the weight of the i
th
 datum. The goodness 
of fit is quantitatively assessed through the chi square parameter χ2: 
 𝜒2 =
1
𝑀
∑ 𝑟𝑖
2
𝑀
𝑖=1
 (7) 
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where M is the number of data points within the autocorrelation curve. However, the 
inherent noise of FCS data can lead to multiple distributions being able to satisfy the 
raw data according to χ2. Therefore a second parameter, known as the entropy score, 
S, is used to ensure the least discrete (narrow) and most uniform distribution is 
chosen at a given χ2 value. S is defined as thus: 
where pi is: 
 𝑝𝑖 =  
𝛼𝑖
∑ 𝛼𝑖
⁄  (9) 
According to MEM, a discrete population of τD would give the lowest value of S and 
is therefore the least acceptable solution for noisy data. S increases as the width of 
the distribution increases; therefore, the distribution providing the maximal value of 
S at a given χ2 is put forward. MEMFCS thus ensures that χ2 is minimised as S is 
maximised. 
MEMFCS begins with an equal weighting (αi) for all specified τDi, with the 
distribution altered through successive iterations to satisfy the raw data. The fitting 
regime is terminated when χ2 remains unchanged in successive iterations. The 
MEMFCS algorithm used in this study was kindly provided by Professor Sudipta 
Maiti et al at the Tata Institute for Fundamental Research (403). Errors associated 
with species identified using MEM are the full width half maximum (FWHM) from 
Gaussian-like peaks observed in the final distribution. 
3.2.6 ThT seeding assay 
ThT assays were performed on a BMG LabTech Optima plate reader as described in 
Section 2.2.7. In brief, 120 M (w/w) 0.1% seeded β2m amyloid fibrils formed at pH 
2 were diluted 4-fold into pH 7.4 or 6.4 buffer (see section 2.2.6 for buffer 
compositions) and depolymerised at 25°C for 30 or 60 min respectively. These 
solutions were then used in seeding assays with 120 M native β2m or ΔN6 (kindly 
provided by Dr Theo Karamanos, University of Leeds) incubated in either pH 7.4 or 
pH 6.4 buffer, with a seed concentration of 10% (w/w) (12 M seeds). Buffers were 
supplemented with 40 µM ThT, the fluorescence emission of which was recorded for 
 𝑆 =  − ∑ 𝑝𝑖𝑙𝑛𝑝𝑖 (8) 
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4 h at 25C. Curves shown are a smoothed line from the average of at least three 
independent replicates. 
3.2.7 Negative stain-transmission and cryo-electron microscopy 
3µl of sample was deposited onto colloidion-copper coated EM grids (prepared by 
Martin Fuller, University of Leeds) and incubated for 30 sec at room temperature. 
The sample was subsequently removed by blotting the grid onto filter paper 
(Whatmann), prior to washing with 2 x 10 µl of 18 M H2O and 1 x 10 µl 2% (w/v) 
uranyl acetate before staining with 10 µl 2% (w/v) uranyl acetate for 30 sec. Excess 
dye was removed and grids dried at room temperature.  Images were recorded using 
a BM Ultrascan 2k x 2k CCD (Gatan) on a Technai T12 TEM (FEI) operating at 120 
keV  For cryoEM, samples were deposited on a Quantifiol 2/1 holey carbon grid 
(Electron Microscopy Sciences) and vitrified by plunging into liquid ethane using a 
Vitribot (FEI).  Samples were examined at cryogenic temperature on a F20 TEM 
(FEI) operating at 200 keV and images recorded using a BM Ultrascan 4k x 4k CCD 
(Gatan).  Individual particles were picked and class averages calculated using 
EMAN2 (411) and RELION (412). Dr Matt Iadanza, University of Leeds, performed 
the cryoEM experiments. 
3.2.8 Dot blots 
Samples were prepared for dot blots by initiating depolymerisation of 600 µM (0.1% 
seeded (w/w)) β2m amyloid fibrils by diluting 4-fold into either pH 7.4 and 6.4 
buffers at a final volume of 100 l (see section 2.2.6 for buffers). Depolymerisation 
was allowed to proceed for 30 and 60 min respectively. Prior to dot blotting, 40 l of 
samples (total protein) under each condition were filtered using a 0.2 m syringe 
filter (Millipore) to partition fibrils from soluble material (filtrate). Total protein and 
filtrate samples (2 µl, 2 µl x 2 for filtrate) were then ‘dotted’ onto a nitrocellulose 
membrane and allowed to dry before the membrane was blocked using 1 x PBS 
containing 0.2% (v/v) Tween-20 (dot blot buffer) supplemented with 10% (w/v) 
Marvel Milk for one hour at room temperature by gently rocking on a rocking 
platform. Membranes were then washed 3 x 5 min in dot blot buffer before 
incubating with dot blot buffer containing 3% (w/v) bovine serum albumin and 
1:5,000 dilution of the W01 primary antibody (kindly provided by Prof. Ronal 
Wetzel, Univeristy of Pittsburgh) overnight at 4
o
C. Membranes were then washed 3 
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x 5 min in dot blot buffer prior to incubating with 1:5,000 horse raddish peroxidase-
conjugated rabbit -mouse IgG antibodies in the same buffer for 1 h at room 
temperature. Membranes were then washed 3 x 5 min in dot blot buffer before 
antibody binding was visualised using Supersignal West Pico chemiluminescent 
susbtrate (Perco) and Amersham Hyperfilm ECL. For 2m control blots, samples 
were prepared in the same way and blocked overnight in dot blot buffer containing 
10% (w/v) Marvel Milk at 4C. Membranes were then washed as described prior to 
incubating for one hour at room temperature in dot blot buffer containing 5 % (w/v) 
Marvel Milk and 1:5000 dilution of -2m antibody for one hour at room 
temperature on a rocking platform. Membranes were then washed and probed with 
secondary antibodies and visualised as described for the W01 antibody. Secondary 
antibody only controls were also performed to ensure binding was not non-specific. 
3.2.9 Circular dichroism 
Filtrate and total protein samples were prepared for CD by diluting 120 M fibrils 4-
fold into pH 7.4 or 6.4 buffer respectively (see Section 2.2.6 for buffer 
compositions). Samples were incubated at 25
o
C for 30 or 60 minutes, respectively. 
Prior to analysis, samples were filtered through a small volume 0.2 µm syringe filter 
(Millipore) and quantified using SDS-PAGE densitometry as previously described 
(Section 2.2.8). Far-UV CD spectra were acquired using a Chirascan plus (Applied 
PhotoPhysics) over the wavelength range of 190 – 260 nm using a 1 mm path length 
Hellma cuvette. Spectra were also acquired for native β2m samples at the equivalent 
concentrations as judged by SDS-PAGE under the same solution conditions. Scans 
were recorded at a rate of 60 nm.min
-1
 with 3 acquired spectra averaged for the final 
display. Buffer-only control spectra were also acquired and subtracted from the 
protein spectra. 
3.2.10 8-Anilinonaphthalene-1-sulphonate (ANS) binding assays 
Filtrate samples were prepared and quantified as stated above (Section 3.2.9). 
Immediately after partitioning through a 0.2 µm filter (Millipore), filtrates were 
diluted 6-fold into pH 6.4 or pH 7.4 buffer (section 2.2.6) containing 250 M ANS, 
previously equilibrated to 25C. Samples were then left to incubate for 2 min prior to 
the acquisition of a fluorescence emission scan ranging from 400 – 600 nm after 
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excitation at 389 nm, using a spectrofluorometer (PTI). The instrument was set up 
with excitation and emission slit widths of approximately 5 nm, and acquired an 
average of two scans, using a step size of 1 nm and an integration time of 0.1.sec
-1
. 
Native β2m and acid unfolded β2m controls at equivalent concentrations were also 
acquired, with data normalised to the highest fluorescence emission of acid unfolded 
β2m samples. 
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3.3 Results 
3.3.1 Benchmarking MEM 
Prior to analysing experimental data, MEM was benchmarked to ensure it could 
reliably detect the correct τD and amplitudes of distinct species in mixed samples 
from simulated data. ACs were simulated in Excel using Equation 5 with an 
additional triplet component. For the two examples shown, the following parameters 
of the autocorrelation function were fixed; Ft = 0.2, τt  = 0.004 ms and K
2
 = 100 nm
2
, 
while 1/N (amplitude) and the τDs of the simulated species are shown in Figure 3.1.1. 
Each data point was assigned a random error value of up to 10% of 1/N.  
In the first example (Figure 3.3.1a), the two species have τD of 0.1 and 1 ms, 
respectively, with the second species contributing 75% of the overall amplitude of 
the simulated curve. In the second example (Figure 3.3.1b), the τD of the longer 
Figure 3.3.1 Benchmarking MEM with multicomponent simulated curves. (a 
and b) Examples of simulated ACs (‘raw’) containing two distinct populations of 
species and the subsequent MEM-derived AC (fit), with residuals. Tau 
distributions and input and MEM derived parameters related to simulated species 
are shown below (τDs and τDe respectively). 
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diffusion component is increased by an order of magnitude to 10 ms and the 
amplitudes between the two species are inversed (see Tables in Figure 3.3.1 for 
inputs). The simulated and MEM-derived ACs are shown in Figure 3.1.1a and b with 
residuals for the fits shown below. Comparison of τD (peak centre position) and 
amplitudes (summed amplitudes of all non-continuous τD associated with the 
corresponding peak) between experimentally derived values (τDe) and those 
originally used to simulate curves (τDs) shows that MEM is able to accurately 
describe the τD and amplitude associated with each species (Figure 3.3.1a and b). 
MEM could not reproducibly resolve two species whose τD values were within an 
order of magnitude of one another (data not shown). Therefore MEM can be used to 
separate species that differ in τD by at least an order of magnitude and can also 
reliably describe the relative amplitude associated to each species.  
3.3.2 Using MEM to fit experimental data – comparison with other methods of 
analyses 
Typical ACs of homogeneous samples can be accurately described using single 
component analysis (SCA) as opposed to using a complex fitting algorithm such as 
MEM. Therefore, dye-only control ACs were fit using both SCA or MEM to see 
whether both methods provide comparative information. SCA was performed on 
control solutions of 1nM Alexa488 collected before and after acquisitions of sample 
ACs under conditions described in Section 3.2.3. Figure 3.3.2a shows the average 
AC from a minimum of 20 x 30 sec individual ACs collected from control solutions 
of 1 nM Alexa488 (black line). The overlayed fit from SCA is shown in red (red 
line). From an unconstrained fit (no parameter within the autocorrelation function 
was fixed during SCA of control curves), the triplet state parameters, Ft and t, and 
the shape parameter K
2
 were derived (see Section 3.1.4 and 3.2.3) and subsequently 
used to fit the same control AC using MEM (Figure 3.3.2b). MEM was as accurate 
in describing the shape of the AC (Figure 3.3.2b – purple line), and describes a 
single, discrete (high signal to noise ratio due to sample homogeneity, therefore tau 
distribution is better defined and more discrete) population of species present within 
solution (Figure 3.3.3).  
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Comparison of τD values calculated using MEM and SCA from the same AC showed 
these to be roughly equivalent (SCA – 91±3.3 µs, vs. MEM – 85±5 µs). Therefore, 
MEM can be used to reliably fit ACs obtained from mono-dispersed, highly 
homogeneous solutions to a high degree of accuracy, when Ft, τt and K
2
 can be 
estimated. 
Although MEM is able to describe the population of species within ACs for which 
the triplet state parameters can be accurately estimated using SCA, it is not possible 
to calculate Ft and τt from ACs that are the product of highly heterogeneous systems. 
In most instances, attempting to fit ACs by SCA that are the product of a 
Figure 3.3.3 Comparison of the goodness of fit of calibrant ACs using MEM and 
SCA.  Raw ACs (black curves) of 1 nM Alexa488 solutions in 1 x PBS 0.001% 
(v/v) Tween at 25 °C are the average of at least 20 x 30 sec acquisitions. The 
triplet state parameters and shape parameter derived from unconstrained SCA (a – 
red curve) of the controls curves were subsequently used to fit the same data using 
MEM (b – purple curve). 
Figure 3.3.2 Tau distribution of species extracted using 
MEM to fit an Alexa488 AC.  Representation of the 
distribution of species extracted from 1 nM Alexa488 
control samples described in Figure 3.3.2 using MEM. 
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multicomponent system leads to the gross overestimation of triplet state parameters. 
This is due to the fitting regime overcompensating for the presence of longer 
diffusion components. Therefore, ACs with varying degrees of heterogeneity and 
under different solution conditions were fitted using MEM with SCA-calculated Ft, 
t, and K
2
 from mono-dispersed, Alexa-488 control solutions collected on the same 
day. Figure 3.3.4 shows that, in addition to dye-only controls being accurately fit 
using MEM when combined with SCA-calculated Ft, τt and K
2
 values (Figure 3.3.2), 
so are ACs corresponding to 30 µM wt β2m with 18 nM R3C488 monomer in pH 6.4 
buffer or fibrils formed at low pH from 30 µM wt β2m with 30 nM R3C488 (Figure 
3.3.4). Both raw ACs for these samples are the average of at least 20 x 30 sec 
individual ACs. Therefore, triplet state parameters calculated by SCA from ACs of 
dye-only controls can be used to estimate the triplet state parameters of subsequent 
multicomponent samples, even when collected under different solution conditions.  
Figure 3.3.4 SCA-derived FT, τt and K
2
 calculated from Alexa488 controls used for MEM 
fitting of more complex solutions. Raw ACs and overlayed MEM fits of 30 µM native β2m 
with 18 nM R3C488 in pH 6.4 buffer (a) and 1% (w/w) seeded 30 µM wt β2m with 30 nM 
R3C488 amyloid fibrils at pH 2 (b). MEM fits were performed using Ft τt and K
2
 calculated 
from SCA analysis of 1 nM Alexa488 control solutions collected on the same day. (c) and 
(d) show the tau distribution of species extracted from ACs described in (a) and (b) 
respectively using MEM. 
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3.3.3 FCS during fibril depolymerisation – data collection 
To detect species populating as fibril depolymerisation proceeds, 120 µM wt β2m 
fibrils containing 120 nM R3C488 were diluted four-fold into either pH 6.4 or 7.4 
buffer containing 0.001% (v/v) Tween-20, and were immediately analysed as 
described in Section 3.2.4. The final concentration of dye-labelled protein had to be 
increased to 30 nM as the majority of R3C488, at least initially, remains sequestered 
within the fibrils, therefore lowering the effective concentration of soluble species 
being detected. Fibrils were infrequently encountered during the depolymerisation 
process. This is most likely due to the self-association of β2m fibrils formed at pH 2 
that takes place upon diluting into near-neutral pH buffers (92). As such, fibrillar 
bundles are sufficiently large to be encountered only rarely within the confocal 
volume. Figure 3.3.5 shows the raw ACs collected during β2m fibril 
depolymerisation at pH 7.4 (a) and pH 6.4 (b). Each curve is the average of up to 60  
individual ACs collected from three individual experiments performed on the same 
day. Each experiment consists of 20 x 30 sec ACs, where the depolymerisation time 
stated is the median within the time window in which the acquisition occurred. ACs 
are displayed normalised to G(0) of the earliest time point within each 
depolymerisation data series. This was performed to correct for differences in the 
relative amplitude of each individual experiment due to the stochastic incorporation 
of R3C488 into β2m amyloid fibrils at low pH. Prior to these time points at pH 6.4, 
the concentration of diffusible dye-labelled species was too low to reproducibly 
Figure 3.3.5 ACs collected during β2m amyloid fibril depolymerisation. 1% (w/w) seeded 
120 µM β2m 120 nM R3C488 amyloid fibrils grown at pH 2 were depolymerised by diluting 
4-fold into pH 7.4 (a) or pH 6.4 (b) buffer at 25°C. Up to five 20 x 30 sec acquisitions were 
made to produce the average AC displayed. The time indicates the median point of the 
collection window. ACs within each data set are normalised to the G(0) of the corresponding 
initial time point to remove the inherent differences of the amplitude of individual repeats. 
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detect. 
The decrease in G(0) of each AC as the depolymerisation time course proceeds is 
indicative of soluble species becoming increasingly populated over time within both 
conditions. This is because the amplitude of the AC is inversely proportional to the 
number of molecules present during the acquisition of the fluorescence fluctuation 
trace (1/N in the autocorrelation function, see Equation 2, Section 3.1.4). The 85 min 
and 135 min time points collected at pH 7.4 and pH 6.4, respectively, appear to 
exhibit increased baselines in comparison with other samples. This could be due to 
the presence of fibrils diffusing through the residence volume, the signal of which 
eventually decays at lag times not plotted upon these curves (approximate τD of 
10,000 ms, see Figure 3.3.4b as an example). It may also be due to mechanical 
instability of the sample stage during data acquisition. In addition, data collected at 
pH 6.4 is inherently noisier than that collected at pH 7.4. This is because less soluble 
material is released during depolymerisation at pH 6.4. As the overall amplitude of 
soluble species generated during depolymerisation is lower at pH 6.4, the signal to 
noise ratio is also lower. 
These ACs were subsequently fitted using MEM to extract population distributions 
that form during molecular shedding from β2m fibrils at pH 6.4 and pH 7.4. The 
normalised ACs, overlayed MEM fits and residuals to each of the curves are shown 
in Figure 3.3.6. In general there is a good agreement between the raw data and 
MEM-derived curves, with a qualitative observation of the distribution of residuals 
confirming all ACs are satisfactorily fitted. Deviations of residual values from a 
random distribution about zero typically take place below 50 µs. Fluorescent events 
taking place on this time scale are most likely to be due to differences between the 
estimated FT and tτ values and those of the experimental AC. This is a caveat of 
MEM, however, it does not impinge on the ability to further analyse these results. 
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Figure 3.3.6 ACs with MEM fits collected during β2m fibril depolymerisation. (a) Raw 
ACs collected 15, 55, 85 and 105 min after initiation of depolymerisation at pH 7.4 are 
shown in black with the MEM-derived AC shown overlayed. Residuals for the fit are 
shown below the curve. (b) As above, but for data collected at pH 6.4 35, 65, 95 and 
135 min after was initiated. 
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3.3.4 Comparison of molecular shedding at pH 6.4 and pH 7.4 
The normalised ACs collected during the initial stages of β2m fibril depolymerisation 
at pH 6.4 (Figure 3.3.6b, 35 min) show a significant, 2-fold, increase at G(τ)= 1 ms 
in comparison with data obtained  at the most equivalent time point during fibril 
depolymerisation at pH 7.4 (Figure 3.3.6a , 15 min). It is likely that this increase is 
due to an elevated concentration of a high molecular weight (HMW) species present 
during depolymerisation under these conditions. By calibrating the confocal volume 
with the fluorescent dye Alexa 488, the tau distribution extracted from the raw data 
using MEM (e.g. Figure 3.3.4c-d) can be converted to an apparent RH scale. The 
calibration requires the experimentally derived τD, and the known Do of Alexa488 
under specific conditions in order to calculate the ωo (see Section 3.1.4, Equation 3, 
and Section 3.2.3). Once ωo
 
is known, it can subsequently be used to determine Do 
from τD of unknown species, which in turn can then be used to determine an apparent 
RH using the Stokes-Einstein equation (Equation 4, Section 3.1.4). Typically, the τD 
of Alexa488 in 1 x PBS pH 7.4 at 25C calculated from the average of a minimum of 
20 x 30 sec ACs gave an approximate ωo value of 350 nm. The calibration of the 
confocal volume was validated using native β2m control solutions (30 M 2m 18 
nM R3C488 in 1 x PBS pH 7.4 at 25C, minimum of 20 x 30 sec acquisitions), 
which gave an apparent RH of approximately 1.9 nm (Figure 3.3.7). This is consistent 
with previous measurements calculated from using different techniques and therefore 
validates the calibration (413). 
Figure 3.3.7 Conversion of tau distribution to apparent RH scale after confocal volume 
calibration. AC of 30 µM wt β2m and 18 nM native R3C488in pH 6.4 buffer with MEM-
derived fit overlayed (green). The apparent RH distribution observed after calibrating the 
confocal volume using dye-only controls is shown in (b). 
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The apparent RH distributions of species that populate during fibril depolymerisation 
are shown in Figure 3.3.8. At pH 7.4, soluble species are dominated by the presence 
of a low molecular weight (LMW) peak with an apparent RH of 2±0.4 nm (Figure 
3.3.8a). This value is consistent with that calculated for β2m monomer controls 
(Figure 3.3.7), and therefore corroborates previous experiments, such as the NMR 
analysis described in Section 2.3.7, suggesting that depolymerisation at pH 7.4 
results in the rapid formation of non-toxic, native monomer, (larger species are 
infrequently observed and are lowly populated - peak between 10 – 100 nm observed 
at 15 and 105 min). The size distribution of species that appear during fibril 
depolymerisation at pH 6.4 however is significantly different. In addition to the 
LMW peak at ~1.8±0.5 nm, a second, larger peak is observed to be significantly 
populated at all recorded time points (Figure 3.3.8b). This species has an apparent 
RH of 20±10 nm between 35 – 95 min, with an increase in apparent RH to 31±20 nm 
135 min after the initiation of depolymerisation. The increase in apparent RH is 
accompanied by an increased broadness (Figure 3.3.8b – 135 min). This is not 
Figure 3.3.8 Apparent RH distributions of species formed 
during fibril depolymerisation. Apparent RH scales were 
calculated at pH 7.4 (a) and 6.4 (b) from MEM-derived tau 
distributions extracted from the ACs shown in Figure 3.3.6. 
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accompanied by a similar increase in LMW peak width, indicating that HMW 
species may exhibit increased heterogeneity as fibril depolymerisation proceeds. 
The sustained presence of HMW species that accumulate during fibril 
depolymerisation at pH 6.4 is likely to be responsible for the delayed reappearance 
of native β2m amide resonances as monitored by NMR, with respect to the loss of 
ThT fluorescence (discussed in Section 2.3.7). In other words, HMW species may be 
an intermediate of fibril depolymerisation that form prior to the refolding of native 
β2m monomer. Comparison of peak heights of LMW and HMW species detected by 
FCS during fibril depolymerisation at pH 6.4 shows that at the earliest time point, 
the relative ratio of LMW to HMW species is most equivalent (Table 3.3.1) At time 
points thereafter the relative LMW:HMW species peak height ratio increases from 2 
– 5 for species observed 135 min after the initiation of depolymerisation (Table 
3.3.1). The increase of LMW species with respect to HMW species over time 
supports the view that HMW species form prior to the formation of LMW species.  
Due to the broadening of the HMW peak detected 135 min after the initiation of 
fibril depolymerisation (Figure 3.3.8b), peak area, as opposed to peak height, was 
also calculated and used to compare the relative populations of both species. Peak 
area was calculated by summing all τD amplitudes that are ≥ 50% of the amplitude of 
the peak height (FWHM) (Table 3.3.1). This comparison shows that a similar 
increase in relative LMW:HMW species ratio is observed between 35 – 65 min, but 
then stabilises, with no further increase between 95 – 135 min as observed when 
comparing peak height. This shows, therefore, that the relative ratio of LMW to 
HMW species equilibrates between 35 – 65 min after the initiation of 
depolymerisation at pH 6.4, with a greater proportion of HMW species only apparent 
with respect to LMW species at the earliest recorded time point (35 min).  
Table 3.3.1 The formation of HMW species precedes that of LMW species. Comparison of 
peak height (the amplitude of τD at the peak centre position) and peak areas (summed τD ≥ 
50% of the amplitude of the peak centre), of HMW and LMW species formed during  
depolymerisation at pH 6.4. 
  peak height peak volume 
time (min) LMW HMW ratio LMW HMW ratio 
35 2.37E-03 1.07E-03 2.2 1.32E-02 5.71E-03 2.3 
65 3.43E-03 7.15E-04 4.8 1.37E-02 3.33E-03 4.1 
95 2.62E-03 6.01E-04 4.3 1.20E-02 3.16E-03 3.8 
135 1.02E-03 1.95E-04 5.2 6.13E-03 1.50E-03 4.1 
Chapter 3 
 
123 
 
The persistence of HMW species at all recorded time points during depolymerisation 
at pH 6.4 indicates an increased stability of these species in comparison with those 
that form during fibril depolymerisation at pH 7.4. This is likely to explain the 
increased dye release potential of soluble material at pH 6.4 (Section 2.3.4), despite 
the overall lower amplitude of fibril depolymerisation vs. time at this pH (Section 
2.3.4). As the filtrate at pH 7.4 also exhibits dye release potential, membrane-active 
species must also be present at this pH (as evidenced by time points 15 min and 105 
min at pH 7.4, Figure 3.3.8a), but the rapid equilibration of HMW species to 
membrane-inactive LMW species, means they must be highly transient, lowly 
populated and rarely encountered during these FCS experiments. The transient 
existence of HMW species at pH 7.4 is supported by the good agreement between 
the rate of loss of fibrils as monitored by ThT fluorescence and the reappearance of 
native 2m during depolymerisation at pH 7.4 (Section 2.3.7). 
Despite the increased persistence of HMW species forming during fibril 
depolymerisation at pH 6.4 explaining differences in membrane disruption potential 
between the two conditions, the broadness of the LMW peak under both conditions 
(in comparison with native β2m controls (Figure 3.3.7)) means that the presence of 
non-native LMW species cannot be ruled out. However, as the broadness of the peak 
is related to the signal to noise ratio of the ACs (greater error, less discrete 
distribution of species according to MEM – Section 3.2.5), it is difficult to comment 
with any degree of confidence about the potential heterogeneity of LMW species 
from this parameter alone. Nevertheless, as different species with τD within an order 
of magnitude of one another cannot be resolved by MEM (Section 3.3.1), the 
position of the peak centre can be informative as to the heterogeneity of LMW 
species in solution. A significant population of LMW oligomers would manifest in a 
shift of the peak centre away from that obtained for native β2m controls. As the 
LMW peak centre falls within range of that for native monomer controls (Figure 
3.3.7) it is most likely that the LMW peak is predominantly monomeric. This is 
supported by the previous NMR experiments, as significantly populated LMW non-
native species would lead to observable non-native chemical shifts at various time 
points during the acquisition of 
1
H-
15
N HSQC spectra as depolymerisation proceeds. 
Chemical shift differences are only observed during the earliest time point collected 
during fibril depolymerisation at pH 6.4 (Figure 2.3.19). 
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As the LMW peak is completely resolved from the small amount of higher order 
species observed during fibril depolymerisation at pH 7.4, the relative number of 
molecules contributing to this peak can be calculated and plotted vs. time. If the rate 
of LMW peak appearance is consistent with native β2m reappearance calculated by 
NMR, then this will confirm that the LMW peak is predominantly native, non-toxic 
β2m. 
The number of molecules within the LMW peak can be calculated by scaling the 
summed amplitudes associated with all τD values that fall within the LMW peak, by 
the overall amplitude of all species extracted from the entire AC (1/N in equation 10) 
and the proportion (or fraction) of the overall amplitude attributed to the LMW peak 
(αi).  
 𝐺(𝜏) =
1
𝑁
 ∑
𝑎𝑖
(1 +
𝜏
𝜏𝐷𝑖
) (√1+.
𝜏
𝐾2. 𝜏𝐷𝑖
)
𝑛
𝑖=1
 (10) 
The way that peak area scales as a function of multicomponency is best illustrated in 
Figure 3.3.9. An AC derived from a homogenous solution containing on average 5 
fluorescent molecules within the confocal volume is shown in Figure 3.3.9a. When 
the number of molecules (N, Equation 10) is increased two fold, the initial amplitude 
of the AC, is decreased by half (0.2 to 0.1, G(0), Figure 3.3.9a and b). The AC in 
Figure 3.3.9b indicates that an additional species (HMW species) of increased τD is 
now observable in solution in addition to the original species (LMW species) from 
Figure 3.3.9a. Each species comprise half of the molecules detected at any one time 
(5 each) so the number of LMW species is unchanged from Figure 3.3.9a. However, 
for multicomponent systems, each species contributes only the fraction of signal 
derived from that species as a function of the total amplitude of the AC (αi in the 
above equation). Therefore each species in Figure 3.3.9b contributes only half of the 
overall amplitude (Figure 3.3.9c LMW species green – HMW species orange). So 
despite the same number of LMW species present within each sample from Figure 
3.3.9a and b, the relative signal has been reduced 4 fold (G(0) from Figure 3.3.9a – c 
reduced from 0.2 to 0.05). This is also seen in the MEM distribution (Figure 3.3.9d), 
where the area of the LMW peak has been reduced four-fold due to the increased 
number of species detected (signal decrease by half) and the heterogeneity of the 
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system ( by half again) (Figure 3.3.9d). In order to calculate the number of LMW 
species populating during depolymerisation at pH 7.4, the LMW peak volume (or 
summed amplitudes from τD within the LMW peak) must be scaled by the overall 
amplitude (1/N) and the fraction to which LMW species contribute to the overall 
amplitude of the AC (αi). 
This analysis was performed for the time points shown in Figure 3.3.8a, with two 
additional time points acquired 5 min and 1440 min after depolymerisation initiation 
at pH 7.4. The resulting ACs are shown in Figure 3.3.10a, normalised to the 5 min 
time point. 
Figure 3.3.10b shows that after plotting the relative number of molecules associated 
with the LMW peak vs. time, the appearance of LMW species is best described by a 
mono-exponential function with an apparent rate constant of 1.4x10
-2
.min
-1
. 
Although slightly faster than that calculated for the rate of appearance of native β2m 
resonances by NMR (1.06x10
-2
.min
-1
), fibrils used in FCS experiments were seeded 
with a ten-fold higher concentration to ensure polymerisation was completed on a 
Figure 3.3.9 Simulation to illustrate how peaks scale in multicomponent ACs. (a) AC derived 
from 5 molecules with τD = 100 µs. (b) Multicomponent AC derived from species in (a) plus 5 
additional molecules with τD = 10 ms. (c) Breakdown of the contribution of both species 
(species a – LMW species –green, HMW species in orange) to the overall AC (blue). (d) 
MEM distributions of (a) and (b). 
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time scale that preceded the hydrolysis of Alexa488 at low pH (maleimide ring 
cleavage occurs under acidic conditions leading to the liberation of free dye). A 
higher seed concentration will generate a fibril population in which the average 
length of fibrils is reduced. The reduction of fibril length (while maintaining fibril 
monomer equivalent concentration) will generate more sites from which 
depolymerisation can proceed, if fibril depolymerisation is mediated from fibril ends 
(as suggested by the length-dependency associated with membrane disruption and 
cellular toxicity caused by β2m fibrils – Section 2.1). Therefore, the difference in the 
rate at which native β2m reappears by NMR and the rate at which LMW species 
populate during depolymerisation as monitored by FCS is likely to be due to 
differences in fibril lengths of the initial fibril population used in each experiment.  
The same analysis cannot be performed at pH 6.4 due to difficulties in calculating 
the relative amplitude of LMW species as they are not exclusively resolved from 
HMW species (due of the larger error associated with ACs collected during 
depolymerisation at this pH (Figure 3.3.6b)). However, the consistency of the 
apparent RH of the LMW peak centre for native β2m controls and species observed 
during depolymerisation at both pH 7.4 and pH 6.4 suggests the LMW peak is likely 
to be predominantly composed of native β2m monomer, as detected by NMR 
(Section 2.3.7). Therefore the LMW species observed during FCS are native, non-
toxic β2m, suggesting that the soluble HMW species, which are most frequently 
Figure 3.3.10 The rate of LMW peak intensity reappearance at pH 7.4. (a) Normalised raw 
ACs collected during fibril depolymerisation at pH 7.4. Curves are shown normalised to 
G(0) of the AC collected 5 min after the initiation of fibril depolymersation. Curves were 
fitted by MEM and 1/N (see equation 10) corresponding to LMW species were calculated as 
described in Figure 3.3.9. The reciprocal of 1/N (peak intensity – y axis in b) is plotted vs. 
time in (b). 
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observed during depolymerisation at pH 6.4, must be the primary source of in vitro 
liposome disruption activity and contribute cellular metabolic dysfunction. 
3.3.5 HMW oligomers interact with native β2m at pH 6.4 
The apparent RH of HMW species increases by approximately 10 nm from ~20 to 31 
nm (Figure 3.3.8b) 135 min after the initiation of depolymerisation at pH 6.4. A 
similar increase in apparent RH is not observed for LMW species. This suggests that 
HMW species may coalesce post-formation, sequester refolded native β2m 
monomer, or both, between 95 – 135 min after the initiation of depolymerisation. 
The increase in apparent RH may also be due to baseline fluctuations within the 
measurement recorded at the 135 min time point. To test whether HMW species re-
interacting with native β2m could be responsible for the increase in apparent RH of 
HMW species 135 min after fibril depolymerisation was initiated, FCS experiments 
were performed in the presence or absence of unlabelled fibrils and native 18 nM 
R3C488 at pH 7.4 and pH 6.4. Depolymerisation of 120 M unlabelled 2m fibrils 
was induced by diluting 4-fold into pH 7.4 or pH 6.4 buffer at 25C. Solutions were 
left for 30 and 60 min respectively before the addition of native 18 nM R3C488. At 
pH 7.4, ACs of R3C488 are identical in the presence and absence of unlabelled 
fibrils, indicating no interaction, or no detectable exchange, between native β2m and 
aggregate species (Figure 3.3.11a). However, at pH 6.4, a significant difference in 
the profile of the AC is observed in the presence of β2m amyloid fibrils (Figure 
3.3.11b). The apparent RH distributions of species within each AC were extracted 
using MEM (Figure 3.3.11c and d). At pH 7.4, a single peak equivalent in apparent 
RH (1.7±0.1 nm) to that observed for native β2m monomer controls (Figure 3.3.7) is 
populated, suggesting that, at least by FCS, native β2m is not capable of re-
interacting with HMW species. The lack of detectable interaction between native 
β2m and HMW species may also be due to the low abundance of HMW species 
populating during depolymerisation at this pH (Figure 3.3.8). At pH 6.4, however, 
the apparent RH distribution shows that, in addition to LMW species, a second, 
HMW species is present with an apparent RH (Figure 3.3.11d 18±8 nm) equivalent to 
those detected during fibril depolymerisation experiments outlined in Section 3.3.4. 
This suggests that β2m fibrils are able to contribute to in vitro membrane disruption 
and the disruption of cellular metabolic activity via a bipartite mechanism at pH 6.4; 
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by initial shedding of persistent, membrane-active HMW oligomers that in turn 
deplete the local pool of native monomeric species. 
3.3.6 Limitations of MEM in quantifying molecular shedded species 
As shown in Section 3.3.1, when different species are adequately separated in the 
time domain, MEM can accurately describe the τD and population of each species. 
This raises the prospect of using MEM to calculate absolute concentrations of the 
HMW species that are formed at pH 6.4. In experimental ACs, however, the 
amplitude associated with each τD is related not only to the relevant concentration of 
the species, but also the brightness, or quantum yield, of the fluorescent moiety when 
incorporated into a higher order species. Neither the quantum yield of dye 
incorporated into labelled oligomers, or the labelling stoichiometry of the higher 
order species, which is also required for calculating particle molarity (how many 
labelled monomers per oligomer), is known, therefore it is not possible to accurately 
quantify the concentration of HMW species relative to native β2m (LMW species) 
Figure 3.3.11 HMW species interact with native β2m at pH 6.4. Raw ACs of 18 nM 
native R3C488 at pH 7.4 (a) and pH 6.4 (b) in the presence and absence of unlabelled 
β2m amyloid fibrils acquired 30 and 60 min after depolymerisation initiation 
respectively. (c) Apparent RH distribution of species extracted from the AC 
corresponding to 18 nM R3C488 in the presence of 30 µM wt β2m fibrils 30 min after 
depolymerisation initiation at pH 7.4. (d) As above, but for fibrils undergoing going 
depolymerisation at pH 6.4 for 60 min. 
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that populate during fibril depolymerisation. However, if species of comparative size 
populate under both conditions, then MEM distributions can provide semi-
quantitative observations of how the population of species differ between the two 
conditions. What MEM therefore shows us is that at pH 6.4, HMW species are 
significantly populated and persistent and can presumably participate in liposome 
disruption and affect cellular metabolic activity. In comparison, fibril 
depolymerisation at pH 7.4 results in the rapid formation of native, non-toxic β2m, 
where HMW species are transient and lowly populated, leading to a lower membrane 
disruption potential, in spite of an increased amplitude of fibril depolymerisation.  
3.3.7 Structural interrogation of molecular shedded species 
Although FCS has confirmed the existence of HMW species presumably responsible 
for fibril-mediated membrane disruption, little has been revealed thus far about their 
structural properties. Therefore the structural properties of these oligomers were 
assessed using several techniques. Initially, fibrils were depolymerised at pH 6.4 for 
30 min and samples prepared for negative-stain TEM. Figure 3.3.12b shows that 
spherical aggregates are observed populating at pH 6.4, with species appearing 
heterogeneous in size and typically ranging from 20 – 50 nm in diameter. No 
oligomers were detected at pH 7.4 (a). This is consistent with the broadness 
associated with HMW species described by MEMFCS during fibril depolymerisation 
at pH 6.4 (Figure 3.3.8). In order to determine whether the size of species in TEM 
experiments is consistent with those observed in FCS, 850 particles were traced from 
electron micrographs. The frequencies of end-to-end distances were sorted into 10 
nm bins and are shown in Figure 3.3.12c. The most common size observed in TEM 
is 50 nm. Apparent RH measurements are typically different from comparative end-
to-end distance measurements obtained using other techniques (such as negative-
stain TEM) due to the additional presence of a hydration sphere (414). The presence 
of a heavy metal stain can also make species appear larger in negative-stain TEM, 
due to the presence of a pool of electron-dense stain about the particles under 
observation. This is likely to account for the differences between apparent RH 
measurements (~20 nm, diameter 40 nm) made using FCS and the distribution of 
end-to-end distances calculated from particle tracing from electron micrographs. 
Nevertheless, there is a good overall agreement between size measurements and size 
distributions of species observed using either technique. 
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Oligomers could also been seen embedded within vitreous ice in samples prepared 
for cryoEM. CryoEM can obtain higher resolution detail (near-atomic) than negative 
stain EM as samples are not contaminated with heavy metal isotopes and remain 
hydrated. Despite this, class averaging of particles could not generate any high-
resolution structures, presumably due to the high degree of heterogeneity within 
oligomers (Figure 3.3.12d). The inability of particle averaging to generate high-
resolution reconstructions of oligomers suggests that they contain little or no fixed 
elements of structure.  
The suggestion from cryoEM that oligomers are unstructured prompted the structure 
of oligomers to be probed with the W01 antibody, which recognises the generic 
cross-β core formed from a range of different amyloid fibrils (80, 81). Dot blots were 
Figure 3.3.12 Detection of molecular shedded oligomers using negative-stain TEM 
and cryo-EM.  Negative-stain EM micrographs of samples at (a) pH 7.4 or (b) pH 6.4,  
30 or 60 min after the initiation of fibril disassembly. Scale bar is 150 nm. (c) 
Distribution of longest end-to-end distances of 850 traced oligomers formed during 
depolymerisation at pH 6.4. Bin size is 10 nm. (d) Particle class averages from 
cryoEM of products of depolymerisation formed in pH 6.4 buffer. (c) and (d) kindly 
performed by Dr Matt Iadanza (University of Leeds) 
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performed on total protein samples and partitioned filtrates of fibril solutions that 
were allowed to undergo depolymerisation at pH 7.4 or 6.4 for 30 or 60 min 
respectively. Samples of the filtrate were repeatedly administered to the membrane 
to ensure that comparable protein concentrations of 2m were present in filtrate and 
total protein samples (α-β2m blot, Figure 3.3.13). Figure 3.3.13 shows that the filtrate 
at both pH 7.4 and 6.4 do not possess the W01 binding epitope, by contrast with 
fibrils.  
To further probe oligomer structure, filtrates generated during fibril 
depolymerisation were analysed using far-UV CD spectroscopy. Filtrates were 
generated as described in Section 3.3.7 and soluble material quantified using 
densitometry of SDS-PAGE gels (Figure 3.3.14). Filtrates were quantified to 
facilitate the direct comparison of CD spectra of molecular shedded material with 
native 2m controls acquired at equivalent concentrations in the respective buffers. 
Figure 3.3.14 confirms the accuracy of using SDS-PAGE densitometry to calculate 
relatively low concentrations of protein (low M range – absorbance at 280 nm 
unreliable at this concentration). Samples generated during fibril depolymerisation 
were loaded alongside three calibrants of known protein concentration and two 
control samples of β2m previously quantified using Beer-Lambert’s law in order to 
confirm the accuracy of the method. A calibration curve was constructed from the 
absorbance of the three calibrant bands against the known concentrations and the 
corresponding equation used to calculate the concentration for unknown samples. 
The 30 µM (1.75 g of protein) and 25 µM (1.45 g) loading controls were 
Figure 3.3.13 Dot blot analysis of molecular shedded 
material. Filtrates generated after depolymerisation at 
pH 7.4 and 6.4 and total protein samples (fibrils) were 
blotted with the W01 and α-β2m antibodies. Control 
blots were performed with fibrils at pH 2.0 
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calculated to a high degree of accuracy using the calibration curve, providing 
confidence for the concentrations calculated for soluble material generated during 
depolymerisation. 
Far-UV spectra of filtrates partitioned during depolymerisation along with spectra of 
native 2m controls collected under identical solution conditions are shown in Figure 
3.3.15a and b (pH 6.4 and 7.4 respectively). For both spectra, a reduction in the 
positive max at approximately 200 nm is apparent compared with native monomeric 
2m controls. The difference is more pronounced at pH 6.4, consistent with a higher 
concentration of non-native species accumulating during depolymerisation at this 
pH. Under both conditions, the negative max value of 217 nm is similar to that of 
native 2m controls. This suggests that a significant proportion of soluble material 
contains -sheet structure, corroborating with NMR (and FCS) showing that native, 
monomeric β2m reappears during depolymerisation. There is also a reduction in 
mean residue elipicity at approximately 230 nm at pH 6.4. For native 2m, the 
Figure 3.3.14 Quantification of filtrates partitioned during fibril depolymerisation.. 
Filtrates generated 30 min or 60 min after depolymerisation initiation were 
electrophoresed with β2m calibrants consisting of 1.25, 0.625 and 0.3125 µg. The 
absorption of bands was calculated and plotted against µg of protein to construct a 
calibration curve. Filtrate concentrations were then calculated from the in-gel 
calibration. Two additional controls of 25 and 30 µM β2m were also loaded onto the 
gel and quantified by this method. 
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absorption in this region of the far UV CD spectra is thought to arise from aromatic-
aromatic  stacking. The loss of signal from this region may be due to higher 
incidence of non-native oligomers populating at pH 6.4. In order to highlight regions 
of the spectra where the greatest changes are observed, the difference spectra were 
calculated by subtracting the native 2m spectra from that of the partitioned soluble 
material (Figure 3.3.15a and b, dashed lines). This confirms that the greatest 
differences are seen between 190 – 210 nm, which is the region of CD absorption for 
intrinsically disordered proteins (415).  
As partially or fully unfolded proteins can display increased solvent-exposed 
hydrophobic surface area, soluble material generated at pH 6.4 and 7.4 was tested as 
to its ability to interact with 8-anilinonaphthalene-1-sulphonate (ANS). ANS is a 
Figure 3.3.15 Far-UV CD and ANS binding studies of molecular shedded species. Mean 
residue ellipticity of the filtrate isolated 30 or 60 min after the initiation of fibril 
disassembly at (b) pH 6.4 or (b) pH 7.4,respectively, measured using far-UV CD. Spectra of 
native β2m (black) were acquired at the same protein concentration. Difference spectra are 
shown in dashed lines. ANS fluorescence emission spectra of the filtrate isolated as stated 
in Section 3.2.10, at (c) pH 6.4 or (d) pH 7.4 and of native β2m at equivalent concentrations. 
Curves are normalised to the maximum amplitude of the spectrum of acid unfolded β2m at 
pH 2.0 (grey dashed line) acquired at the same protein concentration. Native β2m monomer 
controls are shown in black. 
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fluorescent probe known to bind to surface-displayed hydrophobic patches which 
generates a marked increase in fluorescence emission intensity and a blue shift in 
λmax emission wavelength of ANS (416). ANS spectra are shown normalised to the 
equivalent concentration of acid unfolded β2m in Figure 3.3.15c - d. At saturating 
ANS concentrations, the fluorescence intensity of soluble material is approximately 
10 or 6 times greater than the equivalent concentration of native β2m at pH 6.4 
(Figure 3.3.15c) or 7.4 (Figure 3.3.15d) respectively. Both ANS spectra of soluble 
material experience similar λmax blue shifts of approximately 30 nm compared with 
native β2m, indicating a significant enhancement in surface exposed hydrophobicity 
within non-native species shed from fibrils. The similarity of the λmax blue shift 
suggests that non-native species generated at both pH are equivalently hydrophobic, 
although the magnitude of the increase in fluorescence intensity in comparison with 
native control spectra confirms a higher concentration of non-native species populate 
during fibril depolymerisation at pH 6.4. 
3.4 Discussion 
Here, the demonstration of the effect of subtle changes to solution conditions on the 
dynamics and the associated changes to pathological capacity of a disease-associated 
amyloid assembly are described. The rapid assembly and disassembly of functional 
amyloids has been shown to be an important facet of tuning rapid metabolic 
responses in response to the environment within the cell (136–138, 241), but whether 
amyloid fibrils known to cause cellular dysfunction undergo similar condition-
dependent dynamics had not previously been established.  
For β2m, our in vitro characterisation of soluble species forming during 
depolymerisation has shown a remarkable pH dependence; reducing the pH by a 
single unit, from pH 7.4 to 6.4, results in a large increase in the relative 
concentration of HMW species in comparison with native β2m monomer. These 
species are likely to be responsible for membrane disruption displayed by soluble 
material generated during fibril depolymerisation, as the identity of the LMW 
species is predominantly membrane-inactive native β2m monomer. Evidence for this 
is provided from experiments performed in Chapters 2 and 3, including i) NMR, 
which shows the rapid reappearance of native β2m chemical shifts upon 
depolymerisation at pH 7.4, ii) the agreement between ThT kinetic rate constants and 
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the global reappearance of native β2m resonances, iii) the good agreement between 
apparent RH of native β2m monomer controls and LMW species observed during 
fibril depolymerisation and iv) the similarity of the apparent rate which LMW 
species and native β2m resonances reappear by FCS and NMR respectively. Thus 
HMW species formed during depolymerisation can be strongly linked to in vitro 
membrane disruption activity exhibited by soluble material.  
The greater stability of HMW species formed during depolymerisation at pH 6.4 
explains i) the delay between the loss of ThT fluorescence (oligomer formation) and 
the rate of monomer reappearance as studied by NMR; ii) their increased 
accumulation during depolymerisation (Figure 3.3.8); and  iii) the increased 
amplitude of membrane disruption (Section 2.3.4). This is in spite of the decreased 
amplitude of total soluble material generated at pH 6.4 in comparison with 
Figure 3.4.1 Modelling the molecular shedding phenomenon. (a) Disassembly of fibrils at 
pH 7.4 via a 4-state linear model. Species are indicated in the key. (Type A to Type B fibril 
is the initial increase in ThT fluorescence observed in Figure 2.3.6. (b) provides a zoom of 
the initial stages of depolymerisation at pH 7.4. (b) Depolymerisation modelled at pH 6.4. 
(d) Schematic representation of the differences of molecular shedding at the two pH. For 
simplicity, the initial transition between the possible transition of fibril architecture is not 
shown. 
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depolymerisation at pH 7.4 (Figure 2.3.7). The rates calculated from ThT 
fluorescence measurements and NMR, as well as insights provided by FCS, were 
used to model the kinetic response of fibrils under the two sets of conditions. This 
shows that, at pH 7.4, very low populations of oligomers are present throughout 
fibril depolymerisation, as the equilibrium is driven rapidly to native β2m (Figure 
3.4.2a-b, purple line). Conversely, at pH 6.4, the delay between fibril loss (ThT 
fluorescence) and monomer reappearance (NMR), and the observed back-exchange 
between native β2m and HMW species at pH 6.4 (as seen by FCS – Figure 3.3.11), 
means that a pool of oligomers persists throughout depolymerisation (Figure 3.4.2c), 
confirming observations made by MEMFCS (Figure 3.3.8b). 
Why HMW species show such pH dependent stability has not been established in 
this thesis, but one could speculate that it is likely to be to due changes in 
electrostatic charges upon β2m caused by the reduction in pH. This may provide 
some indication as to which residues are important in facilitating oligomer stability 
and would be an interesting avenue in which to further investigate. This is discussed 
in more detail in Chapter 4. 
The latter part of this chapter has attempted to structurally characterise HMW 
species formed during molecular shedding. This characterisation has established that 
oligomers i) lose their cross-β core upon formation, ii) exhibit increased hydrophobic 
surface exposure in comparison to native β2m controls under the same conditions, 
and iii) appear to contain an increase in intrinsically disordered secondary structure 
in comparison with native β2m controls. Importantly, soluble species generated at pH 
7.4 and pH 6.4 exhibit similar structural characteristics, although the incidence is 
more pronounced at pH 6.4. This suggests that a low concentration of HMW species 
must exist at pH 7.4, but are either below the detection threshold of the current FCS 
set up (Figure 3.3.8a) or are too transient to detect. The presence of HMW species 
may also explain the low ionisation efficiency of native 2m during ESI-IMS-MS 
experiments performed in Chapter 2. This explains the small but significant 
amplitude of membrane disruption seen from soluble material generated at pH 7.4. 
In a cellular context, the subtle changes in pH could have significant consequences 
on the monomer-oligomer-fibril equilibria. As previously mentioned, fibrils 
deposited extracellularly, or even cytoplasmically, are often trafficked through 
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endosomal compartments as they seed amyloid aggregation throughout entire tissue 
systems. This trafficking may facilitate fibrils from a variety of diseases entering an 
environment that tunes the equilibrium in favour of generating a large and localised 
pool of membrane-active oligomers. For β2m, endosome maturation after fibril 
internalisation may not only lead to an environment for the optimum generation of 
HMW oligomers (Figure 3.4.3), but also includes the formation of a lipid 
composition enriched in BMP. As shown in Chapter 2, the presence of BMP makes 
LUVs more susceptible to fibril-mediated membrane disruption (Figure 3.4.3). Thus, 
β2m fibril-mediated toxicity may be localised to specific endocytic compartments 
that favourably stabilise molecular shedded oligomers in the presence of preferential 
lipid compositions for membrane disruption (Figure 3.4.3). 
Another interesting question this discovery poses is whether these oligomers are 
equivalent to those that form during the lag phase of fibril assembly at low pH. To 
date, no evidence is available to support their existence during fibril formation, 
raising the possibility of the discovery of a new, previously uncharacterised oligomer 
ensemble. The final chapter in this thesis aims to determine whether the processes of 
polymerisation and depolymerisation are equivalent and opposite or entirely distinct, 
and whether oligomers formed during each process are structurally homologous. 
Figure 3.4.2 A potential hot-spot for 2m amyloid-mediate cellular disruption? 
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Comparing the mechanisms of fibril polymerisation and 
depolymerisation 
 
4.1 Introduction 
As discussed in Section 1.3.4, fibril polymerisation is preceded by the formation of a 
variety of oligomeric species that are required for the initiation of fibril growth (146, 
151, 188, 238, 387, 392, 417, 418). These species are typically thought to be 
responsible for toxicity (2, 20, 21, 25, 184). After the formation of a nucleating 
particle, fibril polymerisation proceeds by an end-dependent process involving the 
templated conversion and incorporation of precursors into the elongating amyloid 
fibril. The morphology of species incorporated during fibril elongation are not 
widely known (419), however, once fibril growth has reached equilibrium, soluble 
species that exchange with fibrils have been shown to be structurally homologous to 
particles that form in the lag phase (188, 238, 392). The structural homology 
between these two types of oligomers, coupled with the fact that soluble species are 
consumed at fibril ends during fibril elongation, suggests that the recycling of 
oligomers from mature amyloid fibrils may be similarly end-dependent. Based on 
this, it may be reasonable to assume that the release of membrane-active soluble 
species upon β2m fibril depolymerisation at near-neutral pH is also end-dependent. 
Previous studies performed in the Radford group have highlighted a 2m fibril 
length-dependent relationship between the extent of membrane disruption and the 
disruption of cellular metabolic activity (245, 341). Briefly, fibrils fragmented in 
order to reduce fibril length display enhanced membrane disruption activity in 
comparison with their longer counterparts. This length dependent phenomenon was 
further shown to be conserved for a range of other fibril types, including fibrils 
formed from -synuclein, A42 and lysozyme (420). For 2m fibrils at least, the fact 
that membrane disruption is length-dependent and is mediated by the release of 
soluble species suggests that 2m fibril depolymerisation at near-neutral pH is likely 
to proceed from fibril ends; shorter FLDs at monomer equivalent concentrations 
possess a greater number of ends from which membrane-active oligomers can be 
released. Nevertheless, the comparison between the number of fibril ends and the 
extent of membrane disruption does not correlate exactly. For example, fibrils 
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fragmented for 48 h cause less than twice the extent of membrane disruption than 
their longer counterparts. This is despite the average fibril length being 
approximately four times shorter (245, 341). Work in this chapter therefore aims to 
investigate the mechanism by which molecular shedding of membrane-active species 
during fibril depolymerisation takes place, in order to rationalise why membrane 
disruption potential does not increase in accordance to the number of fibril ends 
within a fibril population. The end-dependency of seeded fibril polymerisation will 
also be investigated to establish whether polymerisation at low pH and 2m fibril 
depolymerisation at pH 6.4 are equivalent but opposite processes. Finally, the 
structure of oligomeric species that form within the lag phase of 2m amyloid 
assembly will be investigated to probe whether soluble species that form during each 
process are structurally homologous or distinct.  
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4.2 Material and Methods 
4.2.1 Tapping mode atomic force microscopy  
AFM analysis of fibril samples and characterisation of fibril length distributions was 
performed as previously described in Section 2.2.5. Fibril samples fragmented for 
different times were generated by first incubating 120 µM β2m in fibril growth 
buffer and seeding fibril formation with 0.1% (w/w) β2m fibril seeds (see section 
2.2.4) and incubating at room temperature under quiescent conditions for a minimum 
of 48 h. 500 µl aliquots were then placed on a custom made precision stirrer in 1.5 
ml chromacol glass vials and fragmented as previously described at 1000 rpm 
(section 2.2.4). Aliquots of 100 µl were removed at 0.5, 6.5, 18 and 48 h after the 
initiation of fibril fragmentation. A maximum of 200 µl was removed from any 
individual aliquot so duplicate samples were prepared. 
4.2.2 Fibril seeding assay 
The fibril samples generated above were used in a fibril seeding assay to determine 
the end-dependency of fibril polymerisation. To do this, 120 µM β2m monomer in 
fibril growth buffer (Section 2.2.4) was seeded with 10% (w/w) (monomer 
equivalent concentration) of each of the fibril samples generated above. Fibril 
formation was monitored on a Fluostar Omega plate reader (BMG Labtech) by 
supplementing fibril growth buffer with 10 µM ThT. The instrument was operated as 
previously described and samples prepared as previously described (section 2.2.7), 
with the only differences being the gain control was set to 75% of the fluorescence 
emission value of 120 µM pre-formed β2m amyloid fibril control in the presence of 
10 µM ThT. Each seeding assay was performed with a minimum of five repeats. To 
calculate the initial rate of fibril elongation, the initial 10 data points (one time point 
per minute) were fitted using a linear equation with the gradient used as the rate. The 
average of the repeat measurements is displayed as the rate with the standard 
deviation from repeat measurements the error. 
4.2.3 Fibril depolymerisation assay 
Depolymerisation assays at pH 6.4 were performed with a minimum of six repeats 
(except 48 h fragmented fibrils – only four repeats were performed). Fibrils were 
pre-bound by ThT in fibril growth buffer (Section 2.2.4) by incubating 25 µl aliquots 
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of 120 µM fibrils with 40 µM ThT in 96 well plates for 30 min prior to diluting 
samples 4-fold with pH 6.4 buffer (see Section 2.2.6 for buffer composition) pre-
incubated at 25°C for at least 1 h before use. Fibril depolymerisation was then 
immediately monitored exactly as described in Section 2.2.7. Individual repeats of 
ThT fluorescence curves were fit with the following double exponential function 
using Origin Pro v.8.6: 
 𝑦 = −𝐴𝑘1𝑡 + 𝐵𝑘2𝑡 + 𝐶 (1) 
Where A and B are the amplitudes and k1 and k2 are the rate constants for the 1
st
 and 
2
nd
 exponential phases, respectively. The rate constants shown in the results section 
are the average of the repeat measurements and the error is the standard deviation 
The significance is the difference between calculated rates was performed by 
comparing the rates calculated for each replicate measurement of fibril samples 
using a two-tailed student’s t-test of equal variance in Microsoft Excel. 
4.2.4 Fibril formation assay 
120 µM β2m was incubated in a black, clear-bottomed 96 well plates (Costar) in a 
Fluostar Omega plate reader at 25°C in fibril growth buffer in the presence and 
absence of 0.001% (v/v) Tween-20 and supplemented with 10 µM ThT. Fibril 
formation was monitored using instrument parameters outlined in Section 2.2.7. 
Aggregation was performed by shaking plates at 600 rpm in ortibal mode for 50 sec 
prior to recording ThT fluorescence emission every minute (10 sec per read). The 
gain control was set as described in Section 4.2.2. Each aggregation assay was 
performed with a minimum of four repeats. 
4.2.5 Comparison of fibril yield in the presence and absence of Tween-20 
The yield of fibril formation in the presence or absence of 0.001% (v/v) Tween-20 
was compared by quantifying the soluble material remaining within the stationary 
phase using calibrated SDS-PAGE densitometry (Section 2.2.8). Samples were 
prepared for SDS-PAGE by centrifuging 100 µl aliquots of β2m fibrils formed in the 
presence or absence of 0.001% (v/v) Tween-20 by centrifuging at 16300 x g on a 
bench top microfuge for 1 h. 10 µl of the supernatant was then removed, prepared for 
SDS-PAGE and analysed as previously described (Section 2.2.8) 
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4.2.6 Negative stain TEM 
Samples were prepared and analysed as previously described (Section 2.2.1.5) 
4.2.7 FCS of β2m amyloid formation 
FCS data acquisition and analysis by MEM was performed as previously described 
in Chapter 3. Samples were prepared for FCS by diluting native β2m to 120 µM in 
fibril growth buffer supplemented with 0.001% (v/v) Tween-20 with the addition of 
18 nM R3C488 (see Section 3.2.1 for purification and labelling of 2m variant). 
Fibril formation was performed on a Fluostar Omega plate reader as described in 
Section 4.2.4. Aggregation was stopped after 30, 60, 120, 180, 240, 300, 360, 420, 
480 and 540 min so that 50 µl aliquots could be removed from a well and 
immediately analysed by FCS. Samples were analysed by placing them on glass 
coverslips on the sample platform before 20 x 30 sec ACs were recorded for each 
time point. Glass coverslips were cleaned before use by sonicating for 10 min in H2O 
in a water bath, followed by 10 min sonication in 2% (v/v) Hellmanex solution 
(Hellma), then 10 min sonication in H2O and finally sonicating for 10 min in 70% 
(v/v) ethanol. Glass coverslips were then aspirated using a gentle stream of N2 gas 
before storing in sealed beakers. 
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4.3 Results 
4.3.1 Calculating fibril concentrations from FLDs 
In order to explore differences in the mechanism of fibril polymerisation and 
depolymerisation, populations of β2m fibrils with different FLDs were generated. 
This was done to enable the end-dependency of templated fibril elongation and 
depolymerisation to be investigated by using fibril seeds with identical monomer 
equivalent concentrations, but progressively shorter FLDs. FLDs that contain 
significantly shorter fibrils will contain more ends (for the same monomer equivalent 
concentration) that should, in theory, accelerate seeded fibril elongation (providing 
seeded polymerisation is end-dependent) (150). To generate fibril seeds with 
different FLDs, 120 µM of 0.1% (w/w) seeded β2m fibrils were fragmented for 0, 
0.5, 6.5, 18 or 48 h (Section 4.2.1). The corresponding FLDs for these fibril samples 
fragmented for different times were calculated using AFM as previously described 
(Section 2.2.5). Figure 4.3.1 shows that, as fragmentation time proceeds, fibrils 
globally decrease in length, with the weight average length decreasing from 130050 
nm within the unfragmented fibril population to 28610 nm for fibrils fragmented 
for 48 h. These average lengths are consistent with those previously described (245, 
341). 
To study the effect of varying the number of fibril ends on both polymerisation and 
depolymerisation, FLDs were converted to fibril concentrations. This enables the 
accurate determination of the number of fibrils ends in solution as opposed to 
comparing the weight average length determined from AFM analysis (360). To 
convert FLDs into fibril concentrations, the following equation was derived (150): 
 𝐶𝑓 = ∑ (
𝑀𝐸𝐶
4.65 ∗ 𝑙𝑓𝑖
) . 𝑓𝑓𝑖
𝑖
 (2) 
where Cf  is the fibril concentration, MEC is the monomer equivalent concentration 
of β2m within samples, lfi is the length in nm of fibril i within the FLD, and ffi is the 
frequency of lfi as a function of the overall distribution. 4.65 is a constant related to 
the number of β2m monomers per nm of fibril length as calculated from STEM 
analysis of β2m amyloid fibrils formed at low pH (92). This analysis showed that the 
most common density of β2m fibrils was 52 kDa.nm
-1
 (MW of β2m is 11860 Da). To 
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simplify the calculation of fibril concentrations, fibrils were sorted into bin sizes of 
length 50 nm, with the median point within each bin used as lf. The frequency of the 
occurrence of fibrils within each bin was then calculated as a function of the overall 
FLD. 
Table 4.3.1 shows the Cf corresponding to each of the differentially fragmented fibril 
Figure 4.3.1 FLDs of β2m amyloid fibrils fragmented for different amounts of time. 
120 µM pre-formed fibrils were fragmented for 0, 0.5, 6.5, 18 and 48 h using a custom 
made precision stirrer set to 1000 rpm. Fibril length distributions calculated using 
AFM are shown normalised to the total number of fibrils traced within each sample. 
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samples displayed in Figure 4.3.1 when the monomer equivalent concentration is 30 
µM. This should be a useful tool for determining Cf in any assay in which β2m fibrils 
are used and the monomer equivalent starting concentration is known. 
Table 4.3.1 Fibril concentrations calculated from FLDs displayed in figure 4.3.1. 
frag time 
(h) Cf (nM) 
0 h 19.01 
0.5 h 15.37 
6.5 h 40.73 
18 h 63.16 
48 h 74.68 
 
4.3.2 Calculating the end-dependency of fibril polymerisation 
To determine whether 2m fibril polymerisation proceeds from fibril ends, the fibril 
samples characterised above were used in a fibril seeding assay. Fibrils from each 
sample were used to seed amyloid formation of 120 µM β2m in fibril growth buffer 
supplemented with 10 M ThT (10 % (w/w) seed concentration) (Section 4.2.2). 
The rate constant of the seeding assay should be dependent on the number of fibril 
ends in solution, providing that polymerisation is an end-dependent process. The 
increase in ThT fluorescence over time is a manifestation of the following reaction 
mechanism; 
Whereby aX is the number of available ends (or templating surfaces) and is directly 
related to Cf, and n is the number of subunits. During the seeding assay, the increase 
in ThT fluorescence is indicative of the conversion of subunits into the fibrillar form 
and therefore is directly related to kf (forward rate constant). If there is an increase in 
the number of fibril ends (such as is the case upon prolonged fibril fragmentation, 
Figure 4.3.1), kf should increase proportionately as subunits (n) are more rapidly 
consumed.  
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As secondary nucleation processes, such as fibril fragmentation and fibril surface-
induced catalysis of precursors into amyloid-competent structures (73, 146), can 
contribute significantly towards modulating the kinetics of fibril elongation, only the 
most initial data points were used to calculate the initial rate (v0) of seeded fibril 
elongation, as opposed to kf. V0 was calculated by fitting a linear function to the ten 
most initial data points from the seeding assay for all fibrils used as seeds, apart from 
when using fibrils fragmented for 48 h as seeds – only the 7 most initial data points 
were used. This is because upon seeding with fibrils fragmented for 48 h, within the 
first 10 min of the reaction the non-linear phase of elongation has already been 
reached (Figure 4.3.2 – green data series). 
Table 4.3.2 shows that as fibril fragmentation proceeds (Cf increases), v0 increases 
too. To check the linear dependence of the increase between v0 and Cf, both 
parameters were normalised to those calculated for unfragmented fibril samples. 
This allows the proportionality coefficient between the increase in v0 as a function of 
the increase in the number of fibril ends available for seeding to be calculated. 
 
Figure 4.3.2 The dependence upon fibril ends for the initial fibril elongation rate. 
Fibril elongation rates were calculated by monitoring ThT fluorescence of 120 µM 
β2m monomer at pH 2.0 using 10% (w/w) seeds of the fibril samples generated in 
figure 4.3.1. Curves were normalised from 0 – 100 using the initial ThT fluorescence 
(0) value and the ThT fluorescence post fibril elongation (100). The standard 
deviation from five replicates is the error 
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Table 4.3.2 Fibril fragmentation enhances seeding capacity V0 of fibril seeding experiments 
performed as described in Figure 4.3.2. Error is the standard deviation of five replicate 
measurements. Au is the arbitrary unit of ThT fluorescence used to monitor fibril elongation. 
frag time V0 (au/min) error 
0 h 0.54 4.83E-03 
0.5 h 1.78 1.38E-02 
6.5 h 3.84 1.66E-02 
18 h 6.94 6.06E-02 
48 h 10.12 6.81E-02 
 
Table 4.3.3 shows that the increase in v0 between using unfragmented (0 h) and 48 h 
fragmented fibrils as seeds (~19-fold increase) is almost five times as great as the 
corresponding increase in normalised Cf (~4-fold increase). Despite the apparent 
decrease in fibril concentration upon fragmenting fibrils for 0.5 h (20% reduction in 
Cf in comparison with unfragmented samples - Table 4.3.3) v0 exhibits a 3-fold 
increase. This difference may be due to errors in calculating the FLD from 
unfragmented fibril populations due to the previously described difficulties of 
unambiguously tracing longer fibrils using AFM (360). These arise due to the 
limited surface deposition of long fibrils onto imaging surfaces and their more 
frequent cut-off by image boundaries and other fibrils (360).  
Table 4.3.3 Normalised fibril elongation rates and Cf. Fibril elongation rates and Cf of the 
corresponding fibril seeds generated in Figure 4.3.1 are displayed. Each parameter is 
normalised with respect to that generated for unfragmented fibrils. 
frag time 
normalised 
elongation rate 
normalised Cf 
0 h 1.00 1.00 
0.5 h 3.31 0.81 
6.5 h 7.15 2.14 
18 h 12.92 3.32 
48 h 18.84 3.92 
 
To check whether the Cf calculated by AFM for 0 h fragmented fibrils used in these 
assays was accurate, 0 h fragmented fibrils were qualitatively checked by negative 
stain TEM. For the 0 h fragmented fibrils FLD shown in Figure 4.3.1, out of >300 
fibrils whose lengths were quantified, none exceeded 3 µm in length. Figure 4.3.3 
shows that from a single negative stain electron micrograph of 0 h fragmented fibrils, 
at least four individual particles could be identified that were in excess of 3 µm 
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(dotted red lines). None of these would have been analysed by AFM as they cannot 
be traced unambiguously due to their frequent overlap with other fibrils. These long 
fibrils were also not subsequently accounted for upon application of the bias 
correction factor to the observed FLD (Figure 4.3.1, see Section 4.2.1). Because of 
these differences between 0 h fragmented fibril lengths analysed by AFM and EM, 0 
h fragmented fibrils were not used to determine the relationship between fibril ends 
and polymerisation or depolymerisation. V0 and Cf were instead normalised with 
respect to those calculated for 0.5 h fragmented fibrils and are shown in Table 4.3.4. 
 
 
 
Figure 4.3.3 Representative negative stain TEM of unfragmented β2m fibrils. Fibril 
samples exceeding 3µm in length are highlighted by red dashed lines. Red dotted lines 
directly trace over fibrils to illustrate the end-to-end distances 
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Table 4.3.4 Initial elongation rate and Cf of fibril samples normalised to fibrils fragmented 
for 0.5 h. 
frag 
time 
normalised v0 normalised Cf 
0.5 h 1.00 1.00 
6.5 h 2.16 2.65 
18 h 3.91 4.11 
48 h 5.70 4.86 
 
Plotting the normalised parameters displayed in Table 4.3.4 indicates a good linear 
correlation exists between v0 and Cf (Figure 4.3.4, m value 1.1). The agreement 
infers that, as expected, fibril elongation is a predominantly end-dependent process. 
There does, however, appear to be a larger than expected increase in v0 upon using 
48 h fragmented fibrils as seeds (Figure 4.3.4). This may be due to the contribution 
of as yet unidentified secondary nucleation mechanisms, or those that have been 
previously described (146, 152). A similar correlation is observed upon seeding fibril 
elongation with 1% (w/w) fibril seeds as opposed 10% (w/w) (Table 4.3.5 and Figure 
4.3.5), with a similar larger than expected increase in v0 observed when using fibril 
seeds fragmented for 48 h. The good correlation therefore suggests that fibril 
elongation is a predominantly end-dependent process. 
Figure 4.3.4 The correlation between Cf and the initial rate of elongation. Cf and 
the initial elongation rate (k) were normalised by dividing each by the 
corresponding value calculated for fibrils fragmented for 0.5 h (Cf0.5h and ki).The 
resulting plot was fit by a linear function and the gradient of the line (m) used to 
infer the relationship between fibril ends and elongation. 
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Table 4.3.5 The initial rate of β2m seeded fibril elongation using 1% (w/w) seed. Fibril 
samples fragmented for different amounts of time (0.5, 5, 18 or 48 h) were used in fibril 
seeding assays as described in Section 4.2.2. The error is the standard deviation from three 
individual repeats. The normalised elongation rate (dividing each rate by that obtained for 
fibril elongation when using 0.5 h fragmented fibril seeds) and the normalised error 
(expressed as a decimal of the normalised rate) are also shown. 
frag 
time 
V0 (.min
-1
) error 
normalised 
elongation rate 
error 
0.5 h 3.31E-03 3.11E-04 1.00 0.09 
6.5 h 5.96E-03 1.45E-03 1.80 0.24 
18 h 9.82E-03 2.57E-03 2.97 0.26 
48 h 1.60E-02 2.33E-03 4.84 0.15 
 
Figure 4.3.5 β2m fibril elongation is an end-dependent process. (a) 120 µM β2m monomer 
was seeded with 1% (w/w) β2m fibrils fragmented for the time specified in the key. Reaction 
progress curves were monitored by ThT fluorescence (final concentration 10 µM).Curves 
are shown normalised to the highest ThT fluorescence value recorded with each sample. 
Errors represent the standard deviation from three independent repeats. (b) Zoom of the 
curves shown in (a) to show the region from which the initial elongate rate was calculated 
using a linear function. (c) The normalised rate of 1% (w/w) seeded fibril elongation vs. 
normalised Cf. Each parameter was normalised to that calculated for 0.5 h fragmented fibrils. 
Errors are expressed as decimals of the normalised elongation rate. 
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4.3.3 Establishing the end-dependency of molecular shedding 
In order to discover whether fibril depolymerisation (molecular shedding), like 
seeded elongation, also occurs only, or predominantly, from fibril ends, 
depolymerisation kinetics of fibril samples used as fibril seeds in Section 4.3.2 were 
assayed at pH 6.4 (see Section 2.2.6 for buffer details).The relationship between the 
number of fibril ends and the rate of depolymerisation can then be calculated (as 
described above for fibril elongation) to determine the role of fibril ends in the 
release of membrane-active soluble species (Chapter 2). Depolymerisation was 
initiated by diluting 120 µM β2m amyloid fibrils described in Section 4.3.1 to 30 µM 
(monomer equivalent concentration) in pH 6.4 buffer. The kinetics of fibril 
depolymerisation were then monitored using ThT fluorescence (Figure 4.3.6). The 
amplitude of ThT fluorescence is shown normalised to the highest ThT fluorescence 
signal across all four samples (Figure 4.3.6). Interestingly, the intrinsic ThT 
fluorescence is greater for fibril samples with longer FLDs, as shown by the starting 
amplitude, which decreases upon prolonged fragmentation of fibril samples (t = 0 
min in Figure 4.3.6). Why longer fibrils exhibit greater ThT fluorescence is 
unknown, although it may be that fibril ends exhibit structural differences from the 
Figure 4.3.6 Depolymerisation kinetics of fibrils fragmented for different times in pH 
6.4 buffer. Depolymerisation of fibrils fragmented for 0.5, 6.5, 18 or 48 h was 
monitored by diluting 120 µM β2m fibrils 4-fold into pH 6.4 buffer supplemented 
with ThT. Curves are shown normalised to the highest ThT fluorescence amplitude 
observed across the series of samples. Error bars represent the standard deviation of 
up to six individual replicate measurements. 
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cross-β core that is known to bind and increase the fluorescence of ThT. The 
inability of fibril ends to bind ThT and increase its fluorescence would explain why 
fragmented fibril samples exhibit decreased ThT fluorescence, even at monomer 
equivalent concentrations (as is the case here). In addition, the depolymerisation of 
fibrils fragmented for 48 h appears to reach equilibrium at an approximate ThT 
fluorescence value of 0.6. This suggests that depolymerisation is not driven entirely 
toward native β2m monomer, but instead reaches a fibril: soluble material 
equilibrium in which a significant proportion of fibrillar material remains. This is 
consistent with observations made in Chapter 2, which shows that the yield of 
soluble material released during fibril depolymerisation at pH 6.4 is significantly 
lower than that at pH 7.4, as assayed by SDS-PAGE (Figure 2.3.7) and NMR 
(Section 2.3.7). Therefore soluble species must be in equilibrium with fibrils during 
depolymerisation at pH 6.4, although this wasn’t detected in FCS experiments 
designed to probe whether native β2m can back-exchange with higher order species 
(Section 3.3.5). 
The change is ThT fluorescence during fibril disassembly at pH 6.4 is biphasic, with 
an initial increase followed by a slower decay in fluorescence. The rate constants 
associated with the increase and decrease in ThT fluorescence were calculated by 
fitting each curve using the double exponential function described in Section 4.2.3 
(Equation 1). The resulting rate constants (k1 and k2) are shown in Table 4.3.6. The 
error associated with each rate constant is the standard deviation from the six 
replicate measurements. Table 4.3.6 shows that k1 (initial increase in ThT 
fluorescence) is independent of Cf. As such, this suggests that the increase in ThT 
fluorescence is a global phenomenon extending to all ThT binding sites, supporting 
the idea of conformational change of the β2m fibril architecture upon changes to 
solution conditions (Figure 2.3.8). 
Table 4.3.6  Length-dependent fibril depolymerisation rate constants. Fibril 
depolymerisation curves were collected at pH 6.4 by monitoring ThT fluorescence. 
frag 
time 
k1 (.min
-1
) error k2 (.min
-1
) error 
0.5 h 7.98E-02 6.64E-03 9.85E-03 7.18E-04 
6.5 h 8.51E-02 4.06E-03 9.57E-03 8.42E-04 
18 h 8.04E-02 4.05E-03 1.21E-02 4.47E-04 
48 h 7.13E-02 6.73E-03 1.62E-02 3.07E-03 
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In order to determine the role of fibril ends in the loss of ThT fluorescence, the rate 
constant for the decay of ThT fluorescence was used (k2). This can be used, as 
opposed to v0 used to elucidate the role of fibril ends in elongation, because; i) the 
curves shown in Figure 4.3.6 are well described by the double exponential function, 
thus suggesting that secondary mechanisms contribute minimally to the loss of ThT 
fluorescence during fibril disassembly, and ii) k2 is reversible to kf (see reaction 
mechanism in Section 4.3.2 – kr), providing that fibril disassembly proceeds 
predominantly for fibril ends. 
Comparison of k2 between fibril samples fragmented for 0.5 h or 48 h reveals a small 
(<2-fold), but significant (p <0.005) increase in the decay of ThT fluorescence as a 
result of prolonged fibril fragmentation. The comparison of k2 between sequential 
fibril samples as fragmentation proceeds shows that the difference in k2 for fibrils 
fragmented for 0.5 or 6.5 h is insignificant (p value = 0.57), while the differences in 
k2 for fibril samples fragmented for 6.5 or 18 h and 18 or 48 h are small but 
significant (p = 0.013 and < 0.005 respectively). Despite the statistically significant 
increase in k2 between fibril samples fragmented for either 0.5 or 48 h, the loss of 
ThT fluorescence does not show the same degree of end-dependency as seeded fibril 
polymerisation, as k2 exhibits a less than 2-fold increase in comparison with a 5-fold 
increase in v0 when the same fibril samples are used as seeds (Tables 4.3.4 and 
4.3.5). Figure 4.3.7 illustrates this best by plotting normalised k2 vs. normalised Cf. 
Figure 4.3.7 The end-dependency of fibril depolymerisation at pH 6.4. k 2 (the rate 
constant for the loss of ThT fluorescence during fibril disassembly) and Cf were 
normalised to those calculated for β2m fibrils fragmented for 0.5 h. Error bars are the 
standard deviation from a minimum of four independent repeats. 
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As for Figure 4.3.5, Cf and k2 have been normalised with respect to those calculated 
for the fibril sample fragmented for 0.5 h. The proportionality coefficient calculated 
from the linear fit (black line) is only 0.15, showing that the increase in k2 is not 
directly proportional to the increase in number of fibril ends as Cf increases.  
To ensure that the small increase in k2 as the number of fibril ends in solution 
increases is not an artefact of measuring fibril disassembly using ThT fluorescence, 
the release of soluble material was quantified (Section 2.2.8) to provide a second, 
independent observation for the rate of fibril depolymerisation. Figure 4.3.8 shows 
that no discernible difference is detectable in the amount of soluble material 
appearing during fibril disassembly over time between fibril samples fragmented for 
0.5 h or 48 h. Thus, the lack of end-dependent kinetics is not a result of measuring 
fibril disassembly using ThT fluorescence. Therefore, at least kinetically, the 
processes of fibril elongation at low pH and depolymerisation at pH 6.4 are distinct, 
in that fibril polymerisation appears to occur at fibril ends, whilst this may not be the 
case for fibril depolymerisation. 
Figure 4.3.8 ThT fluorescence and the release of soluble material during fibril 
depolymerisation at pH 6.4. The release of soluble material was quantified during fibril 
depolymerisation as described in Section 2.2.8 at the time points after the initiation of fibril 
depolymerisation indicated on the gel. Gels bands corresponding to β2m were quantified 
using the calibrant gel bands shown in (a) and (b). The release of soluble material was 
quantified for fibrils fragmented for 0.5 h (a) and 48 h (b) (clear squares) and is shown 
plotted with the corresponding ThT fluorescence measurements (filled squares). The ThT 
fluorescence is shown normalised to the highest ThT fluorescence reading within each 
sample and the release of soluble material is normalised betwee 0 and 30  µM (starting assay 
concentration. 
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There are several possible explanations for why the rate of fibril depolymerisation 
does not exhibit a direct linear relationship with the number of fibril ends. Firstly, 
the rate of fibril depolymerisation may be length dependent. This is not to be 
confused with end-dependency. Length dependent depolymerisation would mean 
that as fibrils become shorter, the rate at which species dissociate from fibril ends 
would slow down. For instance, fibrils that are fragmented to reduce length 4-fold 
exhibit only a 2-fold rate enhancement for the loss of ThT fluorescence in 
comparison with the unfragmented fibril sample. If the dissociation of species from 
fibril ends is twice as slow for these shorter fibrils than their longer counterparts, this 
would explain why the global rate of depolymerisation, as monitored by ThT 
fluorescence, has only exhibited a 2-fold increase (Figure 4.3.9a). 
A second scenario could be that back-exchange between fibril ends and oligomers 
are greater upon reducing fibril length. The kinetics of depolymerisation monitored 
by ThT fluorescence is the sum of individual rates for the forward and back 
exchange between any number of given species that either exhibit ThT fluorescence 
or not. The simplest model, such as that outlined in the discussion of Chapter 3, 
would involve the conversion of ThT fluorescent fibrils into non-ThT fluorescent 
oligomers. If the equilibrium between these two species is modulated by changing 
the length of fibrils, such that more species were able to back exchange with fibrils 
upon a reduction in fibril length, this could result in a smaller than expected increase 
Figure 4.3.9 Why is the rate of fibril depolymerisation not end-dependent? (a) Fibril 
depolymerisation is length-dependent. Both boxes show fibril species of different lengths 
constructed from monomer equivalent concentrations. Reducing the fibril length 4-fold 
generates 4 times the number of fibril ends – the site of fibril depolymerisation. However the 
reduction in length leads to a reduction in the rate in which species are shed from fibril ends. 
(b) The fibril-oligomer distribution is altered upon reducing fibril length. The ThT decay 
constant is the sum of multiple individual rates for the inter-conversion of ThT positive and 
negative species. Reducing fibril length promotes greater back-exchange of oligomers with 
fibrils, thus reducing the rate of decay of ThT fluorescence in a length-dependent manner. 
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in the rate of depolymerisation as monitored by ThT fluorescence (Figure 4.3.11b). 
The increased back exchange between oligomers and fibrils upon a reduction in fibril 
length may be due to the greater diffusivity of shorter fibrils in comparison with their 
longer counterparts. Evidence for the increased diffusivity of shorter fibrils is 
provided by the favourable surface deposition of shorter fibrils onto AFM imaging 
surfaces (360). The sequestration of longer fibrils into bundles upon diluting fibrils 
into near-neutral buffers (92) may mask fibril surfaces that are capable of 
exchanging with HMW, soluble species, therefore decreasing the rate at which 
oligomers back-exchange with fibrils. 
Although FCS experiments did not show that soluble material can back-exchange 
with fibrils (Figure 3.3.11b and d), this does not rule out the scenario outlined in 
Figure 4.3.9b. To detect back-exchange between HMW species and fibrils within the 
experiments performed in Section 3.3.5 would require native monomeric R3C488 to 
initially interact with HMW species, which in-turn would need to interact with an 
unlabelled β2m fibril. This labelled fibril would then be required to diffuse across the 
confocal volume in order for back-exchange to be detected. As fibrils pre-labelled 
with R3C488 are rarely encountered in the confocal volume during fibril 
depolymerisation experiments (Figure 3.3.6), the lack of detection of HMW species 
re-interacting with fibrils in the back-exchange FCS experiments (Section 3.3.5) may 
be due to the low frequency in which fibrils (fluorescently-labelled via the re-
association of fluorescent, soluble species) are encountered within the confocal 
volume. Indeed, the establishment of an equilibrium during fibril depolymerisation 
(Figure 4.3.7, 48 h fibril sample) at pH 6.4, in which a significant proportion of ThT 
fluorescent material remains, suggests that soluble species do interact with fibrils, as 
outlined in Figure 4.3.11b. The back exchange phenomenon could be investigated by 
FCS as proposed in Section 3.3.5, but instead using 48 h fragmented fibrils, as 
opposed to unfragmented fibrils, to increase the diffusivity of fibril particles so that 
back exchange may be more readily observed. 
Another explanation for why the rate of fibril depolymerisation may not appear to be 
end-dependent include the possible solution-induced fragmentation of longer fibril 
samples upon dilution into near-neutral buffers (Figure 4.3.10a). Dilution of fibrils 
formed at low pH into buffers with different pH values may alter the hydrogen 
bonding capacity of amino acid side chains involved in the formation of the steric 
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zipper motif. In addition, side chains that interdigitate to form the tightly packed dry 
protofilament interface may adopt new charge states (see Section 1.3.1 and 1.4.3). 
Such changes to amino acid side chain charges could lead to structural 
rearrangements within the fibril core observed by CD (Figure 2.3.8). Structural 
rearrangements may also lead to the increased ThT fluorescence observed at the 
initial stages of fibril depolymerisation assays (Figure 4.3.7). Interestingly, the 
equilibrium of fibril depolymerisation towards native β2m is much favoured by 
increasing the pH by a single unit from pH 6.4 to pH 7.4 (Section 2.3.4). This 
suggests that histidine side chains may play an important role in the formation and 
maintenance of the fibril core, as the pKa of the histidine side chain is close to these 
pH values (~pKa 6.1). Increasing the pH from 6.4 to 7.4 may switch the side chain 
imidazole group from an H-bond donor to acceptor, thus potentially altering the H-
bonding network in which the imidazole ring may be involved.  
Although at pH 6.4 the histidine side chain should be predominantly uncharged (as 
pKa is ~6.1), equivalent to the probable charge adopted by His residues upon dilution 
into pH 7.4 buffer, side chain pKa values can be significantly influenced by the local 
environment in which residues find themselves (421). This has recently been shown 
for histidine residues within the colicin E7 immunity protein, where a folding 
intermediate was shown to have histidine pKa values as high as 6.9±0.3 (422). The 
potential role of histidine residues in mediating the increased stability of fibrils 
and/or HMW soluble species at pH 6.4 is suggested by NMR, as His84 is one of the 
residues in which a chemical shift perturbation was detected during the initial stages 
of fibril depolymerisation (Figure 2.3.19bi). The protonation of His84 at pH 6.2 is 
also thought to be a critical event that enhances the amyloidogenicity of monomeric 
β2m at near-neutral pH (157). 
Although the pKa of histidine residues is more pertinent to the differences in fibril 
depolymerisation at pH 7.4 or pH 6.4, other residue side chains, such as the carboxyl 
groups of aspartate and glutamate (pKa values of 3.9 and 4.3 respectively) are likely 
to undergo changes in charge states upon dilution of fibrils into either pH 7.4 or 6.4 
buffer that will alter their hydrogen bonding capacity exhibited at low pH. The 
change in the hydrogen bonding capacity of amino acid side chains may impact both 
the stability of the steric zipper motif of the cross-β core and the dry protofilament 
interface, leading to a reduction in the tensile strength of an amyloid fibril which 
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could result in increased fibril ‘brittleness’ and subsequent fibril fragmentation. If 
longer fibrils are more susceptible to this type of fragmentation, then this could 
potentially explain why k2 does not scale with the number of fibril ends calculated 
within the orginal fibril population. This could be studied by quantifying changes to 
FLDs throughout the depolymerisation process using AFM to see whether a large-
scale reduction of fibril lengths takes place during the initial stages of fibril 
depolymerisation.  
The final possibility to be discussed is that fibril depolymerisation may not be 
strictly mediated through fibril ends (Figure 4.3.10b). Depolymerisation may be a 
combination of both the shedding of oligomers from fibril ends AND from random 
positions along the fibril axis. This may take place due to the possible reductions in 
the mechanical stability of β2m fibrils for the reasons discussed above. Whether fibril 
depolymerisation takes place via this mechanism could be studied using FCS, by 
observing the rate at which soluble species reappear during depolymerisation from 
fibrils that incorporate R3C488 into different positions along the fibril axis. Fibrils in 
which R3C488 has been incorporated randomly during fibril elongation (by 
including R3C488 at the beginning of seeded growth) and those that have been ‘end-
capped’ with R3C488 after fibril elongation has reached equilibrium, should exhibit 
distinct kinetics for the reappearance of soluble material if depolymerisation is 
mediated from fibril ends. These FCS experiments could be performed in addition to 
the AFM experiments discussed previously to ensure that any differences in the rate 
Figure 4.3.10 Potential mechanisms of fibril depolymerisation due to changes in fibril 
stability. (a) Dilution of fibrils formed at low pH into near-neutral pH buffers changes the H-
bonding capacity of the fibril core and disrupts the interdigitated, dry protofilament 
interface. Such changes could induce fibril shearing to reduce the fibril length distribution 
and accelerate depolymerisation. (b) Fibril depolymerisation does not exclusively proceed 
from fibril ends. Due to changes in fibril stability as discussed oligomers predominantly 
dissociate from within the fibril core. 
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at which soluble material released during fibril depolymerisation and detected by 
FCS is not due to the fragmentation of fibrils to generate more fibril ends in solution 
(Figure 4.3.12a). 
4.3.4 Identification of species that form during β2m amyloid formation 
The kinetic differences of polymerisation and depolymerisation raise the possibility 
that distinct species may form within each process. The most toxic species in 
amyloid disorders are reported to be those that are soluble and form prior to mature 
amyloid fibrils (20–22, 24–26, 166, 170–173, 183–185, 196, 209, 423). Highlighting 
structural differences between pre-fibrillar oligomers and those derived from mature 
amyloid fibrils during molecular shedding that are also cytotoxic would be a novel 
insight with important biological impact. Thus, a study was initiated to investigate 
structural differences that may exist between oligomers that form within the 
assembly cascade and those that form during molecular shedding. 
To do this, FCS was employed as it provided the greatest success in identifying non-
native oligomeric species that populate during fibril depolymerisation. To ensure that 
β2m amyloid formation could be studied using FCS, control experiments were 
performed to test whether amyloid formation could proceed under FCS conditions. 
FCS requires the presence of small amounts of detergents in buffers (typically 
0.01%-0.001% (v/v), see Section 4.2.4) to prevent the adsorption of material to the 
cover slip chamber. Adsorption of material can impede the detection threshold of the 
FCS experiment. Different species may also preferentially interact with the 
coverslip, artificially altering the perceived concentration of species in solution. 
Therefore, unseeded amyloid formation of 120 µM β2m at pH 2 (at 25°C, 600 rpm – 
see Section 4.2.4) was studied in the presence and absence of 0.001% (v/v) Tween-
20. ThT fluorescence was used to monitor fibril formation on a plate reader as 
described in Section 4.2.4. The rate of amyloid fibril formation in the presence and 
absence of Tween-20 is similar, although in the presence of Tween-20, the amplitude 
of ThT fluorescence within the stationary phase is substantially reduced (Figure 
4.3.11a). Quantification of soluble material after fibril formation has reached 
equilibrium shows that the presence of this concentration of Tween-20 has not 
affected the fibril yield (Figure 4.3.11b). Therefore, Tween-20 must competitively 
inhibit the binding of ThT or lower the fluorescent yield of ThT when bound. 
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Negative stain TEM of fibrils grown in the presence and absence of Tween are 
morphologically similar (Figure 4.3.13c). Therefore fibril formation can be studied 
by FCS. 
In order to detect amyloid formation by FCS, 18 nM R3C488 was added to 120 µM 
wt β2m at pH 2. ACs were collected during amyloid formation by removing aliquots 
from the plate reader at various time points and immediately analysing the sample by 
FCS. As previously stated in Chapter 3, ACs displayed for the respective time points 
are the average of a minimum of 20 x 30 sec ACs with the corresponding time point 
the median of the collection window. Figure 4.3.12 shows that as aggregation 
proceeds, no change is detected in the amplitude of ACs for the first 300 min, 
suggesting that the majority of material remains soluble and predominantly low 
order. This observation is consistent with previous ESI-IMS-MS experiments 
Figure 4.3.11 β2m amyloid formation at pH 2 in the presence or absence of Tween-20. (a) 
De novo β2m amyloid fibril formation was monitored by ThT fluorescence in low pH buffer 
in the presence (black) or absence (red) of 0.001% (v/v) Tween-20. (b)The fibril yield was 
determined by quantifying the amount of β2m in the supernatant after centrifugation for 1 h 
at 16300 x g. Calibrants were used to determine the concentration of soluble material shown 
in (b). Negative stain TEM of fibrils formed in the presence (black) or absence (red) of 
0.001% (v/v) Tween-20. 
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showing low order oligomers (<6mer) populate during the lag phase of β2m amyloid 
assembly (383). After 300 min, G(0) increases significantly over the preceding time 
points (Figure 4.3.12). This shows that soluble species are being consumed into 
higher order material, thus lowering their relative concentration of low-order, soluble 
β2m which manifests in the perceived increase in G(0). This is because of the inverse 
relationship between G(0) and the number of species detected during the acquisition 
of an AC (see Section 3.3.4, Equation 10). Note the increase in G(0) precedes that of 
the increase in ThT fluorescence (Figure 4.3.10a), suggesting that higher-order 
species populate prior to the formation of amyloid fibrils detected by ThT 
fluorescence. G(0) steadily increases from 300 min onwards, coinciding with the 
increase in ThT fluorescence and the consumption of β2m into amyloid fibrils. The 
detection of amyloid fibrils at low pH is markedly improved in comparison with that 
at pH 6.4 or pH 7.4 as fibrils remain soluble and diffuse under fibril growth 
conditions.
The distribution of species within ACs were extracted using MEM as previously 
described in Section 3.2.5. Tau distributions were then converted to apparent RH  
distributions by calibration of the confocal volume as described in Section 3.2.3. The 
Figure 4.3.12 ACs collected during β2m amyloid formation at pH 2. ACs 
displayed are the average of 20 x 30 sec individual acquisitions collected during 
the formation of 120 µM β2m amyloid formation at pH 2.0. Time points displayed 
are the median of the collection window. 
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resulting apparent RH distributions of species populating during unseeded β2m fibril 
formation at pH 2 are shown in Figure 4.3.13. 
For the first 180 min of β2m amyloid formation at pH 2, the apparent RH 
Figure 4.3.13 MEM distribution of species formed during β2m amyloid formation. 120 µM 
β2m with 18 nM R3C488 amyloid formation was monitored at low pH using FCS. Aliquots 
were removed from the fibril formation assay and immediately analysed by FCS. Each time 
point distribution was extracted from 20 x 30 sec ACs. The time point indicates the median 
of the collection window. 
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distributions are dominated by the presence of a LMW peak (Figure 4.3.13, Table 
4.3.7). These species are likely to correspond to the unfolded monomer and/or LMW 
oligomers similar to those observed from comparative ESI-IMS-MS studies. The 
peak centre ranges from 1.8-3.3 nm (Table 4.3.7), which is consistent with apparent 
RH values of native monomer controls calculated by FCS in Chapter 3 (Figure 3.3.7). 
The narrow distribution of the LMW peak in the absence of higher order species 
suggests a high degree of homogeneity. The exact identity of species within the 
LMW peak cannot be resolved by FCS and therefore may contain a range of LMW 
oligomers that have been shown to form during β2m amyloid formation by other 
techniques (383, 387). In general, in order to resolve two species by FCS, a doubling 
of the apparent RH is required. The doubling of apparent RH is equivalent to an 8-
fold increase in hydrodynamic volume (VH): 
 𝑉ℎ =
4
3⁄ 𝜋𝑅ℎ
3 (3) 
and as Do is inversely proportional to the cubic root of the mass of a protein (424): 
 𝐷𝑜 ∝  
1
√𝑀
3  (4) 
where M is the molecular weight of a protein, then an 8-fold increase in mass is also 
required for a 2-fold reduction of Do, which is inversely proportional to RH. 
Therefore the lower order species observed by ESI-IMS-MS (286, 383) are unlikely 
to be resolvable by FCS. 
Table 4.3.7 Apparent RH distributions of species populated during β2m amyloid formation at low pH. 
  Peak centre (nm) 
time (min) LMW HMW Fibrils 
30 2.6 - - 
60 2.4 - - 
120 2.9 - - 
180 3.3 - - 
240 2.1 28.4 - 
300 1.9 35.2 - 
360 2.1 75.1 - 
420 1.9 48.7 472.5 
480 1.7 48.7 472.5 
540 1.7 60.5 2148.4 
After 240 min a second species appears with an apparent RH centred at 28 nm. As 
time proceeds, the relative concentration of the HMW peak increases in comparison 
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with that of the LMW peak (Figure 4.3.15). This suggests that LMW species are 
consumed into HMW aggregates prior to the formation of β2m amyloid fibrils. There 
is also an increase in the apparent RH of HMW species as time proceeds (Table 
4.3.7). Apart from t = 360 min, where the apparent RH of HMW species is ~75 nm, 
the increase is gradual, from 28 nm (at 240 min) to 60.5 nm after 540 min. 
Interestingly, the large increase in apparent RH of HMW species detected at 360 min 
is the last time point measured before fibril formation proceeds (Figure 4.3.11a). 
Therefore, there might be a critical mass, or aggregate size that is required, before 
fibril formation can begin. 
After 360 min an additional species can be observed with an apparent RH >100 nm. 
The formation of this peak is coincident with an increase in ThT fluorescence, 
suggesting these species are likely to be mature amyloid fibrils. Moreover, the 
relative concentration of these species increases over time in comparison with LMW 
and HMW species. This is concurrent with an increase in apparent RH of the large 
species observed 540 min into the aggregation landscape in excess of 1000 nm 
(Table 4.3.7 – fibrils). This shows that fibrils are continuously being elongated 
during the aggregation landscape. How the relative concentration of each species 
changes in solution over time during the assembly is shown in Figure 4.3.14. The 
Figure 4.3.14 The relative population of species formed during β2m amyloid formation. The 
relative amplitude of LMW species (black), HMW species (orange) and fibrils (purple) 
forming as a function of time and extracted from ACs using MEM. Lines are visual guides 
and are fitted. 
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relative amplitude of species has been normalised to the amplitude of LMW species 
observed at t = 30 min. 
4.4 Discussion 
This Chapter aimed to resolve the mechanism by which fibril depolymerisation 
proceeds and whether species that form within the lag phase of amyloid fibril 
formation are structurally distinct or homologous to those that populate during 
molecular shedding. The discoveries relating to the mechanism of fibril 
depolymerisation, the potential implications, and future work required to fully 
elucidate the mechanism were discussed in detail in Section 4.3.3 and will therefore 
not be reviewed here once more. 
For the characterisation of pre-fibrillar oligomers that form during the lag phase of 
β2m amyloid assembly, FCS has proved successful in identifying at least three 
distinct populations of species that form at different stages during amyloid 
formation. For the first 180 min of amyloid formation, the lag phase is dominated by 
a LMW peak with an apparent RH consistent with that observed for native monomer 
controls performed in Chapter 3. As discussed in Section 4.3.3, FCS is unlikely to be 
able to resolve the presence of additional LMW oligomers that have been shown to 
populate in addition to monomer during the lag phase of β2m amyloid formation 
under similar conditions (Figure 4.4.1a). This is because only 6mers and below have 
been observed by ESI-IMS-MS of β2m amyloid formation at low pH, whereas an 8-
fold increase in mass is required for the 2-fold increase in apparent RH which is 
typically required to resolve species by FCS (Section 4.3.4, Equations 3 and 4). 
Therefore the slight increase in apparent RH of the LMW peak from 30 to 180 min is 
consistent with the formation of LMW oligomers that cannot be resolved by FCS, 
but were seen by analytical ultracentrifugation under similar assembly conditions 
(Figure 4.4.1) (387). In order to elucidate whether these LMW species are forming 
under the conditions used for FCS experiments, AUC could be repeated. 
Interestingly, the HMW species that form after 180 min, but before the onset of 
amyloid fibril formation (Figure 4.3.16), were not detected in AUC experiments  
performed by Smith et al in (387). Amorphous aggregate deposition preceding the 
formation of amyloid fibrils has been shown for β2m aggregation under similar 
conditions by AFM analysis (Figure 4.4.1b and c) (155). Some of these species are 
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similar in apparent size to those observed during FCS experiments, although the 
amorphous aggregates predominantly observed by AFM as the lag phase proceeds 
are significantly larger than those observed by FCS (Figure 4.4.1b) (typically 
between 300 -1 µm in diameter) (155). This suggests that the HMW species detected 
here, which do increase in apparent RH before the onset of amyloid fibril elongation, 
but not to such an extent as previously shown, may be a novel pre-fibrillar species 
that forms during β2m amyloid formation at low pH. 
The data presented here provides a starting point from which a more comprehensive 
analysis of the structural comparison of pre-fibrillar oligomers and those that form 
through molecular shedding can be performed. From these initial observations, the 
apparent RH of HMW pre-fibrillar species are similar to those that form during 
depolymerisation at pH 6.4 (Figure 3.3.8). However, they are consistently larger. It 
would be interesting to investigate the structural properties of these pre-fibrillar 
species in a similar manner to which molecular shedded oligomers formed during 
depolymerisation were assessed. The structure of pre-fibrillar oligomers formed at 
low pH could be studied by CD throughout the lag phase. This will provide 
information as to the secondary structure of LMW and HMW species and whether 
Figure 4.4.1 Pre-fibrillar oligomers previously identified during β2m amyloid 
formation. (a)  AUC performed during β2m amyloid formation under similar 
conditions to those used in Section 4.3.3. AUC revealed that LMW oligomers up 
to tetramers were frequently observed during the lag phase of β2m assembly 
(387). (b) and (c) Representative AFM images of species populated during β2m 
amyloid assembly at low pH. Images were taken 17% and 31% into the lag phase 
(lag phase defined as the time it takes for a 10% increase in ThT fluorescence to 
be reached (155). 
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either begins to propagate significant β-sheet secondary structure prior to the 
formation of fibrils begin. The HMW species observed to form after 180 min of the 
lag phase may be protofilament assemblies of β2m incapable of binding or increasing 
the fluorescent yield of ThT. The β2m fibril is composed of six individual 
protofilaments that arrange into two crescent shaped half-fibrils that stack back-to-
back along the fibril axis (Figure 1.4.3). Protofilaments may form prior to the 
assembly of ThT-fluorescent mature amyloid fibrils. Similar ANS binding assays to 
those performed on oligomers formed during molecular shedding could be 
performed to probe the surface-exposed hydrophobicity of the oligomers. AFM and 
negative stain-EM could also be used to probe the gross morphology of HMW pre-
fibrillar species whose formation precedes that of the mature amyloid fibril. 
Characterising pre-fibrillar oligomers in this way would therefore allow a 
comparison between these and oligomers generated during molecular shedding to 
take place. If the two oligomer populations are found to be significantly different, 
this could hold important consequences within disease, as it expands the repertoire of 
soluble species that are capable of causing cytotoxicity. This would also further 
illustrate the importance of detailed investigations that uncover mechanisms of fibril-
mediated cellular dysfunction. 
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CHAPTER 5 
 
5.1 Discussion 
Amyloid toxicity is a complicated, integrated process, involving the formation of 
multiple potentially cytotoxic species that mediate cellular disruption through a 
variety of distinct mechanisms. For the treatment of amyloid diseases, especially 
those that target toxic aggregates, it is likely that the array of species that disrupt 
cellular homeostasis in models of disease will need to be characterised before 
effective palliative or curative treatments can be developed. This includes those 
species that are formed in vitro, as several examples of species that were initially 
characterised in vitro have been found to occur in cells (82, 113, 170, 184). Thus, 
studying mechanisms of amyloid formation and toxicity in vitro contribute 
significantly towards our collective understanding of the processes underlying 
amyloid diseases. 
Work presented in this thesis has focused primarily on elucidating the mechanism by 
which 2m amyloid fibrils cause membrane disruption in vitro. The hypothesis of 
this work was borne out of the observation made by Goodchild et al, which showed 
that disruption of liposomes by 2m amyloid fibrils is dependent upon pH, where a 
~2-fold increase in the extent of membrane disruption is observed upon reducing the 
pH by a single unit, from pH 7.4 to 6.4 (341). This, coupled with the reduced extent 
of 2m fibril-mediated liposome disruption in the presence of the known fibril 
stabiliser LMW heparin (78, 342), prompted an investigation into the role of fibril 
dynamics in mediating  the disruption of membranes. This was the primary focus of 
Chapters 2 and 3. 
Why is 2m fibril-mediated membrane disruption pH-dependent? 
Several literature examples have highlighted the ability of amyloid fibrils to 
‘recycle’ molecules between the fibrillar and soluble forms under conditions of fibril 
growth (188, 238, 242, 243, 425). Similarly, kinetic analysis of the response of 2m 
amyloid fibrils formed at low pH upon dilution into pH 7.4 or 6.4 buffers revealed 
that soluble material is released as a consequence destabilising 2m fibrils by 
changing the solution conditions. The soluble material formed under both conditions 
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was then shown to be responsible for up to 80% of the membrane disruption 
potential of 2m fibrils under both conditions. Paradoxically, the extent of membrane 
disruption is not directly related to the concentration of material released during 
depolymerisation; the kinetic amplitude of fibril depolymerisation is significantly 
greater at pH 7.4, but the released soluble material is only half as membrane-active 
as that formed during depolymerisation at pH 6.4. As native 2m monomer is 
incapable of disrupting liposomal membranes, the membrane disruption activity 
exhibited by soluble material must be caused by the formation of one or more non-
native, membrane-active species that is/are significantly more populated upon fibril 
depolymerisation at pH 6.4. This was subsequently confirmed using NMR and ESI-
IMS-MS, which showed that the appearance of native 2m during fibril 
depolymerisation at pH 6.4 is delayed significantly with respect to the loss of 
fibrillar material (Figure 5.1.1). This is the first example that subtle changes in 
Figure 5.1.1 The kinetic mechanism of 2m fibril depolymerisation. Upon dilution into 
pH 7.4 (purple) or pH 6.4 (green) buffer, 2m fibrils undergo depolymerisation to 
release soluble material responsible for membrane disruption. Comparison between the 
time constant for the loss of ThT fluorescence (loss of fibrillar material – double 
headed arrow) and the appearance of native 2m (measured by NMR – dashed line), 
reveals that, at pH 6.4, a non-native, NMR-invisible species is significantly populated, 
leading to the delayed appearance of native β2m . It is this species that is presumably 
responsible for the increased membrane disruption at pH 6.4 (ellipsoid, red to orange 
indicates the membrane-activity of non-native species generated under either 
condition). 
Chapter 5 
 
171 
 
solution conditions can impact upon the cytotoxic capacity of an amyloid fibril by 
modulating the concentration of membrane-active soluble species that are initially 
populated upon fibril depolymerisation.  
Subsequently, work presented in Chapter 3 attempted to characterise the non-native, 
soluble species that are responsible for membrane disruption using different 
biophysical methods. MEMFCS identified a HMW species, with an apparent RH of 
~20 nm, which is significantly more populated upon depolymerisation at pH 6.4. The 
apparent size distribution of these species was confirmed by negative-stain TEM. 
Although FCS rarely detected HMW species upon fibril depolymerisation at pH 7.4, 
the ability of soluble material generated during depolymerisation at this pH to cause 
membrane disruption suggests that non-native species must form, as native β2m 
monomer cannot cause liposome dye release. Indeed, further analysis by CD and 
ANS binding experiments revealed that non-native species that are at least partially 
unstructured and possess surface-exposed hydrophobicity do form during fibril 
depolymerisation at pH 7.4. These properties were shared with species that populate 
during fibril depolymerisation at pH 6.4, although a significantly greater proportion 
of soluble material displays surface-exposed hydrophobic patches and is 
unstructured at this pH. The exposure of hydrophobic patches at the surface of 
amyloid oligomers is a feature thought to be responsible for driving the interaction 
between lipid bilayers and aggregates that leads to membrane disruption (see Section 
1.3.6). 
Does molecular shedding contribute to 2m fibril-mediated cellular disruption? 
Although the work presented in this thesis is an in vitro investigation, the secondary 
aim was to test whether the observations made were applicable to the mechanism by 
which 2m fibrils cause metabolic defects in cells. Since 2009, when Xue et al first 
showed that incubating cells with β2m amyloid fibrils causes metabolic defects (245, 
347), work has been ongoing to elucidate the mechanism by which this takes place. 
Subsequently, several observations have been made; i) preventing fibril 
internalisation via endocytosis rescues cells against fibril-mediated cellular 
disruption; ii) once internalised, fibrils are trafficked through the endocytic pathway 
and localise with lysosomes, and; iii) fibril internalisation impairs the lysosome 
proteolytic machinery and causes membrane trafficking defects (340).  
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In Chapter 2, a chemical cross-linking strategy designed to reduce (at least in-part) 
the extent of fibril depolymerisation, resulted a modest, but significant, inhibition in 
the metabolic defects associated with β2m fibril incubation. The inhibition of fibril 
toxicity through the reduction of molecular shedding was corroborated by an 
independent set of experiments which showed that the molecular chaperone, Hsp70, 
is able to prevent fibril depolymerisation in a dose-dependent manner. Hsp70 was 
also able to restore cellular metabolic activity in the presence of β2m fibrils and to 
restore lysosomal proteolysis to basal levels. Hsp70 was significantly better at 
reducing the metabolic defects induced by the presence of β2m fibrils than the 
chemical cross-linking strategy. This is likely to be due to the concerted anti-amyloid 
activities of Hsp70 reported in the literature (236, 370, 373, 376–381). Nevertheless, 
these results indicate that the molecular shedding of cytotoxic species is a 
contributing factor to β2m fibril-mediated cellular disruption. 
Can molecular shedding be a contributing factor within other amyloid disorders? 
The advantage of working with β2m as a model system is that both the biophysical 
nature of β2m amyloid aggregation and the mechanisms of β2m amyloid-associated 
toxicity have been characterised in great detail (78, 92, 100, 155, 157, 159, 304, 329, 
331, 332, 336, 387, 426–430). Therefore, the context of this work can be integrated 
into existing hypotheses of β2m amyloid toxicity to refine the potential mechanism 
by which β2m fibrils cause metabolic defects. The in vitro observations made and 
presented in Chapter 2 were integrated with the established phenomena discussed 
above to put forward a model of β2m fibril-mediated toxicity. This suggests that the 
localised environment of specific endocytic compartments may be most susceptible 
to β2m amyloid toxicity by tuning the molecular shedding equilibrium in favour of 
the generation of membrane-active oligomers (Section 2.4).  
Chapter 2 also discussed the relevance of molecular shedding to other amyloidogenic 
aggregates. Many amyloids (especially those deposited extracellularly) are trafficked 
within the endocytic pathway, thus encountering different environments, one or more 
of which may favour the molecular shedding of cytotoxic species (11, 98, 108, 188, 
218, 220, 244). Evidence for this is provided by the cytoplasmic penetration of 
soluble particles that are trafficked through the endocytic pathway to seed amyloid 
formation in previously healthy cells (216–218, 246). In addition, the dissociation of 
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soluble species from plaques of Aβ42 in mice models of disease have been shown to 
generate an oligomeric ‘halo’ within which cells are most susceptible to amyloid 
toxicity (343). Finally, a recent series of small molecule screening experiments 
identified a set of compounds that bind to the fibril core formed from the Aβ16-21 
fragment (431). Several of these compounds were shown to inhibit Aβ fibril toxicity 
markedly. Although not proven in their study, the authors speculate that the 
inhibitory effect of small molecules is due to the stabilisation of the amyloid fibril 
core upon binding of the small molecules, thus preventing the dissociation of 
cytotoxic species. All in all, this series of experiments suggests that amyloid fibrils, 
through the action of molecular shedding, are likely to be an important reservoir of 
toxicity in other amyloidogenic systems. 
Are species generated during molecular shedding a novel class of β2m-derived 
oligomers? 
The inception of the work described in Chapter 4 was inspired from the same studies 
outlined above and follows on from the work presented in Chapters 2 and 3. Briefly, 
having established that fibril membrane disruption is predominantly mediated 
through the molecular shedding of soluble species, Chapter 4 aims to elucidate why 
the length-dependent membrane disruption potential of β2m amyloid fibrils (and 
cellular disruption, see Section 2.1) does not linearly scale with the number of fibril 
ends within a fibril population. The fragmentation of β2m fibrils, which typically 
leads to a 4-fold reduction in the weight average fibril length, only induces an ~2-
fold increase in membrane disruption potential under a variety of different 
conditions, and in the presence of a variety of different lipid compositions (245, 
341). As discussed in Section 4.1, the polymerisation of amyloid fibrils and the 
recycling of soluble species within the stationary phase of amyloid formation (Figure 
1.3.4a), are generally end-dependent processes. Thus, it would be reasonable to 
assume that molecular shedding induced upon fibril destabilisation would be 
similarly mediated from fibril ends. 
It turns out that establishing the mechanism of fibril depolymerisation is not that 
straightforward. By monitoring the length dependent rate of fibril depolymerisation 
(Figure 4.3.7) and the release of soluble material (Figure 4.3.9), the difference in the 
extent of membrane disruption potential is equivalent to the difference in 
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depolymerisation kinetics between unfragmented and 48 h fragmented fibril samples. 
Why the rate of depolymerisation, unlike the rate of polymerisation (Figure 4.3.2), 
does not linearly correlate with the number of fibril ends poses an intellectually 
challenging question which is discussed at length in Section 4.3.3 and will not be 
repeated here. 
Finally, the differences in the kinetics of β2m fibril polymerisation and 
depolymerisation prompted an investigation of the structural characterisation of 
species that form in the lag phase of β2m amyloid assembly. Highlighting differences 
in the structural properties of pre-fibrillar oligomers (frequently reported as the 
agents of toxicity) and those that form during molecular shedding would expand the 
morphological features of soluble species able to form from a single precursor 
through competing pathways. The potential discovery would hold important 
consequences as to how best to combat amyloid toxicity in vivo. Many therapeutic 
strategies are designed to divert the formation of amyloid through distinct 
mechanisms or to kinetically modulate the aggregation pathway (Section 1.3.8). 
Diverting amyloid formation would therefore require the characterisation of novel 
species formed through the action of small molecules to ensure they do not exhibit 
toxicity. In addition, the action of a small molecule on the entire ensemble of 
amyloidogenic species likely to be found in vivo would have to be investigated, as 
small molecules may have additional effects on other amyloidogenic species that are 
not being specifically targeted (342). 
The initial observations made by MEMFCS show the evolution of three distinct 
species that populate at different times throughout the lag phase of β2m assembly. 
The apparent RH of the intermediate, HMW species formed in the lag phase of β2m 
amyloid fibril assembly is similar to that formed via molecular shedding, although 
this pre-fibrillar species is somewhat larger (according to apparent RH - ~20 nm for 
molecular shedded HMW species and 30 – 75 nm for pre-fibrillar species). With the 
limited structural characterisation of species performed so far, it is too early to tell 
whether these pre-fibrillar speices are distinct from those that form during molecular 
shedding, although MEMFCS has provided a starting point from which a more 
comprehensive analysis can begin. 
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5.2 Future directions 
As is probably the case with the majority of PhD projects, attempting to answer a 
single question has led to the opening of Pandora’s Box. There are now a wealth of 
new directions in which this research can be taken. If I could start a second PhD to 
follow on from this one, there would be three main questions that I would address. 
Firstly, I would like to finish the structural characterisation of pre-fibrillar oligomers 
in order to draw comparisons between the structural properties of these HMW 
species and those that form through molecular shedding. Secondly, it would be 
interesting to investigate in more detail the reasons for why the molecular shedding 
equilibrium is so dramatically altered upon the slight reduction in pH from 7.4 to 6.4. 
More specifically, the role of histidine residues in maintaining the stability of β2m 
fibrils at pH 6.4 could be investigated for the reasons outlined in Section 4.3.3. As 
has been discussed (Section 4.3.3), His84 is thought to play an important role in 
initiating the formation of amyloid aggregation at near-neutral pH of the β2m variant 
ΔN6 (157). It was also shown to be one of the residues that exhibit a non-native 
chemical shift within the early stages of fibril depolymerisation at pH 6.4 (as 
detected by NMR (Figure 2.3.19)). His84 also participates in the formation cross-β 
core of β2m fibrils formed at low pH (117, 409). In lieu of this, does mutating His84, 
or other His residues within β2m (wt β2m has four His residues in total), prevent the 
formation of β2m amyloid fibrils at low pH? If not, does it affect the pH dependent 
fibril depolymerisation observed for wt β2m fibrils formed at low pH? 
Finally, and most interestingly from a therapeutic perspective, a more detailed 
analysis of the mechanism by which Hsp70 modulates the kinetic stability of β2m 
amyloid fibrils at near-neutral pH should be performed. A discussed in Sections 
1.3.6 and 2.3.5, modulation of the proteostatic network is becoming an increasingly 
suggested method for correcting the metabolic defects associated with amyloid 
deposition and toxicity.  
Investigating the mode of binding of Hsp70 to β2m fibrils by cryoEM would be an 
exciting question to pursue. It would be particularly interesting to study β2m 
fibril:Hsp70 complexes at the two molar ratios used to rescue fibril depolymerisation 
in a dose-dependent manner. Such a study could indicate whether chaperone binding 
is observed along the entire fibril axis or is localised to particular regions of the fibril 
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structure. Such observations as to the mechanism of the inhibition of fibril 
depolymerisation may inform as to the sites from which molecular shedding takes 
place. In addition, studying Hsp70:β2m amyloid complexes by FCS would also be 
insightful. FCCS could be performed using differentially labelled β2m fibrils and 
Hsp70 to monitor the interaction between amyloid species and the chaperone at 
different times after the initiation of fibril depolymerisation. Cross-correlating ACs 
between Hsp70 and amyloid species could reveal whether Hsp70 additionally 
interacts with the membrane-active HMW species shown to form during molecular 
shedding. Such an observation may explain why Hsp70 rescues β2m fibril-mediated 
toxicity to a significantly greater extent than chemical cross-linking of amyloid 
fibrils. 
5.3 Concluding remark 
In the grand scheme of things, how much the work presented here contributes 
towards a more comprehensive understanding of the processes that underlie amyloid 
toxicity will be known in time. I hope that the main aim of this project, to add to the 
growing body of evidence that indicates the importance mature amyloid fibrils in 
facilitating amyloid toxicity, has been achieved. And I hope that the avenues of 
research opened as a result of this project will provide fruitful, challenging, but 
ultimately exciting work for enthusiastic successors for several years to come.
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